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ABSTRACT
There has been great controversy involving progesterone (P4) levels during early
pregnancy in cattle. The objectives of these experiments were to determine the effect of
an early low dose administration of P4 or altrenogest (ALT) on pregnancy rates in repeat
breeder (RPB) females, if an increase in pregnancy rates could result from a direct effect
of P4 on the embryo and if ALT could support pregnancy in the absence of a functional
CL. Firstly, ALT was evaluated for use as a progestin in cattle by synchronizing estrus in
beef heifers. There were no differences in the number of females displaying behavioral
estrus or in pregnancy rates when synchronized with ALT or MGA. A second
experiment was designed to determine the effect of P4 or ALT supplementation during
days 3 to 5 on pregnancy rate in RPB cattle. It was determined that 15 mg of P4 or ALT
during days 3 to 5 increased pregnancy rates compared with nontreated breeding
periods. A third experiment was designed to determine if P4 exerted a direct effect on
the embryo. In vitro produced (IVP) embryos were cultured in the absence of a coculture system. At day 3, post-insemination, embryos were cultured in the presence of
P4 and evaluated on days 6 to 9. On day 7 post-insemination, there were significantly
more grade 1 blastocysts from the P4 group compared with other treatment groups.
Also, embryo developmental rates were increased when cultured in the presence of P4
and more of these embryos developed to the hatched blastocyst stage compared with
other treatment groups. After a direct effect of P4 on developing IVP bovine embryos
existed, it was determined that these embryos did not possess P4 receptors. Finally, it
was demonstrated that ALT could support pregnancy in the absence of a functional CL.
These experiments demonstrated that ALT could serve as a progestin in cattle and when
administered in low doses during early pregnancy could improve pregnancy rates in
RPB cows. These results are likely due to a direct effect of P4 on the embryo; however,
this mechanism is by means other than binding the PR.
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CHAPTER 1
INTRODUCTION
It is well known that progesterone (P4) has been shown to be necessary for the
establishment and maintenance of pregnancy in mammals. In addition, P4 has been
proven essential for the initiation of reproductive function in the female. In cattle, P4
treatment of prepubertal females has been demonstrated to hasten the initiation of
cyclicity in heifers (Short et al., 1976; Heitzman et al., 1979). Also, P4 treatment of postpartum cows has decreased the number of days to mating (Brown et al., 1972; Yelich et
al., 1988; Yelich et al., 1995a; Patterson et al., 1995). Wilmut et al. (1980) reported that a
normal period of P4 exposure during the luteal phase was necessary to achieve normal
pregnancy rates during the subsequent estrual period. However, the effects of elevated
P4 during early pregnancy on the developing bovine embryo are still under investigation.
Elevated P4 levels during corpus luteum (CL) formation (metestrus) may have
effects on the developing embryo. Increased circulating P4 levels at the time the embryo
is in the oviduct has been reported to hasten the rate of embryo transport into the uterus
in mice (Kendle and Lee, 1980) and cattle (EL-Banna and Hafez, 1970; Crisman et al.,
1980). This treatment hastened embryo transport along with stimulation of uterine cell
proliferation and differentiation, as well as increased blood flow to the bovine uterus
(Johnson et al, 1997; Rider et al., 1998; Gray et al., 2001). An early rise in P4 has been
reported to alter the pattern of protein synthesis, secretion and overall increase uterine
protein secretions in cattle (Garret et al., 1988). Furthermore, it has been noted that
when early circulating P4 increased there were increased embryo developmental rates
(Lawson et al., 1983; Lawson and Cahill, 1983; Garrett et al., 1987; Garrett et al., 1988).
Thus, with earlier embryo entry into the uterus, there will be a stimulated, receptive
uterus to support further embryo growth and differentiation.
An early increase in P4 levels in pregnant or nonpregnant cows, however, has not
been consistently demonstrated (Shemesh et al., 1968; Pope et al., 1969; Henricks et
al., 1970; Henricks et al., 1971; Sreenan and Diskin, 1983). Ashworth et al. (1989) and
Mann and Lamming (1996) reported that hastened CL development and function would
likely increase pregnancy rates in cattle. There is indirect evidence of faster CL
development positively impacting pregnancy rates, when comparisons were made of the
reproductive performance of pubertal and mature females (Davies and Beck, 1993; Silva
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et al., 2002). In sheep, ewe lambs had lower levels of P4 during metestrus and diestrus
and lowered reproductive performance compared with mature ewes (Davies and Beck,
1993). However, research has failed to demonstrate differences between fertile beef and
dairy cows regarding early P4 levels during metestrus or diestrus (Shemesh et al., 1968;
Pope et al., 1969; Robertson and Sarda, 1971; Bulman and Lamming, 1978; Geisert et
al., 1988). The question of whether or not there is an early increase in P4 levels during
metestrus (presumably from earlier developed luteal tissues) in pregnant females
compared with nonpregnant females remains to be answered. Lukaszewska and
Hansel (1980) reported that P4 levels were significantly higher in pregnant females
compared with nonpregnant females by day 8 (estrus = day 0). Later, Hwang et al.
(1988) demonstrated that the bovine embryo produces luteotrophic prostaglandins.
These luteotrophins had been previously reported to cause increased P4 levels in the
ewe (Pratt et al., 1979). These reports demonstrate that viable bovine or ovine embryos
have the ability to increase P4 levels during early pregnancy.
The next logical step was to administer P4 to mated females in an attempt to
increase pregnancy rates. Unfortunately, this approach has resulted in varied success
rates in cattle. Even with the lack of success, there have been reports of increased
pregnancy rates over controls with P4 supplementation from day 1 to day 7 following
onset of estrus in dairy cattle (Henrick, 1953; Dawson, 1954; Wiltbank et al., 1956;
Johnson et al., 1958). However, these studies used various levels of P4 supplementation
and are primarily veterinary case reports. The majority of these reports, however,
indicated that P4 supplementation from day 6 onward (estrus = day 0) failed to increase
pregnancy rates (Sreenan and Diskin, 1983; Munro and Bertram, 1990; Van Cleef et al.,
1991; Stevenson and Mee, 1991; Mann et al., 1998).
Attempts to increase P4 levels by administration of luteotrophins have also failed
to significantly increase pregnancy rates over that of control females. Administration of
luteotrophins (human chorionic gonadotrophin, hCG or gonadotrophin releasing
hormone, GnRH) during mid-cycle (day 7 or later) to artificially inseminated dairy and
beef cattle have significantly increased circulating P4 levels (Wiltbank et al., 1961;
Rajamahendran and Sianangama, 1992; Lulia et al., 1994). However, the majority of
these studies report no difference in pregnancy rates between treated and nontreated
females (Holness et al., 1982; Sreenan and Diskin, 1983; Walton et al., 1990; Sheldon
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and Dobson, 1993). These studies, taken collectively, indicate that increasing
endogenous P4 levels during mid to late luteal phase does not increase embryo survival
rates. These findings are noteworthy because it is at this time that the embryo is
releasing luteotrophic substances (Lewis et al., 1982; Hwang et al., 1988; Lewis, 1989).
The previous findings led to two hypotheses for the role of P4 in the successful
development during pregnancy: (1) P4 increase must occur during early metestrus for a
successful pregnancy to be established and (2) elevated P4 during the luteal phase
exerts a beneficial effect directly on embryonic growth and survival. The second
hypothesis has recently gained some support. Mann et al. (1996) demonstrated that
elevated P4 levels during the early luteal phase (day 4 and later) resulted in a reduced
luteolytic signal and thereby, allowed the embryo to have a greater chance of sending an
optimal signal for maternal recognition of pregnancy. Furthermore, it was demonstrated
that elevated P4 levels result in conversion of uterine prostaglandin synthesis from PGF2α
(luteolytic) to PGE2 (luteotrophic), elevated interferon tau (a maternal recognition signal)
synthesis by the conceptus and a need for lower amounts of interferon tau to prevent
luteal regression (Mann et al., 1998).
At this time it appears that these two hypotheses are not mutually exclusive and
therefore, the further development of the first hypothesis was part of the objective of this
dissertation. This objective was based on the findings of Gustaffason and Larson (1983)
who demonstrated that when embryos were collected from cows of lowered fertility on
day 7 (estrus = day 0) and transferred to fertile cows, this resulted in reduced embryo
survival. Conversely, when embryos were collected on day 7 (day 0 = estrus) from fertile
cows and transferred to cows with lowered fertility, embryo survival was normal
(Gustaffason and Larson, 1985). These findings suggested that early embryonic
developmental (day 3 until sustained luteal function) under the influence of elevated P4
could possibly exert an effect on increasing embryonic survival. Also, there has been a
need to determine if P4 can exert a direct effect on the embryo.
Another objective of this dissertation was to determine if, the progestin,
altrenogest could serve as a biologically active progestin in ruminant species, such as
the cow. By determining whether altrenogest could serve a bovine progestin, it could be
used to further evaluate the effect of progestins on early embryo development, as well
as, maintaining pregnancy in beef cattle.
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CHAPTER 2
LITERATURE REVIEW
Role of Oral Progestins in Control of Reproduction
MGA in Control of Reproduction
Melengestrol Acetate (MGA) is an orally active progestin commonly used for
estrus suppression and as a growth promotant in beef cattle. For MGA to be orally
active, the progestin has been chemically modified at carbons 6 (methyl and double
bond additions), 16 (methylene addition) and 17 (acetoxy addition) (Lauderdale, 1983).
These modifications allow MGA to remain chemically active as it transverses the rumen
into the circulation.
MGA was originally developed for use as a growth promotant in feedlot heifers
and has been shown to consistently improve weight gain and feed efficiency (Bloss et
al., 1966). Hafez (1987) subsequently reported that MGA improved weight gain and feed
efficiency by preventing behavioral estrus and blocking ovulation, while allowing follicular
development to continue on the ovaries. This resulted in sustained estrogen (E2) levels,
which stimulated a synergistic effect on growth hormone (GH) release that resulted in
increased nitrogen retention and increased protein synthesis.
In cattle, MGA is ~30 times more potent than progesterone (P4) in pregnancy
maintenance and 125 times more potent than P4 for suppressing estrus (Lauderdale,
1983). When fed at a rate of 0.25 mg per head per day, estrus was suppressed in all
heifers and at a rate of 0.50 mg per head per day follicular growth and development
would still occur in the absence of a corpus luteum (CL) (Bloss et al., 1966). However,
Young et al. (1966) reported that when MGA was fed (for 154 days) at a rate of 0.20 mg
per head per day behavioral estrus was only suppressed in 12 of 20 females, while at a
rate of 0.40 mg per head per day, only 3 of 20 females exhibited behavioral estrus and
at a rate of 0.60 mg per head per day no females displayed behavioral estrus.
Furthermore, Zimbelman and Smith (1966a) indicated that 0.42 mg per female per day
of MGA was the minimum requirement to prevent ovulation and behavioral estrus in beef
cattle. An important finding indicated that MGA was equally effective when administered
orally or intramuscularly and when administered orally, MGA was absorbed rather than
degraded in the rumen and/or intestines (Zimbelman and Smith, 1966b). Prior to its use
for estrous cycle synchronization, MGA was reported to maintain pregnancy in bilaterally
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ovariectomized cows (Zimbelman and Smith, 1966c). A dose of 4 mg per female per day
of MGA was found to be the minimum dose required to maintain pregnancy in bilaterally
ovariectomized cows. This was 20 times greater than the dose required to prevent
ovulation in beef cattle (Zimbelman, 1963). More recently, MGA has been used to
support pregnancy in females where detection of endogenous P4 levels were important
(Wright et al., 1994; Bridges et al., 2000).
Use of MGA to control estrus in cycling cows utilizes long term (14 to 18 days)
daily administration of MGA at doses ranging from 0.5 to 1.0 mg of MGA per head per
day (Zimbelman and Smith 1966b; Zimbelman and Smith, 1968a; Zimbelman and Smith,
1968b; Roche and Crowley, 1973; Patterson et al., 1989). In these studies, the interval
from removal of MGA from the ration to the onset of estrus ranged from 3 to 7 days
(Zimbelman and Smith, 1968a; Zimbelman and Smith, 1968b; Roche and Crowley,
1973; Patterson et al., 1989). It should be noted that decades before, Zimbelman and
Smith (1966b) reported low pregnancy rates among MGA-treated females following
artificial insemination (AI). Subsequent reports verified a decrease in pregnancy rates
that occurred in long-term MGA-treated females when compared with those of
nontreated control females (Hill et al., 1971; Lamond et al., 1971). There have been two
reports of no decrease in pregnancy rates following AI in dairy cows administered longterm MGA treatment (Roussel et al., 1969; Boyd, 1970), although decreases in
pregnancy rates among AI dairy cows have been reported with long-term administration
of P4 (≥14 days) and other progestins (Trimberger and Hansel, 1955; Ray et al., 1961;
Hansel, 1967; Wiltbank et al., 1967; Lamond et al., 1971; Wettemann and Hafs, 1973;
Roche, 1974a; Roche, 1974b).
With long-term MGA treatment failing to produce respectable pregnancy rates
among cattle following AI, alternative protocols were developed for the use of MGA. An
attempt to improve pregnancy rates, following long-term treatment with MGA, by
administration of hCG or LH at the time of AI failed to improve pregnancy rates in MGAtreated females (Zimbelman and Smith, 1968a; Zimbelman and Smith, 1968b; Roche
and Crowley, 1973). Researchers aware that long-term progestin treatments decreased
pregnancy rates following AI, continued searching alternative approaches using MGA.
Soon after, a short-term treatment (≤14 days) with MGA was developed, which produced
pregnancy rates similar to control treated females although the degree of synchrony was
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greatly reduced (Wiltbank and Kasson, 1968; Roche, 1974a; Sreenan and Mulvehill,
1975). It was later demonstrated that long-term administration of MGA or other
progestins induced persistent dominant follicles in cattle (Yelich et al., 1997; Cavalieri et
al., 1998; McDowell et al., 1998). This was caused by P4 down-regulating LH receptors,
which are required for ovulation and final maturation of the oocyte (Batra and Miller,
1985; Thiery and Martin, 1991). In addition to the decreased viability of the oocyte, a
persistent dominant follicle altered the steroid hormone secretion pattern and thus,
secretory patterns of the oviduct thereby adversely affect fertilization in vivo (Binelli et
al., 1999).
To circumvent the decreased fertility associated with long-term MGA
administration and to prevent the loss of synchrony with short-term MGA administration,
a short-term MGA protocol was combined with administration of PGF2α. Although Fike et
al. (1997) demonstrated that infertility due to persistent dominant follicles could be
overcome by preventing ovulation of the persistent follicle and inducing ovulation of a
second follicle this procedure was subsequently not practical for on-farm use. Using the
combination of short-term MGA feeding and PGF2α females were administered MGA for
5 days and administered PGF2α following the end of MGA treatment. However, Moody et
al. (1978) reported that when using this approach pregnancy rates remained low. When
the MGA treatment was extended to 7 days and combined with PGF2α, pregnancy rates
among beef cattle still remained low (Patterson et al., 1986; Beal et al., 1988). A protocol
was then developed where MGA was administered for 14 to 16 days and PGF2α was
administered 16 to 17 days following the last feeding of MGA (Brown et al., 1988). This
protocol resulted in increased pregnancy rates which were attributed to a 17 day delay
from MGA removal and the administration of PGF2α. This delay would allow for the
majority of the females to be in diestrus at the time of PGF2α administration (King et al.,
1982). This amendment of the delay from last feeding of MGA to PGF2α administration
was combined with a more abbreviated period of MGA administration (~14 days) to
further improve pregnancy rates following estrous cycle synchronization and AI in cattle.
Mauck et al. (1988) compared the 14-day MGA feeding period with a 7-day
feeding period and determined that the 14-day protocol was superior in pregnancy rates
and degree of synchrony. Later, Coleman et al. (1990) evaluated the effect of a 21-day
MGA treatment period with or without subsequent PGF2α administration (14 days later)
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and found that pregnancy rates were markedly reduced without PGF2α administration.
Today, the optimal MGA protocol for beef cows and heifers is a 14-day MGA treatment
period followed by PGF2α administration 15-days later for cows and 17-days later for
heifers (Kesler et al., 1996).
MGA has also been utilized for estrous cycle synchronization of postpartum
cows. Using the current MGA protocol (14-day MGA administration followed 17 days
later by administration of PGF2α) and AI in postpartum cows acceptable estrual
response, pregnancy rates and increased weight gain were achieved (Yelich et al.,
1988). Yelich et al. (1995a) concluded that MGA was effective in postpartum females
provided that synchronization was initiated when cows had a good body condition score.
In addition, it was reported that 48-hour calf removal increased synchronized pregnancy
rates in postpartum cows synchronized with MGA (Yelich et al., 1995b). The pregnancy
rates achieved following synchronization with MGA and AI in postpartum cattle were in
agreement with the pregnancy rates reported for postpartum cows by Patterson et al.
(1995).
In prepubertal and pubertal heifers, synchronization rates and pregnancy rates
were consistently higher following MGA-estrous cycle synchronization and AI compared
with nontreated control heifers and heifers undergoing estrous cycle synchronization
with other progestins (Deutscher et al., 1989; Goehring, 1989; Jaeger et al., 1992;
Patterson and Corah, 1992).
There have been attempts to test the effectiveness of MGA in non-ruminant
species. Loy and Swan (1966) demonstrated that 10 to 20 mg per day per head of MGA
or 100 mg injections of MAP (6α-methyl-17α-acetoxyprogesterone) were not effective in
controlling estrus or ovulation in the mare. It was concluded that P4 was catabolized to
the urinary metabolite 5α allopregnane rather than its primary urinary metabolite 5β
pregnane. This may have altered the progesterone compound rendering it inert in the
mare. Additional studies demonstrated that although MGA or norgestomet would support
pregnancy in bilaterally ovariectomized cows, however, they were ineffective in
maintaining pregnancy in bilaterally ovariectomized mares (McKinnon et al., 2000).
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Altrenogest for Control of Reproduction in the Mare
Altrenogest (allyltrenbolone, ALT) is an orally active progestin developed for use
in the horse. Altrenogest has been chemically modified by addition of a hydroxyl group
and 3 carbon chain placed on carbon 17 of the progestin (Peters, 1992). Research has
demonstrated that ALT has low anabolic activity and is 20 times less potent than
testosterone or similar progestins when compared for effects on muscle growth in
castrated rats (Peters, 1992). It was further noted that 50% of altrenogest residue
becomes bound to binding proteins and becomes biologically inactive. Based on these
findings (Peters, 1992), the withdrawal period for ALT (known commercially as
Regumate) for equids is 15 days.
There have been no deleterious effects reported of ALT administration to healthy
cycling mares when fed for 86 days at a rate of 0.044 mg per kg of body weight, 0.132
mg per kg of body weight or 0.220 mg per kg of body weight (Shideler et al., 1983). This
observation was based on evaluations for differences in white blood cell counts, platelet
number, creatinine levels, cholesterol, signs of inflammation and overall organ
appearance following necropsy.
The initial development of ALT was for controlling estrus in mares. Squires et al.
(1979) demonstrated that when ALT was orally administered to estrual mares (early in
the breeding season) at a rate of 0.044 mg per head per day for 12 days, behavioral
estrus ceased within 3 days following initiation of ALT treatment and estrus remained
inhibited for the duration of treatment. However, ovulation was not inhibited in all ALTtreated mares during this time. Following the cessation of ALT treatment, ALT-treated
mares had a mean interval to estrus of 4.5 days and had a significantly shorter time
interval from the end of treatment to ovulation and the onset of estrus to ovulation
compared with nontreated mares.
Squires et al. (1979) also reported that initially transitional mares treated with
ALT had a high incidence of continuous estrus compared with a high incidence of
discontinuous estrus seen in control-nontreated transitional mares. In this initial testing
of ALT, Squires et al. (1979) tested for the most efficient stage of estrous cycle to begin
administration of ALT for estrous cycle synchronization and it was reported that the
interval from ALT-treatment to estrus was shorter when ALT-treatment was initiated
during diestrus compared with that of estrus. Although ALT was effective in the control of
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estrual behavior and in estrous synchronization, the inability of ALT to block ovulation in
all mares made this 12-day treatment period unlikely to be the most effective regime,
since it did not allow for sufficient time for CL regression to occur before the end of
treatment (Squires et al., 1979).
Further testing of ALT in transitional mares revealed that it was effective in
abbreviating the transition period in these females (Turner et al., 1981; Webel and
Squires, 1982). When transitional mares were administered ALT (0.044 mg/head/day)
for 15 days there was a significant decrease in the length of estrus and the number of
inseminations required without a decrease in pregnancy rate (Turner et al., 1981). Webel
and Squires (1982) reported similar effects of ALT-treatment in transitional mares and
demonstrated that ALT-treatment during late transition significantly decreased the
interval from treatment to pregnancy.
In the mare, the effect of ALT-treatment on follicular development appears to be
dependant on the size of follicles present on the ovary at time of ALT administration. If
ALT was administered when follicles ≥ 20 mm were present, follicular growth was
suppressed and the number of large follicles (>30 mm) and follicle diameter was
reduced (Turner et al., 1981; Webel and Squires, 1982; Squires et al., 1983). In these
reports of a reduction in development of large follicles (>30 mm) and follicle diameter
usually occurred during a reported increased FSH levels towards end of treatment
period (Turner et al., 1981 and Squires et al., 1983). Subsequently, Wiepz et al. (1988)
demonstrated that ALT and not norgestomet (another progestin) suppressed follicular
activity in late transitional mares and the rise in serum LH following ALT removal was
greater than detected in nontreated control females.
Although ALT had been shown to improve breeding efficiency in transitional
mares, the failure to block ovulation in the mare remained a problem. When ALT was
administered to estrual mares, ovulation occurred in 75% (9 of 12) of treated females
and CL were formed in all of these females (Squires et al., 1983). However, when PGF2α
was administered to ALT-treated cycling, ovulation in diestrous mares was blocked in
60% (3 of 5) of the mares and behavioral estrus was suppressed in all mares (Lofsedt
and Patel, 1989). It was also noted in the cycling mares that large follicles could develop
during ALT treatment and that ALT had only 60% of the binding affinity of P4 in the
hypothalamus and that amount may not be sufficient to block gonadotrophin release. In
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support of this theory, it was shown that P4 in doses of 100 mg per head per day or
greater administered mid-cycle were successful in inhibiting behavioral estrus and
ovulation, but 50 mg per head per day of P4 would inhibit behavioral estrus only (Loy and
Swan, 1966). The discrepancies reported on the efficiency of blocking ovulation and
follicular dynamics are probably due to the dose administered as well as the phase of
reproductive transition at which ALT was administered.
ALT has also been utilized for asynchronous embryo transfer in the mare (Pool et
al., 1987). In females treated with ALT immediately following ovulation, that received a
day-6 or day-7 embryo on day 2 to 5 of ALT-treatment could became pregnant. In the
same experiment it was noted that when ALT-treatment was initiated at day-9 or greater
following ovulation, there was an increased pregnancy rate when recipient females
received day-6 or day-7 embryos. These findings demonstrated that early pregnancy
could be supported with ALT administration. Furthermore, these findings demonstrate
that ALT-treatment could increase the number of females in a group available for use as
embryo transfer recipients. Also, supplementation with ALT has been demonstrated to
prevent embryo loss in 60-day or less pregnant mares that were administered
Salmonella typhimurium (endotoxin) (Daels et al., 1991).
Not only has ALT been demonstrated to support early pregnancy in the absence
of luteal tissue, it has been reported to support pregnancy through gestation in the
ovariectomized mare (Hinrichs et al., 1985; Hinrichs and Kenny, 1987; Hinrichs et al.,
1987). Hinrichs et al. (1985), Hinrichs and Kenny (1987) and Hinrichs et al. (1987)
reported that pregnancies could be established in ovariectomized recipient mares with
supplementation of 300 mg of P4 daily until ~90 days of gestation. However, when 22 mg
of ALT daily was used to support pregnancy, it was ineffective at maintaining pregnancy
to term (Hinrichs et al., 1986). This finding was in contrast to that of McKinnon et al.
(1988), who demonstrated that 22 to 25 mg of ALT administered daily to ovariectomized
pregnant mares was capable of supporting pregnancy to term.
With ALT-treatment prior to and after embryo transfer there was concern
regarding postnatal effects on the developing offspring (Naden et al., 1990a; Naden et
al., 1990b). With a gestation of ~336 days, mares as with cattle must become pregnant
while nursing an offspring. Therefore, it would be of importance to determine detrimental
effects of ALT on lactation and foal growth. However, there have been no reports of
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detrimental effects of ALT on the developing offspring. Following a series of GnRH
challenges in stud colts produced from ALT-treated dams (ALT administered from day20 to day-325 of gestation) there were no differences as a result of treatment of the dam
with ALT (Naden et al., 1990a). In addition, no differences were found in the time to
puberty or in hypothalamic function of fillies produced from dams treated with ALT from
day-20 to day-325 of gestation (Naden et al., 1990b). Furthermore, Sigler et al. (1989)
demonstrated that treatment with 0.044 kg ALT per head per day to lactating mares had
no effect on milk yield, milk composition or foal growth as compared with untreated
control mares.
Altrenogest in Control of Reproduction in Swine
In an early report on the use of ALT for the synchronization of estrus and
ovulation in gilts, 33 of 38 gilts exhibited estrus within 2 to 7 days following the last ALT
administration, when 12.5 mg of ALT per head per day was administered for 19 days
(Davis et al., 1979). Although an increase in ovulation rate with no decrease in
fertilization rates was noted an increased incidence of cystic follicles occurred in ALTtreated gilts. It was proposed that the increase in cystic follicles may have been a
response to the failure of these females to consume the entire dose of ALT. Following
this initial testing of ALT in gilts, it was demonstrated that the minimum dose required for
effective synchronization of estrus in gilts or sows was 10 to 20 mg of ALT per head per
day (Kraeling et al., 1981), while doses of 20 to 40 mg of ALT per head per day were the
most effective for synchronization of estrus and ovulation, without induction of follicular
or luteal cysts. In this study, the interval from the last treatment with ALT to the onset of
estrus was significantly longer for gilts (5.4±0.3 days) compared with that of sows
(6.0±0.2 days).
In conjunction to determining optimal dosage of ALT, research continued on
determining the optimal length of ALT administration. Davis et al. (1979) reported an
increased ovulation rate in gilts treated with 12.5 mg of ALT for 19 consecutive days,
while Pursel et al. (1981) demonstrated that gilts treated with 15 mg of ALT for 18
consecutive days had a significantly greater live litter size at birth and weaning
compared with nontreated control gilts. In a later study, synchronized pregnancy rates
were not different for ALT-estrous cycle synchronization (70.7%) compared with
nontreated controls (73.5%).
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The consistent efficiency of estrous cycle synchronization and ovulation in gilts
resulting from ALT treatment, allowed for improved timed insemination opportunities in
swine breeding herds. Davis et al. (1985) reported that pregnancy rates, litter size and
live pigs at farrowing were not different for gilts treated with 15 mg of ALT for 18 days
and time inseminated at 5, 6 and 7 days following ALT-treatment cessation. It should be
noted that the timing of insemination after ALT withdrawal is influenced by breed of gilts
or sows (Martinat-Botté et al., 1985). It was later reported that ALT-estrous cycle
synchronization could increase the number of gilts detected in estrus compared with the
nontreated control gilts (Davis et al., 1987). An increased litter size has been reported in
ALT-treated gilts mated at their pubertal estrus (Davis et al., 1987), although there have
been other reports that ALT treatment during the prepubertal period was ineffective in
improving breeding success (O’Reilly et al., 1979; Kraeling et al., 1982; Wood et
al.,1992)
To further increase the precision of control of estrus and ovulation in gilts, the
ALT-treatment was combined with gonadotropin administration. These efforts resulted in
a decrease in the time from end of ALT treatment to onset of estrus without changing
ovulation rate or litter size (Varley et al., 1989).
The effects of ALT on ovarian activity in gilts are similar to the effects reported in
the mare. ALT treatment at 15 mg per head per day effectively suppressed behavioral
estrus, however, the time from ALT withdrawal to the onset of estrus was dose
dependant with higher doses of ALT hastening the onset of estrus (Redmer and Day,
1981). Differences in ovulation rate were not detected in this study, although Diehl et al.
(1986) demonstrated that ALT-treatment of inbred pigs with genetically reduced
ovulation rates, increased the ovulation rate without affecting fertilization. There was a
decrease in the number of ovulatory-size follicles (>8 mm) in gilts that received 15 mg of
ALT for 18 days but not in gilts that received 2.5 mg for 18 days (Redmer and Day,
1981). In contrast, gilts that received a higher dose of ALT (15 mg) had a reduction in
the number of cystic follicles compared with gilts that received a low dose (2.5 mg).
Estradiol levels were elevated in gilts treated with low daily doses of ALT, while
the circulating LH and P4 levels were unaffected by this treatment. Conversely, E2 levels
decreased in gilts treated with high daily doses of ALT and LH and P4 levels were
unaffected (Redmer and Day, 1981). These findings were validated by those of Martinat-
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Botté et al. (1985), who reported that the decreased E2 levels during treatment with high
doses of ALT (≥15 mg), due to a decrease in large follicles (>6 mm), which are the
predominant source of E2. In support of this theory, Guthrie and Bolt (1985)
demonstrated that a high dose of ALT (20 mg daily) prevented the estrogen-triggered LH
surge and behavioral estrus in eCG-treated gilts.
It has been hypothesized that the major factor contributing to piglet survival at
birth was fetal hypoxia occurring during parturition (Randall, 1972). Therefore, the ability
to control the time of parturition in the sow could increase the number of live births by
allowing management to increase surveillance during this time. In sows, the time of
parturition can be controlled with PGF2α but the onset of parturition often ranges from 8
to 48 hours following PGF2α treatment (Guthrie, 1985). P4 has also been used to control
the time of farrowing in sows, however, if administration is continued past day 114 of
gestation problems with lactation and uterine involution occur (Nellor et al., 1975).
Administration of 16 mg of ALT per day from day 111 to 118 in pregnant sows followed
by E2 treatment 6-hours following last ALT administration successfully delayed farrowing,
but there was an increase in stillborn piglets (Varley and Brooking, 1981). Following this
observation Guthrie et al. (1984) demonstrated that 20 mg of ALT (days 109 to 112)
followed by PGF2α treatment hastened the onset of parturition after PGF2α administration
compared with females treated only with ALT. There was no increase in stillbirths
observed in the ALT+PGF2α-treated females compared with control-treated females
during this experiment. In a subsequent report the lack of increase in stillbirths noted
with ALT-PGF2α controlled parturition protocol was validated by Guthrie et al. (1987).
After determining that ALT could function as a progestin in swine researchers
began to work in earnest to determine if ALT administration could decrease the interval
from farrowing to estrus. Treatment with ALT from 7 days prior to weaning decreased
the number of sows that experienced delayed estrus without decreasing the degree of
synchrony in the subsequent estrus following group weaning (Martinat-Botté et al.,
1985). Stevenson et al. (1985) reported that treatment with ALT for 7 days prior to
weaning (4-week lactation period) actually increased the interval to estrus 14.5±0.2 days
in ALT-treated females compared with 5.6±0.2 days for the nontreated control sows but
increased the farrowing rate of sows inseminated at their first estrus following weaning.
In early weaned sows (~2 weeks of lactation), ALT treatment increased the number of
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post-weaned sows (97%) detected in estrus following weaning (Koutsotheodoros et al.,
1998). Also, ALT-treated sows had an increased ovulation rate and there was tendency
for increased embryo survival rate in these females found at the time of sacrifice.
Altrenogest in Control of Reproduction in Exotic Species
There have been few reports on the use of ALT in species, other than the horse
or the pig. However, Schwarzenberger et al. (1999) reported an okapi, that had
experienced five abortions due to placental deficiency, was administered 10 mg of ALT
per day from day-50 post-mating until 30 days prior to expected parturition. In this
experiment, the dose of ALT was reduced by 1 mg per day over a 10-day period ending
at the end of ALT-treatment. A female calf was born from this female and no deleterious
health affects were noted in the dam during ALT-treatment. The female calf did die 30
days following parturition, however, this was due to kidney hypoplasia that was not
linked to ALT-treatment.
Effects of P4 on the Oviducts during Early Pregnancy
Disruption of Fertilization
In domestic farm animals (e.g., cattle and sheep), P4 levels are relatively low
during ovulation and fertilization. At 14 hours after ovulation in the cow, circulating P4
levels remain below 0.5 ng/ml (Henricks et al., 1970; Wettemann and Hafs, 1973) and by
day 3 post-ovulation levels are still below 2 ng/ml (Henricks et al., 1971; Wettemann and
Hafs, 1973), however, by 6 days following ovulation P4 levels in both pregnant or
nonpregnant cows are ≥3 ng/ml and peak around day 14 post-ovulation (Henricks, et al.,
1970, Wettemann and Hafs, 1973).
Low P4 levels during ovulation and fertilization have been shown to be beneficial
to fertility in many species. Chang (1967) demonstrated that in vivo fertilization could be
effectively disrupted by administration of P4, at the time of fertilization in rabbits. In
addition, it was noted that when rabbits were treated during estrus with P4, unfertilized
ova and degenerate embryos were often recovered from the uterus. Chang (1967)
suggested that the P4 treatment hastened embryo transport from the oviduct to the
uterus prior to the embryo developing to a stage capable of surviving in the uterus. In
another polytoccus species, the pig, increased P4 levels shortly prior to ovulation was
proposed to be the cause of increased polyspermy at fertilization (Day and Polge, 1968).
Hunter (1968) demonstrated that P4 administration to hamsters 3 days prior to the time
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of fertilization greatly reduced the number of fertilized oocytes. Decreased fertilization
rates, as a result of P4 administration prior to ovulation, are likely a response of P4 downregulating LH release thereby delaying ovulation and lowering fertility (Batra and Miller,
1985; Thiery and Martin, 1991). However, this hypothesis does not explain the increased
frequency of disruption of fertilization when P4 is administered following ovulation.
The disruption of fertilization when P4 treatment was initiated prior to mating was
shown to be caused, in part, by decreased sperm transport in the reproductive tract
(Nutting and Mares, 1970). In contrast, in utero deposition of semen in P4-treated rabbits
increased fertilization rates. The theory of P4 causing disruption of fertilization was
strengthened in the pig, when P4 administration 8 hours prior to ovulation resulted in an
increased incidence of polyspermy compared with nontreated control females (Hunter,
1972). It was concluded that P4 administration caused a relaxation of endometrial tissue
of the oviduct allowing more spermatozoa to reach the ampullary-isthmus junction (site
of fertilization) contributing to the increase in polyspermy in swine.
Chang (1969) demonstrated in pseudopregnant rabbits induced to ovulate midcycle and in P4-treated rabbits there was a greater decrease in fertilized oocytes, and an
increased incidence of oocytes collected from the uterus and increased embryo
degeneration compared with that of nontreated control does. It was concluded the longer
the exposure period to P4 the more dramatic the disruption to fertilization and embryo
transport. Even though the majority of these oocytes were unfertilized the oocytes that
did undergo successful fertilization and rapid transport to the uterus, they were still
capable of developing. When these 1-day old fertilized oocytes were recovered from
these females and transferred to control treated females, 65% of the embryos continued
development.
In contrast, when rabbit does at 23 days of pseudopregnancy were treated with
P4 during estrus and embryos were recovered on day 2 following estrus, 87% of these
treated rabbits had viable embryos, but when day-22 pseudopregnant rabbits were
treated the same way and embryos recovered on day 6, only 45% of the embryos were
viable (Chang, 1969).
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Effect on Oviductal Glycoprotein
The environment in which oviduct-stage embryos develop is believed to be under
the control of circulating E2 and P4 (Leese, 1988). It has been demonstrated that in vitro
cultures of rabbit oviduct epithelium synthesized a sulphated glycoprotein identical to
those demonstrated to exist in oviductal fluid (Barr & Oliphant, 1981; Oliphant and Ross,
1982; Oliphant et al., 1994). A similar glycoprotein was then discovered in sheep and
was termed estrogen associated glycoprotein (EAP) (Sutton et al., 1984). It is believed
that P4 stimulates the production, while E2 stimulates the release, of these glycoproteins
(Leese, 1988). In support of this hypothesis, the secretion of these EAPs increases
during estrus and decreases by days 3 to 4 following estrus in the cow at the time the CL
is becoming mature and increasing P4 secretion. Gandolfi et al. (1989) demonstrated
that the oviduct epithelial cells secrete specific glycoproteins during specific time
intervals in which the embryo transverses the oviduct.
Kapur and Johnson (1986) reported that the embryo could sequester oviductal
proteins into the pervitelline space possibly to later serve as a source of amino acids for
further development. The role oviductal protein plays in embryo development is not
completely understood. However, Whittingham (1968a, 1968b) reported that mouse
embryos cultured on oviduct tissue collected during metestrus had a higher rate of
development than mouse embryos cultured on oviduct tissue collected during diestrus.
This finding was further supported by the finding that fertilized sheep oocytes had higher
cleavage rates when cultured in the presence of EAPs (Nancarrow and Hill, 1995).
However, when sheep zygotes were cultured in the presence of EAPs the cleavage rate
was reduced (Nancarrow and Hill, 1995). These observations may indicate a role of P4
dominance over E2 to suppress of EAP secretion at different stages of embryo
development in the oviduct.
There is still confusion regarding the mechanism of how P4 is involved in EAP
secretion. It was demonstrated that oviduct tissue from the ampulla secreted more
sulfated glycoproteins in the presences of E2 and then P4 when compared with that of
nontreated control rabbit ampulla tissues (Erickson-Lawrence et al., 1989). This
demonstrated that the time of maximum glycoprotein secretion in the oviduct is
concurrent with increasing P4 influence over the oviduct, as the addition of E2 alone
failed to increase sulfated glycoprotein secretion over that of nontreated control
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(Erickson-Lawrence et al., 1989). Thus, it may be concluded that P4 exerts some type of
control over oviductal glycoprotein secretion while the embryo is developing within the
oviduct.
The effect of P4 on EAPs is a possible result of P4 effects on oviductal fluid
release and EAP sequestering. Cline et al. (1977) demonstrated in mice that P4
administration following estrus resulted in a greater accumulation of oviduct fluid in the
ampulla region compared with E2-treated or nontreated control pregnant females. Of the
embryos collected from these females, those collected from E2-treated females had the
lowest developmental rates and had significantly more degenerate embryos from the
nontreated control and P4-treated groups.
These results suggest that one of the roles of P4 during embryo development in
the oviduct is to negate the deleterious effects of asynchronous E2. In cattle, with
impaired fertility due to persistent dominant follicles, there is an increase in E2 (Fike et
al., 1997). This increase has been demonstrated to decrease the amount of glycoprotein
adversely altering the oviductal microenvironment in which the embryo develops (Binelli
et al., 1999). The mechanism by which P4 can regulate these secretions has not been
reported. However, localization of P4 in the bovine oviduct ipsilateral to the ovary bearing
the CL has been reported (Wijayagunawardane et al., 1996). It was demonstrated in
cattle that the ipsilateral oviduct contained a significantly greater concentration of P4
during early pregnancy than during the luteal phase although no differences were
detected between the follicular phase and the interval post-ovulation.
Effects of P4 on Embryo Transport into the Uterus
In various mammalian species, P4 controls the transport of embryos from the
oviducts to the uterus. Roblero and Garavagno (1979) demonstrated that when pregnant
mice were ovariectomized on day-2 post-coitus, embryo transport into the uterus was
inhibited. Addition of E2 failed to reverse this affect, while the supplementation of P4
initiated and continued normal transport of embryos into the uterus. Kendle and Lee
(1980) reported that the administration of antiprogestin compounds (day 1, 2 or 3 postmating) to pregnant mice also inhibited normal embryo transport to the uterus. However,
P4 supplementation again initiated normal transportation, although there was a need for
a continued presence of P4 to maintain embryo transportation to the uterus. Similarly,
when pregnant rats were ovariectomized on days 1 to 3 following ovulation, embryo
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transport was disrupted (accelerated transport of some embryos and retention of others)
(Forcelldo et al., 1982). However, when P4 was supplemented following ovariectomy,
embryo transport was restored to normal. Furthermore, Fuentealba et al. (1988b)
reported that embryo transport in nonpregnant rats (embryo transfer recipients) occurred
more slowly than in pregnant rats. This could be due to differences in P4 levels in the
oviducts of pregnant and nonpregnant rats, as previously shown in cattle
(Wijayagunawardane et al., 1996). These findings supported the hypothesis that P4
controls embryo transport to the uterus.
In sheep, Holst (1974) reported that 8-cell embryos arrive in the uterus ~66 hours
following ovulation. However, when day-2 sheep embryos were transferred into
untreated ovariectomized ewes on day 2, embryo transport was disrupted as in the rat
(Forcelledo et al. 1982). Interestingly, normal sheep embryos were found remaining in
the uterus of these untreated ovariectomized ewes when transferred into the uterus on
day 2 (Moore et al., 1983). Supplementation of E2 and P4 beginning 5 days prior to
transfer and continued until embryo recovery on day 2 in ovariectomized pregnant ewes
failed to restore normal embryo transport. It was hypothesized that this abnormal
transport response was from an inappropriate in vivo hormone levels. The results are
clear, that the disruption of endogenous P4 can disrupt normal embryo transport, which
further indicates a controlling mechanism of P4.
In cattle, ovum transport through the ampulla of the oviduct occurs rapidly (8 to
10 hours following ovulation), most likely from cilia action (EL-Banna and Hafez, 1970).
Embryo transport through the isthmus into the uterus, however, occurs more slowly and
is likely under the control of muscular contractions. EL-Banna and Hafez (1970) further
reported that embryos remained in the isthmic region for sometime before they were
transported into the uterus, 3.5 to 4 days following ovulation. In superovulated females
under the influence of higher P4 levels, embryos were found to be transported more
quickly though the oviducts, presumably by decreasing the effect of an isthmus block
(EL-Banna and Hafez, 1970). Later, Crisman et al. (1980) further verified that P4 was the
controlling factor in embryo transport in the cow. In naturally mated heifers,
administration of P4 24 hours following the onset of estrus stimulated the rate of embryo
transport into the uterus. In contrast, the administration of E2 failed to increase the rate of
embryo transport over that of embryos from nontreated control females.
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It is unknown whether P4 exerts a controlling influence on embryo transport in the
mare. Weber et al. (1991) found that when pregnant mares were administered PGE2,
significantly more embryos (6 of 11) were recovered in the uterus compared with vehicle
and nontreated control pregnant mares. They also demonstrated that the equine embryo
was capable of synthesizing and secreting PGE2 at this time and that PGE2 controlled
the rate of embryo transport into the uterus of the mare instead of P4. Mann and
Lamming (2001) have proposed that early P4 administration in the cow could effectively
alter the ratio of PGE2 to PGF2α synthesis in the bovine uterus in favor of PGE2, although
it is unknown if this altered synthesis pattern occurs in the mare.
Effects of P4 on Uterine Growth and Proliferation
In mammals, the uterus is composed of two primary functional layers; the
endometrium and the myometrium, with secretory glands found in the endometrial layer
(Perry, 1945). The endometrium is composed of two tissue types, a luminal epithelium
and glandular epithelium (Perry, 1945). Generally, the bovine endometrium is populated
by a large number of aglandular carnucles, which are stromal protrusions covered by
luminal epithelium (Wimsatt, 1950; Atkinson et al., 1984). The area between the
carnucles is densely populated with endometrial glands that produce secretions which
promote embryo development (Bazer, 1975). These secretions are composed of a
various assortment of enzymes, growth factors, lymphokines, hormones and proteins.
In the mouse uterus, it has been demonstrated that epithelial cells proliferate in
response to E2 during the early stages of pregnancy (Finn and Martin, 1967). However,
on day 3 of pregnancy there is a transition from increased presence of epithelial cells to
an increase presence of stromal cells (glandular cells), which are regulated by P4 (Martin
and Finn, 1968). Tachi et al. (1972) reported that P4 administration could increase the
number of synchrony of stromal cell proliferation in the mouse.
There is evidence that P4 can act on the uterine glands in concert with the growth
factors that it regulates. Piva et al. (1996) reported that stromal cells cultured in vitro in a
serum-free culture medium were stimulated to synchronously re-enter the cell cycle by
addition of basic fibroblast growth factor (bFGF) and P4. Rider et al. (1998)
demonstrated that this effect could be duplicated with other growth factors (epidermal
growth factor, EGF and transforming growth factor alpha, TGF-α) in the presence of P4.
This effect is a result of synergism between the growth factors and P4, as it was
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demonstrated that P4 or the growth factors alone could not duplicate this effect (Rider et
al., 1998).
In addition to cell growth, P4 can also increase the vascular growth and blood
flow to the uterus (Johnson et al., 1997). Finn and Martin (1967), Martin and Finn (1968)
and Johnson et al. (1997) also demonstrated that P4 supplementation in ovariectomized
sheep stimulated tissue remodeling within the uterus. In addition, Johnson et al. (1997)
reported that P4 treated ovariectomized sheep had increased uterine weights. This is not
unexpected since P4 has been demonstrated to increase cell growth and proliferation of
uterine endometrium (Rider, 1998).
Uterine P4 receptors (PR) have been shown to be stimulated by the pre-ovulatory
E2 surge (Ing and Tornesi, 1997). In response to E2 administration in ovariectomized
ewes, PR upregulation was prolonged in the middle and deep endometrial stromal
tissues, where the majority of the uterine glands are located (Ing and Tornesi, 1997).
However, the greatest expression of PR occurred in the superficial lining of the luminal
epithelium, where the embryo interacts with the uterus. These PR were found to be
expressed within 24 hours following administration of E2.
Zheng et al. (1996) demonstrated that E2 receptors (ER) and PR were inversely
related during early pregnancy in ovine uterine tissues, with the exception of the luminal
stroma. Kimmins and MacLaren (2001) have reported that PR were predominantly,
absent in the luminal epithelium in cycling and pregnant cows. There was also a
reduction in PR in the glandular epithelium layer and in the carnucular regions compared
with intercarnuclar endometrium regions in pregnant cows. In addition, it was reported
that there was a reduction in oxytocin receptors (OR) in the luminal epithelium of
pregnant cows, which may indicate a role of PR reduction in maternal recognition of
pregnancy. The role of P4 in maternal recognition of pregnancy will be reviewed later in
this chapter.
During pregnancy, P4 exerts a calming effect on myometrial contractions of the
ovine uterus (Rhodes and Nathanlielsz, 1990) preventing the disturbance of the
developing embryos once they have entered the uterus. Bonafos et al. (1995) reported
the uterine tone changes morphologically and that contractions increase during the preovulatory phase and then greatly decrease following ovulation in the cow.
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Effects of P4 on the Synthesis and Secretion of Uterine
Proteins and Growth Factors
It is believed that oviductal protein secretion can improve embryo development
and that uterine protein secretion plays an equal or greater role in embryo survival.
Dixon and Gibbons (1979) reported that uterine secretions from P4-treated nonpregnant
cows yielded five major protein fractions. Two of these fractions were composed of
serum proteins, while the other three fractions contained a minimum of nine nonserum
proteins that contained acid phosphatase and lactoferrin. When bovine uterine
endometrial extracts were cultured in vitro, the majority of bovine uterine-specific
proteins tended to be acidic polypeptides opposed to the basic polypeptides that
predominate in the gilt, ewe and mare (Bartol et al., 1985).
Lactoferrin, a well known histotroph protein, has been reported to have
antibacterial properties in women (Masson et al., 1968). Bazer (1975) reported that
many of these proteins in the pig have the same enzymatic and P4 binding properties as
those found in allantoic fluid from pregnant sows. These allantoic proteins were
produced and secreted from uterine endometrial glands and absorbed via the placenta
and sequestered within the allantoic fluid.
Prior to these discoveries, other unique uterine proteins have been described.
Krishnan and Daniel (1967) discovered blastokinin, a unique uterine protein believed to
stimulate blastocyst formation in the rabbit. It was later demonstrated that blastokinin
was more important for the growth of blastocyst-stage rabbit embryos rather than for
development to the blastocyst stage (Whitten and Biggers, 1968; Roberts et al., 1976a).
It was later realized that blastokinin and another uterine-specific protein termed
uteroglobin were the same compound (Bazer, 1975).
In a review of uterine secretions in the pig, it was reported that uterine specific
proteins were induced by P4 (Davis and Blair, 1993). Chen et al. (1975) and Basha et al.
(1979) have reported that uteroferrin release from the uterine glands and transfer of iron
from uterus to the conceptus was controlled by P4. Roberts et al. (1976b) reported that
lysozyme, β-hexosamindiase and cathepsin were also P4 induced uterine proteins, in
swine. Uteroferrin-associated polypeptides (Davis and Blair, 1993), retinol-binding
protein (Adams et al., 1981), plasmin and trypsin inhibitor (Fazlezbas et al., 1985) and βendorphin (Li et al., 1991) have been found in uterine secretions of the pig and appear to
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be regulated by P4. Furthermore, the release of a uterine specific protein termed “purple
protein” has been reported to be under the controlled by P4 (Squires et al., 1972).
Along with the numerous uterine proteins present in uterine secretions, there are
many growth factors present as well. Brigstock et al. (1989) demonstrated that EGF,
insulin-like growth factor I (IGFI), insulin-like growth factor-binding protein (IGFIBP),
colony stimulating factor (CSF), acidic-fibroblastic growth factor (aFGF) and bFGF were
present in the uterine fluid of a multitude of species. In addition, Simmen et al. (1988)
demonstrated that an EGF-like peptide was present in the uterine secretions of the pig.
Many of these factors were reported to stimulate uterine cell growth and endometrial
glandular development (Brigstock et al., 1989). Also, the synthesis and release of IGFI,
IGFIBP and CSF are apparently regulated by P4 (Brigstock et al., 1989).
Different factors can affect the normal pattern of uterine secretions of the female.
In pigs, it has been reported that pubertal females are capable of producing all known
uterine specific proteins, however, the quantity was markedly reduced compared with
that of mature females (Murray and Grifo, 1976). However, when embryos recovered
from adult ewes were transferred to adult ewes and ewe lambs, there were no
differences in lambing rates (Quirke and Hanrahan, 1983). It was concluded that uterine
function was not a likely cause of decreased lambing rates in younger ewes but their
conclusion did not account for the fact that the embryos transferred were all exposed to
the uterine environment of a mature female during early embryonic development.
Gustaffson and Larson (1983) have shown that when day-7 embryos were
collected from repeat breeder cows (RPB) and transferred to RPB females or fertile
control females, pregnancy rates were low in both treatment groups. However, when
day-7 embryos were collected from fertile cows and transferred to RPB females and
control females, the pregnancy rates were normal for embryo transfer (Gustaffson and
Larson, 1985). These studies suggest that exposure to a “healthy” uterine environment
from day 1 to day 7 of the estrous cycle may be critical during early embryo
development.
Comparisons between the uterine function of “fertile” and “infertile” cows have
demonstrated that there are differences between total protein present in uterine
flushings as early as day 5 of the estrous cycle in RPB (infertile) females compared with
control (fertile) females (Guise and Gwazdauskas, 1986). This difference continued
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through day 10 but was no longer apparent by day 15 of the estrous cycle. P4 levels
were also reported to be altered in RPB cows and were suggested to be a cause of the
differences in uterine protein concentrations (Guise and Gwazdauska, 1986). In addition
to lowered total uterine protein, RPB females have lower endometrial glycogen and
nucleic acid content compared with fertile females (Bugalia et al., 1988). The, RPB
females were found to have significantly less acid phosphatase and alkaline
phosphatase enzyme activity in the uterine endometrium. The lower alkaline phophatase
activity is indicative of a disruption or deficiency in carbohydrate metabolism within the
uterine environment.
Deficiencies in uterine metabolism have also been demonstrated in cows
carrying abnormal developing embryos, as determined by embryo recovery on day 7 of
gestation. Specifically, uterine flushings from these females possessed significantly
more glucose and protein compared with uterine flushings from cows carrying normal
embryos (Wiebold, 1988). There was a significantly higher protein content (during first 7
days of pregnancy) in the uteri of females carrying an abnormal developing embryo,
which is opposite to what had been previously reported. However, 70% of the abnormal
embryos were at the cleavage stage on day 7 and therefore, these findings could
represent an artificial increase in uterine protein due to the absence of a viable embryo
to metabolize the uterine carbohydrates and proteins.
An elaborate comparison was made between naturally mated ewes that had
received a day-6 embryo (estrus = day 0) on day 4 (asynchronous transfer), a day-6
embryo on day 6 (synchronous transfer) or a day-6 embryo on day 10 (asynchronous
transfer) and naturally mated ewes that received a day-9 embryo on day 6
(asynchronous transfer), a day-9 embryo on day 9 (synchronous transfer), day-9 embryo
on day 12 (asynchronous) or a day-9 embryo on day 10 of a naturally mated ewe treated
with P4 on days 4 to 9 post-estrus (Wilmut and Sales, 1981). It was discovered that there
were no differences in the total protein recovered from endometrial tissue cultures from
these ewes, however, there were differences between treatment groups in the levels of
30 different proteins evaluated from ewes. These findings demonstrated that the
presence of an advanced stage embryo could accelerate uterine function to match the
stage of the embryo and not the stage of the gestation (Ashworth and Bazer, 1989).
These findings also demonstrated neither P4 nor pregnancy altered total protein
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production, however, they altered the levels of individual proteins (Ashworth and Bazer,
1989). Alterations of uterine secretion during P4 supplemented from days 1 to 5 of early
pregnancy have also been reported in the cow (Garrett et al., 1988).
Interestingly, differences in the endometrial morphology and secretory status of
pregnant and nonpregnant females have also been found (Bonafos et al., 1995). As
determined via ultrasonography, pregnant females had a significantly greater
endometrial echo texture score beginning on day 4 of the estrous cycle (estrus = day 0)
compared with nonpregnant females. The echo texture of the uterus signifies the
thickening for the uterus in preparation of supporting an embryo.
Geisert et al. (1988) reported that as pregnancy continued the complexity of
polypeptide synthesis increased. In addition, there is an increase in two low molecular
weight basic polypeptides in endometrial tissue from pregnant females compared with
nonpregnant cows. However, this increase has also been reportedly to occur with
progression through the estrous cycle. On day 4 of the bovine estrous cycle (estrus =
day 0) only 13 uterine proteins were recovered compared with 78 uterine proteins
recovered on day 8 of the estrous cycle (Bartol et al., 1981). It was also noted that there
was a significant increase in prostaglandins present in the ipsilateral uterine horn of
pregnant females compared with the ipsilateral uterine horn of nonpregnant females.
Correspondingly, it is known that the bovine embryo is capable of producing
prostaglandins on days 7 to 18 of the estrous cycle (Shemesh et al., 1979; Lewis et al.,
1982; Hwang et al., 1988). Collectively, these findings demonstrate how P4 during
pregnancy can regulate the energy substrates in the uterus available to the developing
embryo during early pregnancy.
P4 Effects on Immune System Function during Pregnancy
In the cow, research has been conducted in an effort to determine the effect of P4
on immunosuppression necessary for the developing embryo to continue pregnancy. In
a classical experiment, Rowson et al. (1953) reported that P4-treated females
(regardless of stage of estrous cycle) were found to be more likely to develop
intrauterine infections than untreated females. More recently, it was reported that bovine
uterine flushings collected at day 3 of the estrous cycle were only marginally
immunosuppressive while day-10 flushings were not immunosuppressive and day-18
flushings (regardless of pregnant or nonpregnant) were highly immunosuppressive
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(Fisher et al., 1985). These findings indicate that a window of opportunity exists for an
early embryo to continue development within the uterus with minimal immune response.
It has been demonstrated that uterine immunosuppression could occur in two
ways: (1) through uterine derived immunosuppressive proteins and (2) through
embryonic-derived immunosuppressive proteins (Fisher et al., 1985). Subsequently,
Hansen and Newton (1987) demonstrated that P4 induced bovine uterine protein could
bind IgA and IgM but they could not bind IgG. In the ewe, the immunosuppressive
proteins were demonstrated to be P4 inducible and could effectively delay allograft
rejection (Stephenson and Hansen, 1987). These findings suggest that elevated P4
levels could reduce the incidence of embryo mortality, as a response of uterine immune
response to foreign cells until maternal recognition occurs.
Low and Hansen (1988) reported that P4 could inhibit lymphocyte proliferation in
the uterus. Also, in vitro culture of uterine fluid from P4-treated ovariectomized ewes
could reduce the lymphocyte proliferation response and could further lessen antibody
responses (Stephenson and Hansen, 1990). Later it was reported that there was a
decline in the number of intra-epithelial lymphocytes in the uterus, as early pregnancy
continued (Hansen, 1995). However, the P4 levels required to inhibit lymphocytes in the
bovine uterus were much higher than P4 levels in the blood therefore, it has been
hypothesized that P4 may induce uterine proteins that also inhibit lymphocytes during
pregnancy (Hansen, 1997).
Effects of P4 on Embryo-Uterine Synchrony during Early Pregnancy
It has been established that uterine-specific proteins are regulated by P4, which
predominates during metestrous and diestrous periods in various mammals (McCarthy
et al., 1977; Fischer, 1989; Yang and Foote, 1990). It was not known, however, how
manipulation of the release of these proteins (embryo-uterine synchrony) would affect
embryo growth. In rabbits, P4 administration from 3 days before to the day of mating
(mating = day 0) was found to disrupt fertilization and the majority of the fertilized
oocytes died by day 4 following mating (McCarthy et al., 1977). However, when these
embryos were recovered from the P4-treated does and transferred to nontreated
recipient does on day 3 following mating, most survived compared with those recovered
from P4-treated does on day 4 and transferred to day-4 (mating = day 0) nontreated
recipient does. When the uterine fluid from these rabbits was evaluated, there was a
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greater amount of uterine protein found in P4-treated donors compared with nontreated
recipient females. It was later demonstrated that uterine fluid from day-2 (mating = day
0) P4-treated does would support the development of day-2 embryos from P4-treated
does and day-3 embryos from nontreated control does. In addition, it was demonstrated
that uterine fluid from day-3 (mating = day 0) nontreated control does would support the
development of day-3 embryos from nontreated control does and day-2 embryos from
P4-treated does. These findings illustrated that the synchrony between the embryo and
the uterus was important to establish pregnancy and more importantly, is likely
controlled by circulating P4 and subsequently P4-induced uterine proteins.
Asynchrony between embryo and uterus does not always result in early embryo
death. For example, it has been demonstrated in rabbits that when 8-cell embryos were
transferred into advanced staged uteri (embryo recipient more days post-estrus than
embryo donor) embryo growth was markedly stimulated (Fischer, 1989). Specifically, the
cell diameters were larger, there was an increase in protein synthesis and cell
proliferation was greater for embryos transferred into older uteri than for embryos
transferred to synchronous uteri. However, when advanced stage embryos were
transferred to younger female uteri, the embryos exhibited an increase in degeneration,
a decreased in protein synthesis and retardation of development. This study
demonstrated that the day of gestation was not as important as the stage of maturation
of the endometrium for embryo development. A synchronous match between the embryo
and stage of uterine maturation is critical to the establishment and maintenance of
pregnancy, with this synchrony controlled by P4.
In the absence of P4 treatment during early pregnancy, embryo-uterine
synchrony is more critical to the successful maintenance of pregnancy. When day-3
rabbit demi-embryos and normal embryos were transferred into day-2 or day-2.5
nontreated recipient does, demi-embryo and normal embryo survival rates were low as it
was when day-3 normal embryos were transferred day-3.5 to day-4 nontreated
recipients (Yang and Foote, 1990). Only asynchrony of up to 12 hours would permit
further embryo development in recipients at acceptable rates.
This window of opportunity for embryo transfer has also been reported in sheep.
Wilmut and Sales (1981) reported that when day-3 embryos were transferred into day-6
(estrus = day 0) recipients, there was a marked increase in the developmental rates of

26

the embryos, although the conceptus failed to develop to term. However, when these
asynchronous embryos were transferred back into a synchronous recipient, following
their 3-day exposure to an advanced stage uterus, these embryos maintained their
ability to produce offspring. When this experiment was repeated by transferring day-6
embryos into the uteri of day-9 embryo recipients, no embryos developed to term.
However, a few of these embryos developed to term when transferred back to a
synchronous recipient following their 3-day exposure to an advanced uterus (Wilmut and
Sales, 1981). These experiments demonstrated that the ovine embryo has limited ability
to regulate its development in an attempt to establish synchrony with the uterus. There
appear to be developmental stage limits, as early staged embryos were more adept at
establishing synchrony than more advanced staged embryos.
Lawson and Cahill (1983) reported that P4 can be used to alter the embryouterine relationship when ewes were administered 25 mg P4 on day 0 to day 3 (day 0 =
estrus) of the estrous cycle was shortened by 4 days. More importantly, on day 6 of this
altered cycle the uterus was capable of supporting embryos recovered on day 10 from
nontreated control females. This study further demonstrated P4 may have a functional
mechanism involving maternal recognition.
When embryos are exposed to advanced stage uteri either via embryo transfer
(ET) or P4 supplementation (during early pregnancy) of the embryo increases its
metabolic rate and the reverse occurred when the embryos are exposed to a less
developed uteri (Wilmut and Sales, 1981). Lawson et al. (1983) reported that when
embryos collected from ewes 4 days after mating were transferred into day-1 or day-2
(estrus = day 0) ewes, the embryos were unable to develop past the early blastocyst
stage. This was markedly different from day-4 embryos that where transferred into the
uteri of day-6 or day-7 recipients which experienced accelerated growth and
development and resulted in larger diameter at time of embryo recovery. In addition,
there were fewer degenerate embryos recovered from advanced stage uteri. However,
this was found only with early stage embryos, as day-9 embryos transferred into day-11
embryo recipients failed to develop, while day-9 embryos transferred into day-6
recipients continued to develop in utero to some extent.
In contrast, administration of P4 on day 10 to day 24 of pregnancy in
ovariectomized pigs failed to significantly improve or alter embryo-conceptus
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development (Gentry et al., 1973). Correspondingly, variations in embryo development
due to ovulation intervals has been noted in the pig and hypothesized as a cause of
increased early embryo mortality (Pope et al., 1986). Day-6 embryos (estrus = day 0)
transferred to day-7 recipients were morphologically less developed at day 12 and 13
compared with day-7 embryos transferred to day-6 recipients (Pope et al., 1986).
Interestingly, Morgan et al. (1986) indicated that estradiol (E2) administration could
influence uterine secretions in the pig, as does P4 in other farm animal species. Based
on these findings, the pig is one species in which P4 is critical for the maintenance of
pregnancy but may not play a dominant role in embryo-uterine synchrony.
In the cow, the differences between embryo and uterine synchrony can not
exceed 36 hours and still result in acceptable pregnancy rates via ET (Donaldson,
1985). However, as shown in the ewe, early stage bovine embryos (early morulae) were
capable of withstanding uterine asynchrony better than later stage blastocysts
(Donaldson, 1985). In the cow, as in other species, P4 administration (during early
metestrus) could modify the degree of synchrony between the embryo and uterus
(Garrett et al.,1987; Garrett et al., 1988; Geisert et al., 1991a). To improve pregnancy
rates from ET in cattle, better quality, advanced stage embryos should be transferred to
more synchronous recipients while early stage, good quality embryos could be
transferred to slightly more asynchronous recipients. Bovine embryos are more likely to
withstand the alteration of their uterine environment and thus, establish pregnancy.
P4 administration (day 1.5 to day 5, estrus = day 0) can be utilized to stimulate
synchrony between the bovine embryo and uterus (Geisert et al., 1991a). Garrett et al.
(1987) demonstrated that 100 mg of P4 administered from days 1.5 to 4 (estrus = day 0)
resulted in more advanced stage embryos (hatching or hatched blastocysts) recovered
on day 5 of the estrous cycle compared with embryos (8-cells to morulae) recovered
from nontreated control females on day 5. In addition, when embryos were collected on
day 14 of the estrous cycle, embryos from P4-treated females were significantly greater
in length than embryos from nontreated control females. Garrett et al. (1988) reported
that P4 treatment (days 1.5 to 4, estrus = day 0) altered the uterine-embryo relationship
by altering of uterine synthesis and release of polypeptides. P4 supplementation was
utilized to induce these alterations for asynchronous ET in the cow. Following 100 mg of
P4 administered on days 1.5 to 4, embryos collected from day-8 cows were transferred
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to these day-5 P4-treated females, and normal embryo development continued (Geisert
et al., 1991a).
Effects of P4 on Embryo Developmental Rates
Elevated P4 levels during fertilization or immediately following (prior to 2 days
after ovulation) has been demonstrated to prevent early cleavages in oviduct-stage
embryos. Whitten et al. (1957) demonstrated that presumptive mouse zygotes were
inhibited from further development when cultured in vitro in the presence of P4. This
effect was apparently dose dependant, with doses ≥8 µg/ml of P4 completely inhibited
further embryo development. High concentrations of P4 also inhibit first cleavage and
further development of presumptive rabbit zygotes in vitro (Whitten et al., 1957).
However, when presumptive zygotes were moved to a P4-free medium they resumed
cleavage within 2 to 3 hours following their removal (Daniel and Levy, 1964). Mouse
embryos subjected to 8 µg/ml of P4 at the 2-cell or 4-cell stage failed to continue
development in vitro. However, this effect was not evident when 8-cell, morula or early
blastocyst stage mouse embryos (uterine-staged embryos) were exposed to the same
P4 treatment (Kirkpatrick, 1971).
There have also been reports of increased degeneration in these in vitro-cultured
mice embryos when exposed to P4-treated ovariectomized mice (Kirkpatrick, 1971).
This effect was more difficult to determine in vivo, as embryos recovered from
ovariectomized female mice had significantly fewer cells present compared with
embryos recovered from ovariectomized P4-treated mice, while embryos from both
groups had significantly fewer cells compared with embryos recovered from the
nontreated control females (Roblero, 1973). These studies illustrate that high levels of P4
may have a detrimental effect on oviductal stage embryos, although it is still necessary
for early development of the oviductal stage embryo.
In contrast, Roblero and Izquierdo (1976) reported that low levels of P4 (0.1 µg to
1 µg) or serum alone did not affect 4-cell mouse embryo development in vitro whereas,
the combination of 1 to 4 µg of P4 with serum increased the number of cells per
blastocyst. The number of cells per blastocyst increased even further when the
macromolecular fraction (molecules >1,000 molecular weights) of the serum was used
rather than whole serum. Wang et al. (1984) demonstrated that when P4 was withdrawn
(ovariectomy) during oviductal embryo development in the mouse, there was an arrest in
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embryo development. However, findings from these experiments may be confounded as
early ovariectomy can cause tissue damage (necrosis) and thus confound findings from
these experiments.
In an attempt to circumvent this possible confounding effect of ovariectomy,
McRae (1994) used a P4 antagonist (RU-486) on days 1 and 2 post-coitus to isolate the
effects of P4 on oviduct stage mouse embryos. It was demonstrated that treatment with
RU-486 significantly reduced the number of day-4 mouse embryos collected from
treated females compared with vehicle-treated or untreated control females. In addition,
more of the embryos recovered from RU-486-treated females were retarded in
development and possessed fewer cells compared with embryos recovered from vehicle
and nontreated control females. A similar decrease in embryo development occurred
when P4 antibodies were administered on day-3 and/or day-4 post-coitus to pregnant
ferrets (Heap et al., 1989). These studies illustrate that high levels of P4 may have an
inhibitory effect on oviduct-stage embryos, although some P4 may still be necessary for
early development of oviduct-stage embryos.
Age is one maternal factor that can affect circulating levels of P4 during early
pregnancy. It has been reported that aged female rats have an increase in delayed
embryo development, as well as, an increase in the number of degenerate embryos
present in the uterus by 5 days following mating (LaPolt et al., 1990). This was found to
be associated with lower P4 and higher E2 concentrations, on day 4, when compared
with younger female rats, which did not exhibit delayed development or an increase in
degenerate embryos. Furthermore, Binart et al. (2000) have reported that the
administration of P4 12 hours post-ovulation could rescue embryo development in mice
with luteal insufficiency.
It has been proposed that the P4 levels from the previous cycle in sheep are also
important for establishing pregnancy (Wilmut, 1985). In ovariectomized sheep, there was
a marked increase in the number of abnormal embryos when a priming P4 dose (during
the luteal phase of the previous estrous cycle) was omitted from the hormone
replacement treatment (Miller et al., 1977). Miller and Moore (1983) demonstrated that
when priming P4 was omitted prior to E2 administration (to induce estrus) uterine
secretions were delayed to 4 to 6 days following estrus (~2 days later than normal).
However, it was noted that the content of the secretions were not modified. This pattern
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was also found by Wilmut et al., (1985), who concluded that adequate P4 levels in the
ovine estrous cycle prior to becoming pregnant was as important as adequate P4 levels
during early pregnancy.
The mare appears to be one species that early P4 levels may not play a critical
part of early pregnancy as has been previously noted for other species. There has been
a report that P4 supplementation during early pregnancy (day 0 to day 6, ovulation = day
0) does not affect embryo developmental rates in the mare (Ball et al., 1992). When
embryos were recovered from pregnant mares receiving 450 mg of P4 on day 0 to day 6
following ovulation there were no differences in embryo developmental stages, embryo
diameter or number of cells per embryo when compared with embryos collected from
nontreated control mares (Ball et al., 1992).
Contrary to evidence from in vivo embryo development there has also been
evidence suggesting that P4 may not have a great effect on in vitro produced (IVP)
bovine embryos (Fukushima and Fukui, 1985; Fukui and Ono, 1989; Goff and Smith,
1998). Fukushima and Fukui (1985) demonstrated that the addition of steroid hormones
(including P4) did not improve developmental rates of IVP bovine embryos. Similarly,
Fukui and Ono (1989) and Fukui (1989) reported that the supplementation of P4 or E2 in
the presence of fetal calf serum or estrous cow serum to IVP embryos co-cultured on
oviduct cells did not increase the number of bovine embryos developing to the blastocyst
stage. Furthermore, it was demonstrated that co-culture on endometrial stroma cells in
the presence of P4 failed to increase the number of IVP bovine embryos reaching the
blastocyst stage compared with nontreated control IVP embryos (Goff and Smith, 1998).
In contrast to these reports, there have been reports of increased blastocyst
development in IVP mice, rabbit and bovine embryos cultured in the presence of P4 (ELBanna and Daniel, 1972; Wiemer et al. 1987; Lavaranos and Semark, 1989). EL-Banna
and Daniel (1972) reported that developmental rates of IVP rabbit embryos were
increased when the embryos were cultured with uterine proteins and P4
supplementation. It was suggested that this increase may have been due to a complex
of free P4 bound to uterine proteins that became available to the embryos. In addition,
Wiemer et al. (1987) reported that the presence of P4 stimulated blastocyst development
in bovine embryos co-cultured on fetal uterine cells. Similar findings have been reported
in mice (Lavaranos and Semark, 1989).
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Effects of P4 on Embryo Metabolism
Although, P4 has been shown to increase uterine protein and carbohydrate
content in uterine secretions, there is evidence that P4 may improve metabolism
efficiency of these components by the embryo. In mice, P4 administration to
ovariectomized females has been shown to alter the rate of glycogen metabolism, which
resulted in increased embryo glycogen metabolism and increased the amount of labeled
carbon utilization (Edirisinghe and Wales, 1984). In contrast, it has been reported that E2
does not affect glycogen metabolism, and this is of interest because an E2 surge is
required in mice for normal implantation to occur (McCormack and Greenwald, 1974). It
has also been demonstrated that P4 administration in the mouse increases the amount
of nonglycogen, acid-insoluble macromolecules (Edirisinghe and Wales, 1984). This
indicates that P4 may be involved in channeling carbon from storage compounds (e.g.,
glycogen) into metabolic pathways, thus increasing the synthesis of macromolecules
(Edirisinghe and Wales, 1984). These findings support the theory that P4 may be the
agent responsible for the low levels of glycogen found in in vivo embryos compared with
IVP embryos (Edirisinghe and Wales, 1984). It is unknown if P4 exerts this affect directly
on the embryo or if the change in embryo metabolism is caused by P4 altered uterine
secretions.
In the mare, it has been demonstrated that P4-treated pregnant mares resulted in
a four to five-fold increase in the activities of the Embden-Meyerhof Pathway of these
embryos compared with embryos from nontreated control pregnant mares (Brück et al.,
1997). It is important to note that oviduct-stage embryos utilize the HexoseMonophosphate Oxidation Pathway, while uterine embryos utilize the Embden-Meyerhof
Pathway. The increase in maternal P4 levels does not need to be greatly increased to
increase embryonic glucose metabolism (Brück et al., 1997). However, it was unknown if
P4 directly influences glucose metabolism in the embryo or if this effect was mediated by
P4 induced proteins (Brück et al., 1997).
In addition to protein and carbohydrate metabolism, embryos from several
species of have been reported to possess the ability to metabolize steroids during early
development (Huff and Eik-Nes; 1966; Wu, 1985; Wu and Matsumoto, 1985; Wu, 1987).
Huff and Eik-Nes (1966) demonstrated that rabbit blastocysts were capable of
metabolizing 20α-dihydroprogesterone, 5β-pregnan-3α-ol-20-one and 5β-prenaediol.
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The activity of 17β-hydroxysteriod dehydrogenase was determined to be capable of
converting E2 to estrone (E1) in in vitro pre-implantation mouse and rat embryos (Wu and
Matsumoto, 1985).
Wu (1985) also demonstrated that IVF-produced hamster blastocysts readily
metabolize progesterone predominately into 5α-dihydroprogesterone (5α-DHP) and to a
lesser degree allopregnanolone (AP). Three β-hydoxysteriod dehydrogenase (3β-HSD)
is thought to be the responsible enzyme for the metabolism of P4 in the hamster (Wu,
1985). It was reported that the mouse blastocyst was also capable of metabolizing P4
(Wu, 1987). However in the mouse, the main P4 metabolite was found to be AP while
5α-DHP was found in lesser amounts. It was demonstrated that much of the 5α-DHP
was converted to AP. These studies suggest a mechanism by which the embryo may be
able to alter uterine secretions and thereby, adjust the uterine environment to better
support its stage of development. At this stage, P4 metabolism by the embryo has not
been investigated in the cow and ewe and unfortunately, these species serve as the
main models to demonstrate the abilities of embryos to increase or decrease their rate of
development to reflect the stage of development of the uterus.
Effects of P4 on Post-Implantation Development
In sheep, Kleeman et al. (1994) demonstrated that early P4 administration, days
1 to 6 following mating, could subsequently influence the developing fetus later in
gestation. The fetuses of pregnant ewes treated with P4 had significantly greater crownrump lengths and weights when compared with fetuses of nontreated control pregnant
ewes. In addition, Kleenman et al. (2001) proposed that the increase in fetal length and
weight were a response to increased heart, skeletal and muscle growth of the
conceptus.
P4 supplementation via serum supplementation to in vitro culture systems in
cattle has been suggested as a model for the study of “large calf syndrome” that occurs
as a result of in vitro culture of embryos (Barnes et al., 2000). It has been suggested that
expression of embryonic insulin-like growth factor 2 (IGF2) and P4-induced endometrial
expression of IGFBP2 may be two of the factors responsible for this over development of
calves born.
Although, E2 has been established as a more important factor in embryo-uterine
synchrony in the pig, exposure of porcine embryos to advanced uteri has resulted in
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similar developmental effects as noted in sheep (Wilson et al., 2001). Wilson et al.
(2001) demonstrated that when day-2.5 porcine embryos were transferred to day-3.5
recipients, significantly heavier fetuses resulted, possessing larger placental surface
areas and longer uterine implantation sites in embryo recipient females.
Embryonic P4 Synthesis during Early Pregnancy
There is strong evidence that early stage embryos were capable of synthesizing
steroid hormones (Huff and & Eik-Nes, 1966; Seamark and Lutwakmann, 1972; Perry et
al., 1973; Gadsby et al., 1980; Wilson et al., 1992; Chiappe et al., 2002). Huff and EikNes (1966) have reported that rabbit blastocysts possessed enzymes that would enable
them to synthesize cholesterol and pregnenolone from acetate. It was later reported that
P4 and its metabolites, 20α-dihydroprogesterone and 17α-hydroxyprogesterone, were
present in the ovine blastocyst and blastocoel fluid (Seamark and Lutwakmann, 1972).
P4 and E2 are also synthesized in swine blastocysts (Perry et al., 1973). Shemesh et al.
(1979) reported that bovine blastocysts (day 13 or greater) were capable of synthesizing
P4, testosterone and E2 (Shemesh et al., 1979). Subsequently, Gadsby et al. (1980)
demonstrated that day-13 bovine blastocysts were capable of synthesizing E2. It was
later reported that day-10 bovine and swine IVP embryos were capable of synthesizing
and secreting P4, E1 and E2 (Wilson et al., 1992).
More recently there is evidence that P4 may act in an autocrine manner on the
developing bovine embryo (Chiappe et al., 2002). In this study IVP bovine embryos
cultured and it was reported that 3β-HSD activity occurred in mature bovine oocytes and
bovine embryos at the 1-cell, 2-cell, 8-cell, morula, blastocyst and hatched blastocyst
stages. It was noted that 3β-HSD activity occurred at a high rate from the mature oocyte
to the 4-cell stage and then became very active at the blastocyst and 100% active in the
hatched blastocyst stage.
The presence of 3β-HSD allows the embryo to synthesize steroids including P4
(Chiappe et al., 2002). It was also suggested that the reason for a greater increase in
activity in the 3β-HSD enzyme was that only embryos that possessed active 3β-HSD
were permitted to continue normal development. This study provides evidence that there
can be an autocrine function involved in P4 stimulation of embryo development.
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P4 Levels in Pregnant and Nonpregnant Females
Short (1958a) and Short (1959b) was one of the first to report circulating P4
levels in the pregnant cow. A decade later, Shemesh et al. (1968) reported that by day19 post-mating there was significant differences between circulating P4 levels in
pregnant cows compared with nonpregnant cows, however, no differences were
detected from day-10 to day-18 post-mating. Pope et al. (1969) reported they failed to
detect differences in circulating P4 between pregnant and nonpregnant cattle prior to day
14 of the estrous cycle (estrus = day 0), however, there was a significant decrease
following on day 14 in nonpregnant cows, with this difference attributed to the process of
luteal regression.
In addition, Bulman and Lamming (1978) found that there were no differences in
P4 levels prior to day 13 between pregnant and nonpregnant dairy cows when using milk
samples to determine P4 levels. Furthermore, Robertson and Sarda (1971) failed to find
a difference in circulating P4 levels prior to the time of luteolysis between pregnant and
nonpregnant cattle. Other researchers have failed to find differences in P4 levels
between pregnant and nonpregnant cows prior to day-16 (Sreenan and Diskin, 1983) or
day-17 post-mating (Geisert et al., 1988). The researchers who failed to find a difference
prior to day-16 post-mating suggested that the maintained P4 levels in pregnant cows
compared with nonpregnant cows was simply a result of the embryo maintaining CL
function.
In contrast, Henricks et al. (1970) reported that differences from day 10 to day 16
of the estrous cycle in circulating P4 did exist between pregnant and nonpregnant bovine
females. It was reported that P4 increased at a rate of 0.61 ng/ml per day from day 8 to
day 14 in pregnant females, while this rate was only 0.15 ng/ml in nonpregnant females.
This rate of increase significantly increased circulating P4 levels from day 10 to day 14 in
pregnant females compared with nonpregnant females, however, by day 16 P4 levels
were similar between the two groups. Henricks et al. (1971) reported significantly higher
circulating P4 levels in pregnant cows compared with nonpregnant cows as early as day
6 of the estrous cycle (estrus = day 0), while Erb et al. (1976) reported significantly
higher P4 levels in pregnant cows compared with nonpregnant cows by day 8 (estrus =
day 0). Moreover, Lukaszewska and Hansel (1980) demonstrated that P4 levels were
higher from day 10 onward (estrus = day 0) in conjunction with greater CL weights in
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pregnant compared with nonpregnant dairy cows. These findings demonstrated that
differences in P4 levels were likely present, however, individual animal differences in P4
levels or possible blood sampling frequencies could be the reason for the variation
reported for P4 levels between pregnant and nonpregnant cows over the years.
Sexual maturity and age can also affect the systemic level of P4 in pregnant and
nonpregnant cattle. Byerley et al. (1987) reported that pregnant heifers on their first and
third post-pubertal cycles had higher P4 levels compared with nonpregnant heifers at
their first or third post-pubertal cycles. When comparing sexually mature and immature
ewes, it has been demonstrated that pregnant ewe lambs had lower P4 levels compared
with pregnant mature ewes by day 13 of pregnancy (estrus = day 0) and that this may
contribute to the decreased lambing rate noted in ewe lambs (Davies and Beck, 1993).
In contrast, cattle tend to follow a reverse pattern related to sexual maturity, as Silva et
al. (2002) reported that dairy heifers, which tend to be more fertile than multiparous
cows, have increased P4 levels on day 4 and day 7 of the estrous cycle (estrus = day 0)
compared with multiparous cows. These findings are in agreement with those Mann and
Lamming (1996), who showed a correlation between the rate of embryo development
and levels of P4 following ovulation. They found that more embryos with abnormally
small diameters were recovered from cows with lowered circulating P4 levels at day-5
post-estrus (estrus = day 0) compared with cows with normal or elevated circulating P4.
These findings suggested that P4 levels, as affected by age or sexual maturity, can
control the growth rate of early stage embryos in vivo.
Remsen and Roussel (1982) reported that in dairy heifers, pregnancy resulting
from ET was closely correlated to P4 levels at the time of ET. They reported that 80% of
the females that failed to maintain pregnancy from ET had P4 levels below 2.0 ng/ml at
time of ET. These findings on the day of transfer did not correlate to those reported by
Hasler et al. (1980), who reported that circulating P4 levels from days 3 to 9 of the
estrous cycle (day 0 = estrus) between pregnancy and nonpregnant females were not
correlated with ET pregnancy rates. A correlation between pregnancy rates and the
duration of estrus was found, with cows having a shorter duration of estrus had
significantly higher P4 levels on day 3 of the estrous cycle compared with cows with
longer durations of estrus. Similarly, Silva et al. (2002) reported no difference in P4 levels
from day 4 and day 7 between pregnant and nonpregnant ET recipient cows. These
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findings suggest that even though a relationship between levels of P4 at the time of ET
the likelihood of a pregnancy being established based on circulating P4 levels around the
time of transfer as a result of ET can not be predicted. However, increased levels of
circulating P4 from day 3 to day 7 (estrus = day 0) may increase the probability of a
pregnancy being established from ET in early P4 deficient cattle.
Although increased levels of circulating P4 during early pregnancy may increase
pregnancy rates, there is likely a threshold that when not reached or surpassed can
result in detrimental effects on the establishment of a pregnancy (Henricks et al., 1971;
Erb et al., 1976; Bulman and Lamming, 1978; Wilmut et al., 1985). These abnormal
circulating P4 levels or the start of P4 secretion (start of luteal tissue function) may be a
cause of infertility in RPB females. Bulman and Lamming (1978) reported that ~20% of
the RPB females sampled had significantly higher P4 during insemination and
immediately afterwards. This finding supports that of Erb et al. (1976), who
demonstrated that infertile services were associated with increased P4 levels
immediately following ovulation. This was in addition to a report that females with
degenerating embryos ≥2-cell recovered on day-3 post-mating (estrus = day 0) had
significantly higher P4 levels 2 days prior to the onset of estrus than females in which
normal embryos ≥4-cell were recovered on day 3 (Henricks et al., 1971).
Correspondingly, Maurer and Echternkamp (1982) reported that females with normal
developing embryos had higher P4 levels on day 3 and day 6 (estrus = day 0) compared
with females that had degenerating embryos in vivo.
Furthermore, Wilmut et al. (1985) demonstrated that when ovariectomized ewes
did not receive exogenous P4 until day 4 or later (estrus = day 0), only 18% remained
pregnant compared with 70% that remained pregnant when P4 administration was
initiated prior to day 4. Ashworth et al. (1989) demonstrated that more ewes remained
pregnant to natural mating when they reached 50% of their luteal phase P4 levels early
in the estrous cycle.
The majority of embryo mortality occurs between day 3 and day 19 of the estrous
cycle (estrus = day 0) (Ayalon, 1978). In the normal, fertile cow successful fertilization
occurs ~90% of the time from natural mating. However in ~25% of females, embryo loss
has occurred by day 11 to day 13 of the estrous cycle (Ayalon, 1978). These findings
were similar to those of Diskin and Sreenan (1980), who reported the majority of
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embryonic morality in cattle occurred by day 12 following mating. This is quite different
when compared with RPB cows where 25% of embryos are lost by day 3 post-mating
and an additional 25% lost by day 11 to day 13 (Ayalon, 1978). More recently, it has
been reported that AI fertilization rates in dairy cows were ~90%, while ≤50% of
inseminated dairy cows calved from a single insemination (Lamming et al., 1989).
These results confirms that marked embryo mortality occurs following mating in cattle.
The same embryonic loss pattern has also been reported in sheep, where only
5% to 10% of unfertilized oocytes were recovered from mated ewes with the majority of
embryo mortality occurring before the third week of gestation (Wilmut et al., 1986).
Furthermore, Ashworth et al. (1989) reported that <6% of early embryo mortality
occurred as a result of chromosomal abnormalities. This leaves a large percentage of
nonpregnant ewes that are the result of reasons other than fertilization failure and
embryonic chromosomal abnormalities.
The most common explanation for high rates of embryo mortality occurring
before luteolysis has been that the embryo failed to send a strong enough maternal
recognition signal or an in appropriately timed maternal recognition signal. Lukaszwaska
and Hansel (1980) suggest that the embryo was in some manner stimulating CL
function. When day-13 to day-15 (estrus = day 0) ovine embryo extracts were in vitro
cultured with ovine or bovine luteal tissue there was a significant increase in P4, (Godkin
et al., 1978). It was also determined that the embryo was not producing measurable
amounts of P4 at this time. This demonstrated that the conceptus was capable of
elevating maternal P4 levels. This further supports the hypothesis that there was a
difference in P4 levels between pregnant and nonpregnant females prior to luteolysis.
Beal et al. (1981) have reported that day-18 bovine embryos secreted a
luteotrophic substance that increased P4 levels when cultured with dispersed luteal cells
in vitro. Also, Thibodeaux et al. (1994) reported that bovine embryos and trophoblastic
vesicles when cultured with in vivo collected luteal cells stimulated P4 secretion in these
luteal cells. This embryo-induced luteotropic effect was also found to occur in rabbits
(Nowak and Bahr, 1983). When embryos were removed from pregnant rabbits the
circulating P4 levels would decline to the baseline in psuedopregnant rabbits, indicating a
direct luteal stimulatory effect from the embryo.

38

Hwang et al. (1988) demonstrated that day-7 (estrus = day 0) in vivo-produced
blastocysts produced PGE2, and as the embryo developed it obtained the ability to
synthesize and secrete PGI2 and serotonin (both are luteotrophins). Lewis et al. (1982)
reported that bovine blastocysts could convert arachidonic acid into prostaglandins when
cultured in vitro with endometrial slices. Using [H3] arachidonic acid it was reported that
bovine blastocysts produce considerable amounts of PGF2α and PGE2 (Lewis, 1989).
These findings were consistent with reports of greater circulating PGE2 levels in
pregnant compared with nonpregnant females (Lewis et al., 1978; Silvia et al., 1984;
Vincent et al., 1986; Parkinson and Lamming, 1990). It had been previously reported
that PGE2 administered during the luteal phase could extend the lifespan of the CL in the
ewe (Pratt et al., 1979). Collectively, these results demonstrate the embryo’s ability to
increase P4 levels during the luteal phase in vivo prior to maternal recognition.
P4 supplementation prior to time of embryo transfer has been shown to increase
uterine secretions and effectively alter the secretion pattern of proteins and alter embryo
development or possibly allow for asynchronous embryo transfer (Wilmut and Sales,
1981; Garrett et al., 1988). In addition, P4 has also been reported to play a part in
maternal recognition. Vincent et al. (1985) found that when P4-treated day-6 ewes that
received day-10 blastocysts, resulted in an increase in PGE2 beginning on day 8
compared with day 12 in mated ewes. It was not known at the time whether P4 increased
uterine PGE2 and/or embryo-derived PGE2. However, it has been reported that P4
administration could prevent early luteal regression caused by an intrauterine device in
the ewe which was accompanied by an increase in PGE2 that was believed to be of
uterine origin (Warren and Hawk, 1972).
Mann et al. (1994) attempted to correlate the post-ovulatory rise (metestrus) in P4
to the timing of the luteolysis. It was demonstrated that P4 played a role in the synthesis
of uterine PGF2α in the cow (Lamming and Mann, 1995a). In addition, Mann and
Lamming (1995) have concluded that mated cows with lower P4 levels during early
pregnancy had a significantly stronger luteolytic signal than mated cows with higher
levels of P4 during early pregnancy. It was also reported that higher P4 levels during the
estrous cycle (diestrus) exerted an inhibition on the luteolytic mechanism thereby,
increasing the chances of the embryo establishing maternal recognition.
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In a subsequent experiment, Mann et al. (1998) demonstrated that an increase of
only 0.6 ng/ml during the early luteal phase was sufficient to alter the timing of the
luteolytic signal. Furthermore, it was shown that an early P4 rise could advance the
luteolytic signal but elevated levels of P4 weakened the luteolytic signal (Mann et al.,
1998). Embryos that experienced increased levels of P4 during early pregnancy were
capable of synthesizing and secreting larger quantities of interferon-tau (the primary
maternal recognition signal in cattle) and in these pregnant females, less interferon-tau
was then required to maintain the CL (Mann et al., 1999). An increase in embryonic
interferon-tau was also found in embryos recovered from cows administered P4 from day
1 to day 4, following the onset of estrus (Garrett et al., 1988).
Gawronska et al. (2000) demonstrated that under P4 domination the uterus would
produce more PGE2 than PGF2α. This finding was confirmed when Shaham-Albalancy et
al. (2001) demonstrated that low concentrations of P4 during the luteal phase increased
in PGF2α metabolite (PGFM). This could represent a mechanism by which low P4 during
the luteal phase could cause early termination of pregnancy. Mann and Lamming (2001)
reported inseminated cows with increased P4 levels during early pregnancy (~day 4 to
day 9) had altered the uterine ratio of PGE2 to PGF2α to favor PGE2. Embryos collected
from these females also synthesized more interferon-tau in vitro than embryos collected
from cows with lower early P4. In addition, when interferon-tau was administered to
these females, the females with high levels of early P4 required higher levels of
interferon-tau to initiate luteolysis than did females with low levels of early P4. These
results indicate that early P4 levels control the timing and degree of the luteolytic signal,
however, it is unknown if this effect is controlled by ovarian P4 alone or a combination of
embryo-uterine relationship via luteotropins stimulated P4 levels.
Maintenance of Pregnancy in Ovariectomized and Luteoectomized Females
Hess (1921) and Schmaltz (1921) (cited by McDonald et al., 1952) were the first
to report that CL removal in the cow during pregnancy would result in pregnancy
termination. Following these findings, Raeside and Turner (1950) attempted to
determine the amount of P4 supplementation required to support pregnancy in dairy
cows following CL ablation at 44, 48 or 76 days of gestation. In this study, it was
discovered that 25 mg of P4 per day per head dissolved in olive oil commencing
administration on the day of CL ablation was insufficient to support pregnancy, however,
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the administration of 50 mg of P4 per day per head maintained pregnancy in two of four
females for 100 days at which time P4 supplementation was ceased and the two
pregnant females aborted within 4 days of the end of P4 supplementation.
In a subsequent study by Raeside and Turner (1951) it was reported that when
CL ablation occurred it was dependant upon the stage of gestation as to whether
supplemental P4 was required to maintain the pregnancy. Using 75 mg and 100 mg of P4
dissolved in sesame oil and administered daily following CL ablation at 58 to 68 days of
gestation in mature dairy cows, it was determined that if P4 was administered until day
162 to day 237 of gestation and then ceased pregnancy would continue until day 254 to
day 282 of gestation (McDonald et al., 1952). However, if daily P4 administration was
ceased at day 76 or 137 of gestation the pregnancy would be terminated. Furthermore,
McDonald et al. (1952) reported that of the females that did continue pregnancy to term
following CL ablation and P4 supplementation until ~day 162 of gestation, at parturition
there was a high incidence of dystocia and retained fetal membranes.
In a follow-up study, McDonald validated previous findings of Raeside and Turner
(1951) that stated the continuation of pregnancy following CL removal without
supplementing P4 was dependant on the stage of gestation. When mature pregnant
dairy cows underwent CL removal from 92 days to 236 days of gestation no female that
underwent CL removal prior to day 171 of gestation continued pregnancy to term and
produced a live calf. If CL removal occurred on or after day 191 of gestation pregnancy
continued in all females (n=6), however, these females experience dystocia and a high
incidence of retained placental membranes.
Although it was previously demonstrated that the CL of pregnancy could be
removed during gestation and depending on the stage of gestation and 50 mg or greater
of P4 supplementation daily pregnancy could continue, however it was unknown how
early the CL could be removed and allow pregnancy to continue. Hawk et al. (1960)
using ovariectomy at day 5 to day 7 post-estrus maintained pregnancy in six pregnant
dairy cows until ~day 60 of gestation when these animals were sacrificed and it was
determined the fetuses were live. The ovariectomized pregnant dairy cows were
administered 25 mg of P4 per 100 lbs of body weight and 6.25 mcg of estrone per 100
lbs of body weight. This study demonstrated that pregnancy could be continued in the
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absence of ovaries as early as day 5 of gestation and normal implantation could occur in
the absence of ovaries provided that P4 and E1 were supplemented daily.
In an effort to dispense with the difficulty of daily steroid administrations, Johnson
and Erb (1962) tested the efficiency of administering 500 mg of Delatutin (17-alphahydroyprogesterone-17-n-caproate) or 500 mg repositol progesterone (progesterone in
propylene glycol), progestins and progesterone with a longer half life, weekly. However,
pregnancy could not be maintained in ovariectomized pregnancy dairy cows receiving
only weekly administrations of delatutin or repositol progesterone. It was reported that in
the control group that received daily administration of P4 these females experienced a
high incidence of retained placental membranes.
There have been successful reports of using progestins instead of progesterone
in supporting pregnancy (Zimbelman and Smith, 1966; Kesler, 1997). Using ovariectomy
at ~day 170 of gestation and supplementing 4 mg of MGA daily until ~277 days of
gestation the oral progestin MGA would support pregnancy to term with a lower
incidence of dystocia and retained placental membranes (Zimbelman and Smith, 1966).
Later, it was demonstrated that two 15 mg norgestomet implants administered s.c. into
the ear could maintain pregnancy in pregnant beef heifers ovariectomized at 10 days
following AI (Kesler, 1997). These implants were removed at day 273 of gestation.
Calving rates were lower compared with sham surgery controls and there was a high
incidence of dystocia (67%), retained fetal membranes (67%) and calf survival was low
(33%). These findings demonstrate that pregnancy can be supported in the absence of a
CL or ovaries and with or without supplementing P4 dependant upon stage of gestation
that CL removal or ovariectomy is performed. However, regardless of the method of
maintaining pregnancy partition is difficult and results in a greater probability of dystocia
and fetal placental membrane retention occurring.

42

CHAPTER 3
THE USE OF ALTRENOGEST TO SYNCHRONIZE ESTRUS
IN YEARLING BEEF HEIFERS
Introduction
Altrenogest (ALT) is an orally active progestin that has been developed to control
reproductive function in nonruminant domestic animals. During the past two decades
ALT has become a commonly used progestin in the mare (Squires et al., 1979; Webel
and Squires 1982; Squires et al., 1983) and the sow (Davis et al., 1979; Davis et al.,
1987; Martinat-Botte et al., 1985). ALT has been found to safely and effectively suppress
behavioral estrus in mares, when administered at 0.044 to 0.220 mg per kg of body
weight (Shideler et al., 1983). When administered at a rate of 0.044 mg per kg of body
weight, ALT has been effective in the synchronization of estrus in cycling mares (Squires
et al., 1979) and transitional mares (Turner et al., 1981; Weber and Squires, 1982).
However, there have been several reports that ALT did not completely block ovulation in
all cycling or transitional mares treated (Squires et al., 1979; Turner et al., 1981; Weber
and Squires, 1982). In addition, ALT has been demonstrated to decrease the number of
large follicles and size of the dominant follicle in the mare (Turner et al., 1981; Webel
and Squires, 1982; Squires et al., 1983). These decreases from a mean follicle size of
39.9 mm in ALT-treated mares compared with a mean follicle size of 41.5 mm in controltreated mares and a mean of 0.60 follicles that were >40 mm following treatment with
ALT compared with a mean of 0.79 follicles >40 mm in the control treatment group were
not detected when mares were administered another progestin, norgestomet (Wiepz et
al., 1988).
Hinrichs et al. (1985) and Hinrichs and Kenny (1987) demonstrated that
bilaterally ovariectomized mares could serve as embryo transfer (ET) recipients when
administered ALT for at least 7 days prior to ET. Also, ALT has been reported, in mares,
to support pregnancy in the absence of ovarian luteal tissue (McDowell et al., 1988;
Daels et al., 1991). In addition, ALT has been reported to support pregnancy in an Okapi
with a history of fetal mortality (Schwarzenberger et al., 1999).
Although ALT has not been reported to maintain pregnancy in the absence of
luteal tissue in sows, there have been reports that ALT can control the time of parturition
(Guthrie, 1985; Varley et al., 1985; Guthrie et al., 1987). Furthermore, it has been
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reported that ALT can increase fertility in postpartum sows when administered prior to
weaning (Stevenson et al., 1985; Koutsotheodoros et al., 1998). The physiological
actions of ALT are comparable with those of other progestins and/or progesterone (P4) in
other domestic animals.
Although ALT has been reported to function as a progestin in the mare and the
sow, research indicates that various progestins used in cattle (e.g., norgestomet and
melegestrol acetate) were not effective in maintaining pregnancy in the mare (Loy and
Swan, 1966; McKinnon et al., 2000).
With the removal of norgestomet (Synchro-mate B®) from the commercial market
in the United States, fewer progestins are now available to cattle producers for use in
estrous synchronization regimens. Melengestrol acetate (MGA) is a commonly available
orally active progestin used for estrous synchronization in cattle, however, this protocol
is time consuming requiring a 31-day treatment schedule. Also, when MGA was
administered for 7 days there has been a noted reduction in fertility following breeding
with only 40 to 55% pregnancy rates reported (Beal et al., 1988; Patterson et al., 1989).
However, when used in a 31-day estrous synchronization protocol, yearling heifers had
pregnancy rates of 64 to 77% following artificial insemination (AI) (Deutscher et al.,
1989; Jaeger et al., 1992; Patterson and Corah, 1992). The use of a 31-day estrous
synchronization schedule allows an additional estrous cycle prior to AI that may be a
factor in the reported improvement in pregnancy rates after synchronization using the
31-day protocol.
The availability of an additional orally active progestin that could effectively
synchronize estrus with a shorter treatment period to breeding than MGA would add
more flexibility for cattle producers when selecting an estrous synchronization regime.
However, as described MGA usage results in reduced fertility rates, in beef cattle,
following a 7-day treatment period but these reduced fertility rates were not found when
norgestomet was used for 7 days (Patterson et al., 1989). This led to the question, would
a 7-day treatment schedule with ALT serve as an effective oral progestin in cattle?
Therefore, the objective of this study was to determine if ALT could effectively
synchronize estrus in beef heifers without reducing fertility following a 7-day treatment
protocol.
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Materials and Methods
Experimental Animals
This experiment was conducted between the months of April and June for three
consecutive breeding seasons at the Center for Reproductive Biology at Louisiana State
University, St. Gabriel, Louisiana. All animals were treated in accordance with guidelines
set forth by the Animal Care and Use Committee of the Louisiana State University
Agricultural Center. During this 3-year period, 256 crossbred (Red Angus and Simmental
based) beef heifers ranging in age from 12.3 to 15.7 months, body weights from 345 to
447 kg and body condition scores from 5 to 6 (scale of 1=emaciated to 9=obese)
(Richards et al., 1989) were used in Experiment 3.1. These heifers were maintained on
pasture (Coastal bermudagrass) and supplemented with 1.36 kg of ground corn per
female per day beginning 30 days prior to and throughout the treatment period (Figure
3.1).
Experimental Design
After 60 days of feeding, all heifers that failed to reach a pre-breeding target
weight of 345 kg at the time of PGF2α administration were removed from this study. This
target weight was selected based on research that demonstrated that the majority of
heifers of these two breed types would not be cycling until this target weight was
reached (Thallman et al., 1999). In each of the three breeding seasons, heifers were
blocked by age and weight then randomly assigned to one of two treatment groups. In
each of the three breeding seasons the ALT treatment group was administered ALT
(Regumate, Intervet, Inc., Millsboro, DE) orally (manually mixed into feed ration) at a rate
of 0.044 mg per kg of body weight per head per day for 7 consecutive days and then
administered 25 mg PGF2α (Lutalyse, Pharmacia and Upjohn Co., Kalamazoo, MI) on
the 7th day (Figure 3.1). During each breeding season the MGA treatment group was
administered MGA (melengestrol acetate, Animal Science Feeds, Nacodogoches, TX) at
a rate of 0.4 to 0.5 mg per head per day in the feed for 14 days and then were
administered 25 mg of PGF2α 17 days after MGA withdrawal (Figure 3.1). Even though
the duration of treatment was different for females in each treatment protocol, the
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Figure 3.1. Estrous synchronization protocols were arranged so that prostaglandin
(PGF2α) was administered simultaneously in both treatments. This allowed
for estrus detection and AI to occur concurrently in both treatment groups.

46

regimens were arranged so that all heifers received PGF2α and subsequently artificially
inseminated during the same time interval (Figure 3.1).
Experimental Procedures
Estrus detection was performed with the aid of the HeatWatch System® (DDX,
Inc., Boulder, CO), using transponders that were attached to heifers at the time of PGF2α
administration. The Heatwatch System® records when a female was mounted by
detecting pressure applied to the mount transponder for a minimum of 3 seconds and a
minimum of 3 mounts in an hour. The HeatWatch System® was used in addition to two
daily observation periods (morning and evening) not less than 45 minutes each.
All inseminations were carried out by experienced technicians (n=2) using semen
from one of two Red Angus bulls (Genex Cooperative, Inc., Shawano, WI) of proven
fertility. At the time of AI, heifers were given an AI score of 1 to 3, with ‘1’ being the most
difficult to AI and ‘3’ the least difficult to AI. The criteria for a score of 1 was that the
insemination required greater than 3 minutes to transverse the cervix, while a score of 2
was assigned to an insemination that required 1 to 3 minutes to transverse the cervix
with the insemination stylet. An AI score of 3 was assigned to inseminations that
required less than 1 minute to transverse the cervix. All inseminated females were
examined for pregnancy ~30 days after the onset of estrus via transrectal
ultrasonography using an Aloka 500-V ultrasound unit (Corometrics, Wallingford, CT)
equipped with a 5 MHz rectal probe. A pregnancy was defined as the presence of a
fetus with viable heart beats. Following parturition, calf viability, sex and birth weight
were recorded.
Statistical Analysis
The heifers that were determined to respond to treatments were those which
exhibited behavioral estrus within 7 days following the end of the estrous
synchronization protocol. There were no significant differences in estrual response within
a treatment group between breeding seasons thus, all data were pooled for further
statistical analysis. The pregnancy rate per treatment was determined by dividing the
number of heifers pregnant by the number of heifers inseminated. This excluded nine
heifers, five of which experienced illness or lameness requiring veterinary intervention
prior to 30 day pregnancy examinations and four heifers whose reproductive tract
abnormalities prevented uterine deposition of semen. Calving rates were calculated as
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the number of heifers calving from the number of pregnant heifers. Estrous response
rates, pregnancy rates and calving rates were analyzed using procedures for categorical
data, Chi square, in SAS (SAS Institute. Inc., Gary, NC). Independent variables were
age, body weight, synchronization protocol, sire, AI technician and all interactions. The
Proc GLM procedure was used to determine differences in duration of estrus, number of
mounts and pregnancy rates in response to independent variables.

Results
The physical characteristics (i.e., age and weight) of the heifers that reached the
345 kg target weight were similar for each treatment group (Table 3.1). Overall, the
number of heifers that exhibited standing behavioral estrus in the ALT-treated group (48
of 69; 70%) was significantly greater (P<0.05) compared with the number in the MGAtreated group (37 of 75; 50%) (Table 3.2). The mean(±SE) interval from PGF2α
administration to the onset of estrus was not significantly different (P>0.05) between
ALT-treated (55.7±2.6 hours) and for MGA-treated heifers (55.3±4.3 hours). The
distribution pattern of the time to onset of estrus post-PGF2α was similar for both
treatment groups (Figure. 3.2). However, the duration of estrus and number of mounts
per heifer, monitored via the HeatWatch System®, were statistically different between
treatment groups. Heifers in the ALT-treated group had a significantly less (P<0.05)
mean number of mounts per female of 35±4 with a mean duration of estrus of 8.5±0.6
hours and compared with the mean of 48±6 mounts with a mean duration of estrus of
10.6±0.7 hours for the MGA-treated group (Table 3.2).
There was no effect of treatment on mean AI scores at time of insemination
(Figure. 3.3). In this study, there were no significant differences (P>0.05) in time to the
onset of estrus and duration of estrus between pregnant and nonpregnant females
(Table 3.3). Overall, there was a significant difference (P<0.05) in the mean number of
mounts per female between pregnant (48±5.0) and nonpregnant females (33±5.0).
There was no statistical difference in the pregnancy rates for ALT-treated (27 of
41; 66%) compared with MGA-treated heifers (23 of 35; 66%) (Table 3.4). A total of nine
heifers (two from the MGA group and seven from the RGM group) that responded to
estrous synchronization protocols were removed from the pregnancy data.
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Table 3.1. Characteristics of mixed-breed beef heifers that reached the pre-determined
target weight (345 kg) and were exposed to two estrous synchronization
protocols using either altrenogest (ALT) or melengestrol acetate (MGA)
progestin treatments
Treatment
group

1

No. per
group

Mean±SE
age (day)

Mean±SE
weight (kg)

Mean body
condition score1

ALT

69

432±3.0

371±2.1

5.9±0.1

MGA

75

431±2.6

373±2.3

6.0±0.1

Body condition scores (1=emaciated to 9=obese).
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Table 3.2. Effects of estrous synchronization treatments on the percentage of heifers
exhibiting estrus, interval to the onset of estrus following prostaglandin
(PGF2α) administration, duration of estrus and number of mounts per female
in mixed-breed beef heifers
Behavioral characteristics (mean±SE)
Treatment
group

Number in
estrus (%)

Onset of estrus
post-PGF2α (h)1

Duration of
estrus (h)1

Number of
mounts/female2

ALT3

48/69 (70%)b

55.7±2.6a

8.5±0.6a

35±4a

MGA4

37/75 (50%)a

53.3±4.3a

10.6±0.7b

48±6b

a,b

Within a column, means with different superscripts are significantly different (P<0.05).
h = hours.
2
Indicates the number of mounts per female for the synchronized estrus.
3
ALT=altrenogest.
4
MGA=melengestrol acetate.

1
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Figure 3.2. Distribution of time to the onset of estrus following prostaglandin (PGF2α)
administration for altrenogest (ALT)-treated and melengestrol acetate
(MGA)-treated heifers.
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Figure 3.3. Artificial insemination (AI) scores assigned to heifers that exhibited estrus
that were synchronized with either altrenogest (ALT) or melengestrol
acetate (MGA).
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Table 3.3. Time from prostaglandin (PGF2α) administration to the onset of estrus, mean
duration of estrus and number of mounts per female during estrus for
altrenogest (ALT)-treated and melengestrol acetate (MGA)-treated pregnant
and nonpregnant beef heifers
Behavioral characteristics (mean±SE)
Treatment
group

Status

Time to the onset of
Duration
estrus post-PGF2α (h)1 of estrus (h)1

Number
of mounts/♀

ALT

Pregnant
Nonpregnant

58±2.6
53±5.7

8.4±0.6
9.8±1.5

37±5.8
35±6.8

MGA

Pregnant
Nonpregnant

56±6.1
48±5.1

11.2±0.9
9.4±1.4

58±8.4
32±9.4

Total

Pregnant
Nonpregnant

57±3.0
50±3.6

9.5±0.5
9.6±0.9

48±5.0a
33±5.0b

a,b
1

Within a column, means with different superscripts are significantly different (P<0.05).
h=hours.
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Table 3.4. Pregnancy rates, calving rates and mean birth weight of calves produced
from heifers synchronized with either altrenogest (ALT) or melengestrol
acetate (MGA)
Treatment
group

1

Number
pregnant (%)1

Number
calving (%)

Calf birth
weight (kg)

ALT

27/41 (66%)

23/27 (85%)

33.5±1.0

MGA

23/35 (66%)

20/23 (87%)

34.1±1.0

Due to the inability to transverse the cervix during insemination four heifers were removed from
pregnancy data. Five additional heifers were removed due to severe illness prior to 30-day
pregnancy evaluation.
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Four of these females (two from MGA and two from RGM) were removed due to an
inability to transverse the cervix during insemination while five heifers were removed due
to severe illness before the 30-day pregnancy evaluation.
In this study, there were no significant differences (P>0.05) in the calving rates
between the ALT-treated (23 of 27; 85%) and the MGA-treated group (20 of 23; 87%)
(Table 3.4). In addition, there were no differences in calf birth weights nor were there
abnormal effects among offspring produced from heifers synchronized with either ALT or
MGA. Furthermore, there was no significant effect of estrous synchronization treatment
on the sex ratio of calves from heifers treated with ALT or MGA (Figure 3.4). During the
course of three breeding seasons the ratio of male to female calves for the ALT-treated
calving females were: 33% to 67%, 40% to 60% and 50% to 50% for years 1, 2 and 3,
respectively. The male to female calf ratio for MGA-treated calving heifers were: 45% to
55%, 50% to 50% and 45% to 55% for years 1, 2 and 3, respectively. All calves from
both treatments developed normally and heifer calves subsequently came to puberty as
expected.
Discussion
The objective of this study was to evaluate the ability of a progestin (altrenogest)
to serve as an estrous synchronization regimen in beef heifers. These results
demonstrated that ALT can be an effective progestin, in cattle, when used for estrous
synchronization. Although there was a statistical difference in estrous response rates
between ALT-treated and MGA-treated heifers, this is likely not an indication of the
superiority of ALT over MGA for estrous synchronization. The likely cause of the
statistical difference may be due to the use of a range of 0.4 to 0.5 mg of MGA per
female per day in the MGA-treated group. It should be noted that Zimbelman and Smith
(1966a) have reported that 0.4 mg was the minimum required dose to prevent ovulation
and behavioral estrus in cattle. Therefore, the use of 0.4 to 0.5 mg of MGA resulted in
estrous synchronization but may not have been at an optimal level consumed by each
heifer, even though the estrous response rate among MGA-treated beef heifers was
consistent with ranges reported for MGA estrous synchronization in heifers of similar
ages and weights (Selk et al., 1987; Mauck et al., 1988; Jaegar et al., 1992; Lamb et al.,
2000). The estrous response rate for the ALT-treated group was similar to that of others

55

Figure 3.4. Sex ratio of calves produced from heifers synchronized with
either altrenogest (ALT) or melengestrol acetate (MGA)
treatments.
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who used a different progestin (norgestomet) based synchronization regimen for
yearling beef heifers (Patterson and Corah 1992; Larson et al., 1996; Lamb et al., 2000).
Bloss et al. (1966) reported that at a dose of 0.25 mg to 0.5 mg of MGA per head per
day in beef cattle could effectively prevent behavioral estrus and allow for follicular
development to occur.
At this station, altrenogest was administered to five cycling mature beef cows at
days 16 to 18 of the estrous cycle and behavioral estrus was blocked and follicular
development occurred (Ferguson, unpublished observations). Moreover all females
developed a dominant follicle by the 3rd day of altrenogest treatment and these follicles
began to regress thereafter (Ferguson, unpublished observations) with all females
entering estrus within 5 days following withdrawal of ALT. These observations suggest
that altrenogest and MGA may both have similar affects on suppression of estrus
behavior and altrenogest may not have a deleterious effect on follicular dynamics, as
reported in the mare (Turner et al., 1981; Webel and Squires, 1982; Squires et al.,
1983).
Based on the observation that there were no significant differences in AI scores,
altrenogest does not appear to adversely affect reproductive tract morphology or
oviductal/uterine secretions. Also, with no differences occurring in the duration of estrus
and number of mounts per female between the altrenogest-treated and MGA-treated
heifers, altrenogest appears not to adversely affect behavioral estrus when compared
with a commercially available progestin (i.e. MGA). In evaluating behavioral estrus
between pregnant and nonpregnant females there was a significant increase in the
number of mounts per estrus without a significant increase in the duration of estrus in
pregnant females. This suggests pregnant females had a more intense estrous period
(mounts per hour) at the time of mating when compared with similar heifers that
subsequently did not become pregnant after mating. Therefore this post-treatment estrus
intensity may be correlated to fertility.
AI pregnancy rates achieved from both the altrenogest and MGA protocols in this
study were similar to AI pregnancy rates reported for yearling beef heifers synchronized
using the MGA protocol of 65% (Mauck et al., 1988) and 64% (Patterson and Corah,
1992), but slightly less than pregnancy rates for beef heifers reported by Jaeger et al.
(1992) of 77%, and Lamb et al. (2000) of 76 to 81%. The calving rate from heifers
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impregnated following synchronization with altrenogest or MGA was consistent with this
stations herd calving rate for a 60-day breeding season. These findings indicate that
there are no apparent problems with estrous synchronization and AI, heifers maintaining
pregnancy and calving following altrenogest treatment.
The heifer calves produced from altrenogest-treated heifers exhibited normal
growth rates and normal estrous behavior upon reaching puberty. This finding is in
agreement with similar studies involved in analyzing growth rate of fillies and colts
produced from altrenogest-treated pregnant mares (Naden et al., 1990a). Naden et al.
(1990a) reported no differences between the age at puberty, characteristics of the
estrous cycle or fertility between fillies produced from altrenogest-treated pregnant
mares or control pregnant mares. However, it was noted that fillies produced from
altrenogest-treated pregnant mares had higher serum LH and FSH early in life (e.g. birth
to 7 months-of-age) but was not different in colts. Also, there was no reported difference
in age at onset of puberty in colts produced from altrenogest-treated pregnant mares
compared with those from control pregnant mares (Naden et al., 1990b). It would be
difficult to speculate on the potential differences in gonadotrophins occurring in
prepuberal heifer calves produced from altrenogest synchronized females due to the
brief pre-breeding treatment with altrenogest compared with gestational treatment with
altrenogest in the pregnant mares.
Heifer calves conceived during the first replicate were used in both treatment
groups of the third year replicate. When these heifers produced from altrenogestsynchronized pregnancies were synchronized with altrenogest or MGA they responded
to progestin treatments, became pregnant and delivered live healthy calves. There
appeared to be a trend of more heifer calves produced from altrenogest synchronized
females compared with control females; however, more observations may be needed in
this study to determine an effect of ALT on altering calf sex ratios.
These results demonstrate that a 7-day ALT treatment followed by 25 mg of
PGF2α on the 7th day can be an effective method of estrous synchronization in yearling
mixed-breed beef heifers. Although MGA has been a commonly used oral progestin for
estrous cycle synchronization in beef heifers, it requires a 31-day treatment schedule. In
addition, MGA is less palatable to cattle thereby, requiring it to be pre-mixed with other
feedstuffs or top-dressed with molasses to improve its palatability. In contrast, ALT
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appears to be palatable and heifers readily accept it injected directly into their mouth or
top-dressed on ground corn. In conclusion, this is believed to be the first reported use of
ALT for estrous synchronization in cattle. These results indicate that ALT can be
effectively used for estrous synchronization in heifers; however, further research is
needed to substantiate these findings.
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CHAPTER 4
EFFECTS OF ADMINISTRATION OF P4 OR ALTRENOGEST ON DAYS 3 TO 5
POST-MATING ON PREGNANCY RATES
Introduction
Repeat breeder (RPB) females represent a substantial economic loss to beef
producers. Unfortunately, these animals can only be identified in hindsight. Research
comparing differences between the physiology of subfertile females and fertile females
has provided some insight for improving pregnancy rates among RPB females. Bilateral
ovariectomy with subsequent steroid replacement therapy has failed to enhance
pregnancy rates among RPB beef females compared with that of fertile females (Hawk
et al, 1963). Thus, ovarian dysfunction was not believed to be a primary causative factor
involved in subfertile matings (Hawk et al., 1963). It was later demonstrated that
differences in ovarian function did exist between fertile and nonfertile beef cattle
matings. Bage et al. (2001) reported that RPB females enter estrus with similar follicular
morphology as fertile females but generally experience a prolonged estrus resulting from
a consistent delay in the pre-ovulatory LH peak (Erb et al., 1976; Gustafsson et al.,1986;
Albihn, 1991). Additionally, a higher baseline cortisol level and an increased
responsiveness to adrenocorticotropic hormone challenges are characteristic of RPB
beef females, supporting the hypothesis that decreased fertility may be a result of stress
related delayed ovulation (Bage et al., 2000).
Although stress can be a causative factor for decreased pregnancy rates in RPB
females, other factors such as luteal insufficiency can also detrimentally affect
pregnancy rates in RPB females. Shelton et al. (1990) determined that the postovulatory increase of progesterone (P4) during metestrus was delayed in RPB females
compared with fertile heifers. In vitro culture of metestrous luteal tissue collected from
RPB females was less responsive to LH and PGE2 stimulation (Shelton et al., 1990).
Albihn (1991) reported that corpora lutea (CL) collected from RPB females had
significantly less luteal tissue volume per CL compared with luteal tissue volume per CL
collected from fertile females.
These findings have increased the controversy regarding differences in P4 levels
during metestrus and diestrus between pregnant and nonpregnant cattle (Sreenan and
Diskin, 1983). It is possible that a less than normal rise in circulating P4 levels following
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mating may hinder embryonic development rates in cattle (Gustafsson et al., 1986;
Shelton et al., 1990). In contrast, Linares et al. (1982) found no correlation between
circulating P4 levels and abnormal embryo development in cattle. However, when day-7
embryos were recovered from RPB beef females and transferred to virgin heifers,
embryo survival rates were lower compared with embryo survival rates in virgin heifers
receiving embryos from other virgin heifers (Gustafasson and Larsson, 1983). In a
subsequent study, embryo survival at day 16 or day 17 of the estrous cycle was found to
be lower in RPB females compared with virgin heifers and less day-7 embryos
recovered from RPB females continued to develop when transferred to virgin heifers
compared with embryos collected from virgin heifers and transferred to RPB females
(Gustafasson , 1985).
These results indicate that a portion of the RPB females may have deficient
uterine secretory function resulting from insufficient ovarian function. Stanchev et al.
(1991) reported that virgin heifers have significantly more endometrial P4 receptors than
RPB heifers, although no differences in P4 levels were detected in these females. Also,
often overlooked in these early studies, there has been a trend for a greater increase in
P4 from day 3 to day 6 following the onset of estrus in pregnant females compared with
P4 levels in nonpregnant females (Erb et al., 1976; Linares et al., 1982; Gustafasson et
al., 1986; Shelton et al., 1990).
There have been attempts to improve pregnancy rates in RPB females by
supplementing P4 or luteotrophins, however, these treatments have resulted in
contradictory results regarding pregnancy rates. The administration of hCG or GnRH
during mid-cycle (day 7 of the estrous cycle) has routinely failed to improve pregnancy
rates (Holness et al., 1982; Sreenan and Diskin, 1983; Walton et al., 1990). Also, when
P4 was administered to RPB beef females ~day 7 of the estrous cycle, there was no
consistent increase in pregnancy rates (Wiltbank, et al., 1956; Johnson, et al., 1958; Van
Cleef et al., 1991; Stevenson and Mee, 1991).
The failure of P4 administration to RPB females on day 7 to improve pregnancy
rates may be a factor of imprecise timing. Therefore, the objective of this experiment
was to determine if an artificially induced rise in P4 by administration of low doses of P4
or altrenogest (ALT), on day 3 to day 5 following the onset of estrus could increase
pregnancy rates in RPB females.
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Materials and Methods
Experimental Animals
Experiment 4.1
Crossbred beef heifers (predominantly Red Angus and Simmental) that were
obtained from the Center for Reproductive Biology at Louisiana State University, St.
Gabriel, Louisiana, that ranged in age from 13 to 15 months and body condition scores
(BCS) (scale: 1 = emaciated to 9 = obese) from 5 to 7, were used in Experiment 4.1.
These females were maintained on Costal bremudagrass pasture while being subjected
to estrous synchronization (altrenogest or controlled internal drug releasing device,
CIDR, protocols). All heifers were treated in accordance with guidelines set forth by the
Animal Care and Use Committee of the Louisiana State University Agricultural Center.
Following AI, these heifers were blocked on age, body weight and estrous
synchronization protocol, and then randomly assigned to one of two treatment groups.
Experiment 4.2
In Experiment 4.2, crossbred mature beef cows and heifers (predominantly Red
Angus and Simmental) that were obtained from the Center for Reproductive Biology at
Louisiana State University, St. Gabriel, Louisiana ranged in age from 3 to 10 years and
with BCS ranging from 5 to 8 at the time of treatment. These females were maintained
on Costal bremudagrass pasture. All animals were treated in accordance with guidelines
set forth by the Animal Care and Use Committee of the Louisiana State University
Agricultural Center.
Experimental Design
Experiment 4.1 was a preliminary experiment designed to evaluate the use of
oral administration of ALT on days 3 to 5 following mating to improve pregnancy rates in
heifers following estrous synchronization and artificial insemination (AI).
Experiment 4.2 was designed to test the efficiency of P4 or orally administered ALT
supplemented on days 3 to 5 following mating to improve pregnancy rates in RPB
females. For this experiment, RPB females were defined as cows that that failed to
become pregnant from AI breeding or from embryo transfer during a consecutive 2-year
interval (Figure 4.1). All of these females were then exposed to two fertile Red Angus
bulls for a 60-day breeding season and failed to become pregnant, as determined by
rectal palpation, 90-days following the end of the 60-day breeding season. This breeding
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Figure 4.1. Experimental protocol for classifying females as fertile and repeat breeder (RPB) cows.
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period was designated as the nontreated breeding period in this study. These females
were then classified as RPB females. In the last replicate RPB heifers were also used
and were defined as yearling heifers that were exposed to two fertile Red Angus bulls for
a 60-day breeding season and failed to become pregnant, as determined by rectal
palpation, 90-days following the end of 60-day breeding season.
The control treatment group consisted of cows that were exposed to the same
two fertile Red Angus bulls the previous year, as the females classified as RPB females,
but became pregnant and produced a live healthy calf. The reason for selecting females
mated a year previous to the year that RPB females were exposed to bulls was due to
the 285-day gestation period for the females. By selecting females mated the previous
year it was possible to identify the “fertile” females in retrospect due to the fact they
produced a calf to a 60-day breeding season. The control females then served as a
control treatment group for Experiment 4.2, to determine bull fertility during the treatment
period.
Experimental Procedures
Experiment 4.1
In Experiment 4.1, all females underwent estrous cycle synchronization using
either a CIDR (EAZI-Breed, InterAg, Hamilton, New Zealand) or ALT (Regumate,
Intervet, Millsboro, DE) protocol and were inseminated with semen from fertile beef bulls
(n=3, used across the treatment groups) ~12 hours after the onset of estrus. Following
AI, these females were blocked on estrous cycle synchronization protocol, age and body
weight and then randomly assigned to one of the following treatments. The females
allotted to the ALT treatment group, (n=19) were brought to a restraining chute and
orally (per os) administered 15 mg of ALT on days 3, 4 and 5 following AI (Figure 4.2).
Females selected for the control treatment group (n=36) were brought to the chute on
days 3, 4 and 5 following AI and temporarily restrained but received no further treatment.
All females were examined for pregnancy, 30 days after onset of estrus via transrectal
ultrasonography using an Aloka 500-V ultrasound unit (Corometrics, Wallingford, CT)
equipped with a 5 MHz rectal probe. A pregnancy was defined as the presence of fetus
with a viable heart beats.
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Figure 4.2. The experimental procedure for altrenogest (ALT) treatment of
heifers in Experiment 4.1.
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Experiment 4.2
In Experiment 4.2, all females were pastured with two fertile Red Angus bulls. To
allow for pregnancy determination from only one estrous period the experimental
breeding season (fall) was limited to 25 days and pregnancy exams occurred 30 to 33
days following the 1st mating. To aid in estrus detection, females in replicate I were
outfitted with HeatWatch® estrus detection transponders (HeatWatch®, DDX, Boulder,
CO) prior to exposure to bulls and in replicate II, Estrus Alert patches (Estrus Alert,
Apple Valley, MN) were used to aid in estrus detection. Visual observations not lasting
less than 45 minutes twice daily were used to aid in estrus detection.
In replicate I, females in the P4 treatment group (RPB cows) (n=14) were
administered 15 mg of P4 (Progesterone, Sigma Chemical, St. Louis, MO)
subcutaneously (sc) dissolved in 3 ml of 100% ethanol on days 3, 4 and 5 after the onset
of estrus (day 0=onset of estrus) (Figure 4.3). Females in the control group (fertile cows;
n=14) were administered 3 ml of 100% ethanol sc on days 3, 4 and 5 after the onset of
estrus.
In replicate II, females (RPB cows, n=6 and RPB heifers n=4) in the ALT
treatment were administered 15 mg ALT orally on days 3, 4 and 5 after the onset of
estrus (day 0=onset of estrus) (Table 4.1). Females in the control group (fertile cows,
n=8) were brought to the chute on days 3, 4 and 5 after the onset of estrus and were
restrained but received no further treatment (Table 4.1 and Figure 4.4).
Blood samples were obtained via jugular venipuncture on days 3, 4, 5 and 6
after the onset of estrus and before treatment administration. These samples were
stored on ice immediately following collection and were subsequently centrifuged at 300
x g for 10 minutes. The serum was then stored in a freezer (-4°C) until analysis was to
be performed. In replicate I, serum samples were analyzed following extraction with
acetone for P4 levels using a commercial progesterone radioimmunoassay kit
(Diagnostic Systems Laboratory, Webster, TX). In replicate II, serum samples were
analyzed using a commercial progesterone radioimmunoassay kit (Coat-A-Count
Progesterone, DPC, Los Angeles, CA). These commercial progesterone
radioimmunoassays are not cross-reactive with altrenogest. Females were examined for
pregnancy ~30 days after the onset of gestation via transrectal ultrasonography
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Figure 4.3. The experimental procedure for cows in replicate I of Experiment 4.2.
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Table 4.1. Treatments for experimental groups in Experiments 4.1 and 4.2
Experiment

Treatment group
1

Description

n

Treatments

4.1
4.1

ALT
Control

Heifers
Heifers

19
36

15 mg of ALT
No ALT

4.2
4.2

P4
Control

RPB2 Cows
Fertile Cows

14
14

15 mg of P4
Vehicle3

4.2
4.2
4.2

ALT
ALT
Control

RPB Cows
RPB Heifers
Fertile Cows

7
6
8

1

Altrenogest=ALT.
RPB=Repeat breeder.
3
The carrier for progesterone (P4) was a 3 ml dose of ethanol.
2
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15 mg of ALT
15 mg of ALT
No ALT

Figure 4.4. The experimental procedure for cows in replicate II of Experiment 4.2.
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using an ultrasound machine (Aloka 500-V, Corometrics, Wallingford, CT) equipped with
a 5 MHz rectal probe.
Statistical Analysis
Pregnancy rates within Experiments 4.1 and 4.2 were analyzed using procedures
for categorical data, Chi-square test in SAS (SAS Institute, Inc., Gary, NC). In
Experiment 4.2, serum P4 levels were analyzed by repeated measures analysis of
variance (ANOVA). Differences in serum P4 levels among pregnant and nonpregnant
females were detected using a general linear model (Proc GLM) and Tukey’s Test. The
rise in P4 was determined by subtracting the individual serum P4 value on day 3 from the
individual animal serum value on day 4. Statistical differences in rise of P4 were
determined using the LS means procedure in SAS.
Results
Experiment 4.1
In Experiment 4.1, there were no effects of either estrous synchronization
protocol on pregnancy rates (Table 4.2). In contrast, there were significantly more
(P<0.05) pregnant heifers following AI (9 of 19; 44%) in the post-AI ALT treatment group
compared with the number of heifers pregnant in the control (no ALT) treatment group (7
of 36; 19%) (Table 4.2).
Experiment 4.2
In Experiment 4.2, there were no differences in pregnancy rates between treatment
groups. Pregnancy rates for replicate I were: 6 of 14 (43%) in P4-treated RPB cows and
10 of 14 (72%) in control-treated cows (Table 4.2). In replicate II, the pregnancy rates
were: 3 of 6 (50%) for the ALT-treated RPB cows, 3 of 4 (75%) in ALT-treated RPB
heifers and 4 of 8 (50%) for control-treated cows. However, overall there were no
significant differences (P<0.05) between pregnancy rates during the treatment and
nontreatment periods amoung RPB females. The pregnancy rates for RPB cows,
regardless of P4 or ALT treatment, was 9 of 20 females (45%) during the treatment
period compared with 0 of 20 (0%) during the nontreatment period. The pregnancy rate
for RPB heifers was 3 of 4 females (75%) during the treatment period compared with 0
of 4 females (0%) during the nontreatment period.
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Table 4.2. Pregnancy rates for females treated with progesterone (P4) or altrenogest
(ALT) on days 3, 4 and 5 of the estrous cycle

Experiment

Category

Treatment
group

Number
pregnant

Percent
pregnant

4.1
4.1

AI Heifers
AI Heifers

ALT
Control

9/19
7/36

44a
19b

Replicate I
4.2
4.2
4.2

RPB Cows
RPB Cows1
Fertile Cows

P4
No P4
Control

6/14
0/14
10/14

43a
0b
72a

Replicate II
4.2
4.2
4.2
4.2
4.2

RPB Cows
RPB Cows1
RPB Heifers
RPB Heifers1
Fertile Cows

ALT
No ALT
ALT
No ALT
Control

3/6
0/6
3/4
0/4
4/8

50
0
75
0
50

Pooled
Pooled
Pooled

RPB Pooled
RPB Pooled
Fertile Cows

P4 or ALT
No P4 or ALT
Control

12/24
0/24
14/22

50a
0b
64a

1

Indicates the nontreatment 60-day breeding season that was 5 to 6 months prior to the P4
treatment (25-day) breeding season and included the same two fertile bulls used during
treatment period, for repeat breeders (RPB).
a,b
Means within a column with different superscripts are significantly different (P<0.05).
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The mean(±SE) serum P4 levels for RPB females exposed to bulls in the P4
treatment group were: 0.49±0.09 ng/ml (day 3), 1.7±0.34 ng/ml (day 4), 1.86±0.34 ng/ml
(day 5) and 2.21±0.21 ng/ml (day 6). The serum P4 levels for RPB females in the ALT
treatment group were: 0.67±0.27 ng/ml (day 3), 0.85±0.20 ng/ml (day 4), 2.04±0.44
ng/ml (day 5) and 2.35±0.69 ng/ml (day 6). Due to mechanical failure of the restraining
chute, blood samples were not collected on all RPB heifers. In both replicates there were
no significant differences (P>0.05) in mean serum P4 levels among control females
therefore, the data from both replicates were pooled for this group. Overall, the mean
serum P4 levels for fertile females in the control group were 0.45±0.07 ng/ml (day 3),
0.81±0.08 ng/ml (day 4), 1.59±0.18 ng/ml (day 5) and 1.95±0.16 ng/ml (day 6). There
were no significant differences (P>0.05) among serum P4 levels between P4 or ALT
treatment groups.
In Experiment 4.2 replicate I, mean serum P4 value was significantly lower
(P<0.05) on day 3 (0.25±0.01 ng/ml) in RPB females treated with P4 that were
diagnosed as pregnant compared with P4-treated RPB females on day 3 (0.67±0.01
ng/ml) diagnosed as nonpregnant (Table 4.3 and Figure 4.5). Also, on day 4, the mean
serum P4 value was significantly higher (P<0.05) for P4-treated RPB females diagnosed
as pregnant (2.30±0.7 ng/ml) compared with P4-treated RPB females diagnosed as
nonpregnant (1.22±0.1 ng/ml) (Table 4.3 and Figure 4.5). In addition, there was a
significantly (P<0.05) greater increase (rise) of mean serum P4 levels from day 3 to day
4 in pregnant RPB females (2.07±0.7 ng/ml) compared with nonpregnant RPB females
(0.55±0.12 ng/ml). There were no differences in mean serum P4 levels on day 5,
(1.67±0.15 ng/ml compared with 2.01±0.60 ng/ml) and day 6 (2.22±0.17 ng/ml compared
with 2.20±0.34 ng/ml) between pregnant and nonpregnant P4-treated RPB females,
respectively (Table 4.3 and Figure 4.5).
In Experiment 4.2 replicate II, mean serum P4 levels were not significantly
different (P>0.05) for pregnancy status (pregnant vs. nonpregnant) in ALT-treated RPB
females on day 3 (0.81±0.52 ng/ml compared with 0.54±0.30 ng/ml), day 4
(0.87±0.35ng/ml compared with 0.85±0.27 ng/ml), day 5 (1.96±0.23 ng/ml compared
with 2.12±0.95 ng/ml) or day 6 (1.92±1.08 ng/ml compared with 2.78±1.02 ng/ml),
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Figure 4.5. Serum progesterone (P4) levels in pregnant (preg) and
nonpregnant (nonpreg) repeat breeder (RPB) cows
administered 15 mg of P4 on days 3, 4 and 5 after the onset
of estrus.
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Table 4.3. Serum progesterone (P4) levels in progestin-treated (altrenogest, ALT) and
nontreated females on days 3, 4, 5 and 6 after onset of estrus in Experiment
4.2
Mean(±SE) serum P4 levels
Treatment
group

Pregnancy
status

n

P4
P4

pregnant
nonpregnant

6
8

ALT
ALT

pregnant
nonpregnant

3
3

Control
Control

pregnant
122
nonpregnant 6

Day1
3

Day
4

Day
5

Day
6

0.25±0.0a
0.67±0.1b

2.30±0.7a
1.22±0.1b

1.67±0.1
2.01±0.6

2.21±0.1
2.20±0.3

0.81±0.5
0.54±0.3

0.87±0.3
0.85±0.3

1.96±0.2
2.16±0.9

1.93±1.1
2.78±1.0

0.44±0.1
0.43±0.1

0.89±0.1
0.61±0.2

1.87±0.2c
0.89±0.2d

1.98±0.2
1.89±0.3

1

Number of days after the onset of estrus.
In this group, blood samples were not collected on one female.
a,b
Means within a treatment and column that have a different superscripts are significantly
different (P<0.05).
c,d
Means within a treatment and column that have a different superscripts are significantly
different (P<0.06).
2

74

respectively (Table 4.3). There were no differences in the rise in mean serum P4 levels
from day 3 to day 4 between pregnant (0.05±0.19 ng/ml) and nonpregnant (0.51±0.09)
RPB females. In the control group, there was no significant difference (P>0.05) between
pregnant and nonpregnant females for mean serum P4 levels on day 3 (0.44±0.08 ng/ml
compared with 0.43±0.14 ng/ml) or day 4 (0.89±0.09 ng/ml compared with 0.61±0.19
ng/ml), respectively (Table 4.3 and Figure 4.6). However, the rise in mean serum P4
levels from day 3 to day 4 was significantly greater (P<0.05) in the pregnant females
(0.44±0.06 ng/ml) compared with nonpregnant females (0.20±0.09 ng/ml). There was a
statistical difference (P<0.05) in the mean(±SE) serum P4 levels between pregnant and
nonpregnant control females on day 5 (1.87±0.22 ng/ml compared with 0.89±0.16
ng/ml), respectively but not different on day 6 (1.98±0.17 ng/ml compared with 1.89±0.39
ng/ml), respectively (Table 4.3 and Figure 4.6).
Discussion
The overall pregnancy rate (28%) for heifers in Experiment 4.1 was lower than
expected. The likely cause of this low overall pregnancy rate was that many of the
heifers were probably inseminated during their first or second estrous period after the
onset of puberty. It has been previously reported that pregnancy rates were lower when
heifers were mated during their first or second estrous cycle compared with their third
estrous cycle after the onset of puberty (Byerley et al., 1987). However, treatment with a
low dose of ALT on days 3 to 5 following the onset of estrus did significantly increase
pregnancy rates (44% vs. 19%). This is believed to be the first report investigating the
effects of altrenogest treatment from day 3 to day 5 following the onset of estrus and AI,
on subsequent pregnancy rates.
There have been reports of various attempts at administration of P4, progestins
or luteotrophic substances during the early to mid-luteal phase to increase pregnancy
rates but these reports are conflicting and the treatment protocols vary greatly across
laboratories (MacMillan et al., 1991; Van Cleeff et al., 1991; Larson et al., 1995; Smith et
al., 1996; Mann et al., 1998). Usually, P4 or luteotrophic substances, such as hCG or
GnRH are administered at ~day 7 of the estrous cycle possibly due to the fact that the
majority of embryo transfers occur at day 7 of the estrous cycle. None of these research
groups have evaluated the effects of a progestin treatment from day 3 to day 5 following
estrus.
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Figure 4.6. Serum progesterone (P4) levels in pregnant (preg) and
nonpregnant (nonpreg) “fertile” control (cont) cows on days 3,
4 and 5 after the onset of estrus.
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In Experiment 4.2, we can not compare the serum P4 levels between RPB
females and “fertile” control females because the RPB females in replicate I received P4
that was >99% cross-reactive with the P4 assay used in this study. The rise in serum P4
from day 3 to day 4 was greater in pregnant females compared with nonpregnant
females in the control group. We propose that this increase in P4 levels is beneficial to in
vivo embryo development. Shelton et al. (1990) reported a delayed increase of P4 levels
following ovulation in subfertile cows compared with the levels in fertile heifers. Among
P4-treated RPB cows there was a significantly greater rise of P4 levels in the pregnant
females compared with the levels in nonpregnant females. Since the administered P4
was highly cross reactive (>99%) with the P4 assay, an artificially induced rise in P4 from
day 3 to day 4 after the onset of estrus was noted. Those RPB females with a marked
increase in serum P4, following P4 administration often were those females diagnosed as
pregnant 30 days after the onset of estrus. Although the mechanism of this response is
unknown it is possible that the nonpregnant RPB females metabolized the administered
P4 more quickly than pregnant RPB females.
In replicate II, the RPB females were treated with ALT and because ALT does
not cross react with the P4 assay, the endogenous serum P4 levels could be monitored.
The rise in serum P4 (day 3 to day 4) was not different between pregnant and
nonpregnant females. This was possibly due to a low number of observations in this
group. However, these results must be interpreted with caution because the altrenogest
administered was not cross reactive with the P4 assay, although it appears to be
biologically active. Interestingly, the rise in P4 (day 3 to day 4) from the nonpregnant
ALT-treated RPB females was greater than the rise in pregnant control females. It
should be noted, however, that the day 3 serum P4 level, in these ALT-treated RPB
females were higher than in the pregnant control females. This has been reported to be
characteristic of subfertile dairy cows (Erb et al., 1976; Wilmut et al., 1980).
Erb et al. (1976) and Wilmut et al. (1980) have reported that females tended to
have higher P4 levels immediately following ovulation during an infertile mating than
during a fertile mating. Also, above normal physiological P4 levels during ovulation have
been suggested as a cause of delayed ovulation, and result in decreased fertilization
and pregnancy rates (Hill et al., 1971; Erb et al., 1976; Ireland and Roche, 1982). As a
result, even though the rise in P4 in nonpregnant ALT-treated RPB females was
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numerically greater than the rise in the pregnant control females, the premature elevated
P4 levels could have disrupted fertilization preventing the formation of a viable embryo.
The mean serum P4 levels on day 5 after the onset of estrus were different in the
pregnant and nonpregnant control females. This suggests that the natural increase in P4
may normally occur between day 4 and 5 in fertile females although it is interesting that
pregnancy rates were markedly increased when P4 or ALT were administrated on day 3
in RPB females. Furthermore, in the P4-treated RPB there was a significant difference in
serum P4 on day 3 and 4 in the pregnant and nonpregnant females. Historically,
differences in serum P4 levels have not been reported between pregnant and
nonpregnant females prior to day 10 after mating (Shemesh et al., 1968; Henricks et al.,
1970; Bulman and Lamming, 1978; Lukaszewska and Hansel, 1980). However, in the
present study blood sampling was conducted at 24-hour intervals, as well as the use of
defined fertile (control group) and nonfertile females (RPB group), which could have
allowed for the detection of these differences in P4 levels.
The pregnancy rate for control females is in agreement with the reported
literature for fertile females from a single mating (Ayalon, 1978). However, treatment of
RPB females with P4 or ALT significantly improved pregnancy rates comparable with
those of fertile control females. There have been previous attempts to improve
pregnancy rates in RPB cattle (dairy cows, dairy heifers and beef cows) using a variety
of regimes that utilized GnRH, GnRH analogues, hCG, P4 and progestins. Lee et al.
(1983) reported that GnRH administration at time of insemination significantly increased
pregnancy rates in RPB dairy cows. However, Phatak et al. (1986) failed to find a
significant increase in pregnancy rates among RPB dairy cows using GnRH at time of
AI. It has been found that RPB females characteristically exhibit a longer duration of time
from the pre-ovulatory LH peak until ovulation (Erb et al., 1976; Gustafsson et al., 1986).
Therefore, the inconsistency of the GnRH treatment at time of insemination probably
results from the given number of RPB females that experience delayed ovulation within
a given herd. This same inconsistency of GnRH treatment at the time of AI has also
been reported in normal beef and dairy cattle (Macmillan et al., 1986; Stewart et al.,
1987; Ryan et al., 1991; Mee et al., 1993; Drew and Peters, 1994).
Attempts to increase pregnancy rates in RPB females by stimulating endogenous
P4 production with luteotrophins during diestrus has failed to significantly increase
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pregnancy rates; hCG administration on days 4 to 19 (Holness et al., 1982), hCG
administration on day 5.5 (Walton et al., 1990) and GnRH administration on day 11
(Sheldon and Dobson, 1993). Additionally, these findings are confounded by the reports
that GnRH or hCG can significantly increase P4 levels when administered during this
phase of the estrous cycle in cattle (Rajamahendran and Sianangama, 1992; Schmitt et
al., 1995).
The administration of P4 or progestins after day 6 post-mating has failed to
increase pregnancy rates in fertile beef and dairy cattle (Munro and Bertram, 1990; Van
Cleef et al., 1991; Stevenson and Mee, 1991; Mann et al., 1998). However, when P4 or
progestins are administered prior to day 6 after breeding there was an increase in
pregnancy rates in normal beef and dairy cows (Johnson et al., 1958; Robinson et al.,
1989; Macmillan et al., 1991; Larson et al., 1995). The increased success of P4
supplementation prior to day 6 after breeding compared with luteotrophin administration
prior to day 6, may be the result of differences in luteal tissue development between
fertile and nonfertile females. Albihn (1991) reported that RPB heifers had significantly
smaller luteal tissue volumes compared with those of fertile heifers. This difference may
prevent administered luteotrophins from increasing endogenous P4 to beneficial levels or
may delay the increase of P4 to an inappropriate time. In addition, the luteal tissue from
RPB cows has been reported to be less responsive in vitro to luteotrophins compared
with luteal tissue of fertile females (Shelton et al., 1990). These observations suggest
that direct supplementation of P4 has been more effective in RPB cows than
administration of luteotrophins.
The mechanism of early P4 supplementation on improved embryo developmental
rates and increased pregnancy rates is still conflicting and unclear. In embryo transfer
(ET) recipients, there have been reported increased pregnancy rates with P4
supplementation beginning on ~day 7 (Salgado and Donaldson, 1984; Broadbent et al.,
1992; Nishigai et al., 2002), although, Moore, (1985) and Smith et al. (1996) reported
findings to the contrary. However, administration of hCG at the time of embryo transfer
has been reported to consistently fail to increase pregnancy rates in embryo transfer
recipients (Looney et al., 1984; Ellington et al., 1991). The failure of P4 supplementation
beginning at day 6 of the estrous cycle or thereafter to increase pregnancy rates in ET
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recipients is in agreement with results of P4 supplementation in naturally mated or AI
females from other studies.
In sheep, early P4 administration (days 1 to 6 after mating) has significantly
increased fetal mass and crown rump length at 72 days of gestation (Kleemann et al.
1994). In addition, it has been reported that exposure of ovine embryos to advanced
stage uteri resulted in increased pregnancy rates (Wilumt and Sales, 1981). In cattle,
Garrett et al. (1987) reported that early P4 supplementation on days 1.5 to 4 after the
onset of estrus to naturally mated females resulted in a significant increase in
developmental rates of embryos recovered on day 7 or day 14 compared with control
females. Moreover, early P4 supplementation on days 1.5 to 4 after the onset of estrus,
allowed for the continued development of day-7 to day-8 blastocysts transferred to day-5
recipient females (Geisert et al. 1991a). EL-Banna and Hafez (1970) and Crisman et al.
(1980) have reported that early P4 administration stimulated the rate of migration of
bovine embryos from the oviduct to the uterus. This corresponds with reports that early
P4 supplementation stimulated uterine secretions and function in supporting embryonic
development (Garrett et al., 1988; Geisert et al., 1992; Barnes, 2000). Collectively, it is
likely that early P4 supplementation hastens the transport of the embryo into the
stimulated uterus providing a more hospitable environment for the developing embryo.
In conclusion, early supplementation of P4 or ALT to RPB females resulted in
increased pregnancy rates after AI and bull exposure. The increased pregnancy rates
are likely the result of an induced rise in P4 between days 3 to 5 after the onset of estrus.
These data suggest that supplementation of low doses of P4 should be considered as a
practical and effective treatment for subfertile cattle.
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CHAPTER 5
EFFECT OF PROGESTERONE ON BOVINE EMBRYO
DEVELOPMENT IN VITRO
Introduction
Progesterone (P4) has been shown to be the principal hormone of pregnancy in
the cow (McDonald et al., 1952). Although, the necessity of P4 during early pregnancy
has been accepted, there have been various studies that attempted to determine the
effects or mechanism of action that P4 exerts during this interval. A few of these studies
have focused on the effects P4 exerts on pregnancy through the uterus (Garret et al.,
1988).
There has been much controversy over the efficiency of P4 supplementation to
improve pregnancy rates when administered to mated females (for review see Sreenan
and Diskin, 1983). A few studies have indicated that used P4 supplementation during
early pregnancy (prior to day 7) has demonstrated positive effects on pregnancy rates or
embryo developmental rates (Garret et al., 1988; Geisert et al., 1991a). In the cow, P4
levels begin to increase from day 3 following the onset of estrus (Henricks et al., 1970;
Henricks et al., 1971; Kindahl et al., 1976) at which time, the embryo is about to enter
the uterus (EL-Banna and Hafez, 1970). However, when P4 is administered to the
pregnant cow prior to this time, there has been reported a hastened rate of transport of
the embryo from the oviduct into the uterus (Crisman et al., 1980). This increase in
transport following P4 administration occurs in other species, such as the mouse
(Roblero and Garavagno, 1979), the rat (Forcelledo et al., 1982), the sheep (Moore et
al., 1983) and the pig (Day and Polge, 1968). In addition, if P4 is administered prior to
fertilization the number of cleavage stage embryos is then decreased in the hamster
(Hunter, 1972), the rabbit (Chang, 1967; Chang, 1969; Nutting and Mares, 1970), the
sheep (Johnsson et al., 1974), the pig (Day and Polge, 1968) and the cow (Hill et al.,
1971; Imwalle et al., 2002).
After the embryo migrates from the oviduct into the uterus, P4 prevents uterine
myometrial contractions (Rhodes and Nathanielsz, 1990), which allows for a ‘quiet’
environment for embryo development to occur. Concomitantly, P4 stimulates the
production and release of many uterine proteins and growth factors (Dixon and Gibbons,
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1979; Garrett et al., 1988; Geisert et al., 1988; Rider et al., 1998; Barnes, 2000) as well
as immunosuppressive proteins (Fisher et al., 1985).
It has also been demonstrated that low P4 levels during early pregnancy can
increase the intensity of the luteolytic signal (and increased prostaglandin F2α metabolite)
on days 12 to 16 of the estrous cycle (Mann and Lamming, 1995). Conversely, it was
later demonstrated that high levels of P4 during early pregnancy could decrease the
intensity of the luteolytic signal by decreasing PGF2α levels though inhibitory effects on
oxytocin receptors (Lamming and Mann, 1995a) and alter the timing of the luteolytic
signal (Mann et al., 1998). Elevated P4 levels during early pregnancy also resulted in
increased embryo production of interferon tau, increased uterine PGE2 levels and
decreased uterine PGF2α levels as well as a need for less interferon tau to prevent
luteolysis from occurring (Niswender et al., 1994; Mann and Lamming, 2001). It is
unknown by which mechanism P4 stimulates increased interferon tau production from
the concpetus and a direct effect on developing embryos has not been established.
Although the necessity of P4 during early pregnancy is accepted and there have
been several studies relating to P4 supplementation in pregnant females, there have
been few attempts to determine the effects of P4 supplementation on embryos in an in
vitro culture (IVC) system (Whitten, 1957, Kirkpatrich, 1971, Roblero and Izquierdo,
1976, Wiemer et al., 1987). Early studies have suggested that P4 supplemented media
had an inhibitory effect on early stage mouse embryos (Whitten, 1957; Kirkpatrick, 1971)
and rabbit (Daniel, 1964) embryos. Other studies have indicated that elevated levels of
P4 prior to or at time of fertilization have detrimental effects in vivo (Day and Polge, 1968;
Chang, 1969; Fraser and Maudlin, 1979; Hill et al., 1971).
Fukui et al. (1982) demonstrated that P4 supplementation to in vitro oocyte
maturation culture (IVM) systems decreased the rate of bovine oocyte maturation and
that the addition of P4 to fertilization culture medium did not improve the number of
cleavage stage embryos (Fukushima and Fukui, 1985). Similarly elevated P4
concentrations at the time of fertilization are generally a characteristic of infertile females
or repeat breeder females (Erb et al., 1976, Gustaffason et al., 1986). Thus, addition of
P4 during fertilization or immediately there after in vitro would be at a time that P4 is not
readily available to the ovum or embryo and may be a major problem with some
approaches to hormone supplementation of embryo culture systems.
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IVC with P4 supplementation in conjunction with oviduct or uterine cell co-culture
systems has not increased the number of bovine embryos developing to the blastocyst
stage (Wiemer et al., 1987; Fukui, 1989; Goff and Smith, 1998, Reggio et al., 1998),
although it was shown to increase blastocyst yield in vitro in the mouse (Lavaranos and
Seamark, 1989).
The main drawbacks of the studies to determine the effect of P4 on embryo
development have apparently been addition of P4 at an inappropriate time or the use of
co-culture systems that prevent the detection of direct effects because of supplementary
cell interactions. Therefore, the objective of these experiments were to determine if P4
exerts a direct effect on the developing IVC bovine embryo when supplemented at
appropriate stages of embryo development, in the absence of a monolayer co-culture
system.
Materials and Methods
Media Preparation
Oocyte maturation medium was prepared and equilibrated at 39˚C and 5% CO2
at a commercial company processing center (BOMED, Inc., Madison, WI or OvaGenix
LP., San Angelo, TX). Other media was prepared at the Center for Reproductive Biology
at Louisiana State University, St. Gabriel, LA and equilibrated at 39˚C and 5% CO2. For
the fertilization medium, Brackett-Oliphant (BO) stock medium was prepared as
described in Appendix A and B and for embryo culture, CR1aa stock medium was
prepared as described in Appendix C (Rosenkrans and First, 1994).
The oocyte washing and fertilization media were prepared by the addition of 38
ml of BO-A stock solution to 12 ml of BO-B stock solution at which time 0.685 mg of
pyruvic acid (P-4562, Sigma Chemcial Co., St. Louis, MO), 50 µl of Gentamicin (15750060, Gibco, Grand Island, NY) and 25 µl of 10,000 IU/ml heparin sodium were added.
BO-caffeine (semen washing and fertilization medium) was prepared by the addition of
24.3 mg of caffeine sodium (C-4144, Sigma Chemical Co., St. Louis, MO) to 25 ml of
BO-AB solution. BO-BSA 0.3% medium (oocyte washing) was prepared by the addition
of 30 mg of bovine serum albumin (BSA; A-7511, Sigma Chemical Co., St. Louis, MO) to
10 ml of BO-AB solution. The BO-BSA 0.6% medium was prepared by the addition of
30 mg of BSA to 5 ml of the BO-AB solution.
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In Vitro Fertilization
For insemination, semen from a fertile Holstein bull (CSS 7H5918, Genex
Cooperative Inc., Shawano, WI) was thawed in a water bath at 40°C for 15 to 45
seconds and then was placed in a 15 ml conical tube (Corning 15-ml conical tubes;
Myriad Industries; San Diego, CA) with 9 ml of BO-caffeine solution and centrifuged at
200 x g for 6 minutes. After completion of the 6 minute cycle, the supernatant was
removed while leaving the semen pellet and 9 ml of BO-caffeine solution was added to
the semen pellet. This solution was then centrifuged again at 200 x g for 6 minutes. The
supernatant was removed again and the semen was resupended in 4 ml of BO-caffeine
solution and 4 ml of BO-BSA 0.6% medium. Then 100-µl droplets of this solution were
made in 35 mm Falcon™ plastic petri dishes (Becton and Dickinson, Lincoln Park, NJ)
under mineral oil (Sigma M-8410, Sigma Chemical Co., St. Louis, MO) and then placed
in an humidified incubator at 39°C and 5% CO2.
Following a 24-hour oocyte maturation period, oocytes were removed from the
maturation medium and washed through two 35 mm Falcon™ plastic petri dishes each
containing 3.5 ml of BO-BSA 0.3% medium. Once the oocyte washing was completed,
15 to 20 oocytes were placed per 100-µl fertilization droplet and all dishes were returned
to the incubator for 5 to 6 hours.
In Vitro Culture
After a 5 to 6 hour insemination period, oocytes were removed from the
insemination droplets and washed through two 35 mm Falcon™ plastic petri dishes
each containing 3.5 ml of 10 ml TCM-199 (Gibco Laboratories, Grand Island, NY) and 30
mg of fatty acid-free bovine serum albumin (FAF-BSA) (Fatty Acid Free-BSA, A-4503,
Sigma Chemical Co., St. Louis, MO) solution. Once oocytes were washed, cumulus cells
were removed by vortexing (Vortex-genie mixer, Scientific Products, McGraw Park, IL)
the inseminated oocytes for 3 minutes in 1 ml of TCM-199 and 1 mg of hyaluronidase
(H-3506, Sigma Chemical Co., St. Louis, MO).
The inseminated oocytes were then washed through two dishes of 3.5 ml of
TCM-199 and 30 mg of fatty acid-free bovine serum albumin FAF-BSA. Following the
washing steps, inseminated ova were then placed in 50-µl droplets of modified CR1aa
[9.5 ml CR1aa medium (Appendix C), 200 µl of BME amino acid solution (B-6766, Sigma
Chemical Co., St. Louis, MO), 100 µl of MEM amino acid solution (11140-050, Gibco
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Laboratories, Grand Island, NY), 10 µl of Gentamicin (Gibco Laboratories, Grand Island,
NY), 1.46 mg of L-glutamine (G-5763, Sigma Chemical Co., St. Louis, MO) and 30 mg
FAF-BSA]. The dishes were then placed in an air-tight modular incubator (BillupsRothenberg®, Del Mar, CA) that was filled with 5% CO2, 5% O2 and 90% N2 gas for 4
minutes at 2 psi and then placed in a humidified 5% CO2 incubator at 39°C.
At 72 hours post-insemination, sperm exposed ova were removed from embryo
culture medium and placed in fresh CR1aa embryo culture medium that was modified by
the supplementation of 500 µl of 10% heat-inactivated fetal bovine serum (FBS,
SH30070.02, Hi Clone Laboratories, Logan, UT).
Experimental Design
In Experiment 5.1, modified CR1aa supplemented with ~15 ng/ml of P4
(Progesterone, Sigma Chemical Co., St. Louis, MO) dissolved in 100% ethanol, was the
designated P4-treatment group for embryo culture (Treatment A), and the standard
modified CR1aa medium served as the control treatment (Control) for embryo culture
(Treatment B). At 72 hours post-insemination, morphologically good quality 8-cell
embryos were randomly allotted to Treatments A and B. The cumulus cells were
removed from all inseminated ova, allowing an embryo culture environment that
precluded somatic cell involvement. This experimental design allowed the detection of
direct effects of treatments on embryo developmental and development rates.
In Experiment 5.2, Treatments A and B in Experiment 5.1 were continued;
however, a carrier-vehicle treatment (Vehicle) of modified CR1aa supplemented with 10
µl of 100% ethanol was added to the experimental design. In this experiment, 173 IVFderived embryos were allotted to the P4 treatment group (Treatment A), 170 embryos
were allotted to the vehicle treatment group (Treatment B) and 168 embryos were
allotted to the control treatment group (Treatment C).
In Experiments 5.1 and 5.2 embryos were placed in treatment medium and
returned to the airtight modular incubator inoculated with 5% CO2, 5% O2 and 90% N2
gas for 4 minutes at 2 psi and then placed in a humidified 5% CO2 incubator at 39°C.
Medium was changed at 7 days post-insemination and embryo culture was discontinued
at 9 days post-insemination.
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Embryo Evaluation
All embryo evaluations were conducted by using an inverted microscope (Nikon
Diaphot, Tokyo, Japan). At 72 hours post-insemination, embryos were evaluated to
determine those that had reached the 8-cell or greater stages, at which time the
embryos at less than the 8-cell developmental stage were discarded. Additional embryo
evaluations were completed at 6, 7, 8 and 9 days post-insemination and embryos at the
morula, early blasocyst (EBLST), blastocyst (BLST), expanded blastocyst (EXBLST),
hatching blastocyst (HTBLST) or hatched blastocyst (HBLST) stages were recorded for
each of these observational days. On day 7, blastocysts were randomly selected from
each treatment to measure embryo diameter. Embryo diameter measurements were
collected by use of an inverted microscope equipped with a video camera connected to
an S-VHS VCR and a color monitor and used to evaluate the embryos using a
micrometer slide. The embryos were placed on the inverted scope and their projected
image was measured on the television screen. In addition to these measures embryos
were assigned a red score based on the stage of embryo development and
morphological quality as developed by Ryan et al. (1992).
Statistical Analysis
In Experiments 5.1 and 5.2, statistical differences between the mean number of
embryos that reached the morula stage on day-6 post-insemination, the blastocyst stage
on day-7 post-insemination and the hatched blastocyst stage on day-9 post-insemination
were determined by using procedures for categorical data, with Chi square analysis.
Statistical differences between mean embryo diameters on day-7 post-insemination
were determined by Chi square analysis. The effects of treatments on embryo
developmental rates (mean number of embryos at each developmental stage on various
days post-insemination) were determined by the analysis of variance (ANOVA)
procedure of the general linear model procedure and statistical differences were
determined by the least squares method. All statistical procedures were performed
using the SAS statistical package (SAS Institute, Inc., Gary, NC).
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Results
Experiment 5.1
In Experiment 5.1, a total of 280 bovine oocytes (in 3 replicates) were
inseminated and 221 (79%) developed to the 2-cell stage and 206 (74%) reached the 8cell stage or greater by 3 days post-insemination. On day-6 post-insemination, there
tended to be more (P<0.07) 8-cell embryos developing to the morula stage in the P4
treatment group (70 of 104; 67%) compared with the control group (52 of 102; 51%)
(Table 5.1). On day-7 post-insemination, there were significantly more (P<0.05)
blastocysts in the P4-treated group (61 of 104; 59%) compared with the control treatment
group (41 of 102; 40%). On day-9 post-insemination, the P4 treatment group produced
significantly more (P<0.05) hatching and hatched blastocyst (41 of 104; 39%) compared
with the control treatment group (20 of 102; 20%).
The rate of in vitro embryo development was accelerated by treatment with P4 in
this experiment. On day-6 post-insemination there were significantly more (P<0.05)
embryos at the early blastocyst stage (42 of 98; 40%) and blastocyst stage (4 of 98; 1%)
in the P4 treatment group compared with the control group with (18 of 98; 18%) of
developed embryos at the early blastocyst stage and (0 of 98; 0%) at the blastocyst
stage, respectively (Table 5.2). On day-8 post-insemination there was a significantly
greater (P<0.05) proportion of all developed embryos at the hatched blastocyst stage
(29 of 98; 28%) in the P4 treatment group compared with (10 of 98; 11%) hatched
blastocysts in the control treatment group (Table 5.3).
From the blastocysts randomly selected from the P4 (n=23) and control (n=9)
treatment groups on day-7 post-insemination, the P4-treated embryos had a significantly
larger mean±SE diameter (P<0.05) (183±2.1 µm) than the control treatment embryos
(172±4.3 µm) (Table 5.4). More embryos were measured in the P4 treatment group than
the control treatment group because more blastocysts were present in the P4 treatment
groups at the time of the measurements.
Experiment 5.2
In Experiment 5.2, a total of 881 bovine oocytes (in 5 replicates) were
inseminated with 749 (85%) developing to the 2-cell stage and 511 of these oocytes
(58%) developing to the 8-cell or greater stage embryos by day-3 post-insemination. On
day-6 post-insemination, one replicate was not evaluated for development and thus, the
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Table 5.1. Number of P4-treated and control 8-cell bovine embryos in Experiment 5.1
that reached the morula, blastocyst and hatched blastocyst developmental
stages in respective treatments
Treatment
group

No. morulae1 (%)

No. blastocysts2 (%)

No. hatched
blastocysts3,4 (%)

P45

70/104 (67)a

61/104 (59)a

41/104 (39)c

Control

52/102 (51)b

41/102 (40)b

20/102 (20)d

1

Morulae were evaluated at 6 days post-insemination.
Blastocysts were evaluated at 7 days post-insemination.
3
Hatched blastocysts were evaluated at 9 days post-insemination.
4
Hatched blastocysts represents embryos developing to the hatching or hatched blastocyst
stage.
5
P4=progesterone.
a,b
Within a column, numbers with different superscripts are significantly different (P<0.10).
c,d
Within a column, numbers with different superscripts are significantly different (P<0.05).
2
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Table 5.2. Number of P4-treated and control 8-cell bovine embryos in Experiment 5.1
cultured in respective treatments that reached morula, early blastocyst,
blastocyst or expanded blastocyst stages on day-6 post-insemination
Treatment
group

1
a,b

No.
morulae (%)

No. early
blastocysts (%)

No.
blastocysts (%)

No. expanded
blastocysts (%)

P41

23/98 (22)

42/98 (40)a

4/98 (1)

0/98 (0)

Control

34/98 (33)

18/98 (18)b

0/98 (0)

0/98 (0)

P4=progesterone.
Within a column, numbers with differing superscripts are significantly different (P<0.05).
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Table 5.3. Number of P4-treated and control 8-cell bovine embryos in Experiment 5.1
cultured in respective treatments that reached early blastocyst, blastocyst,
expanded blastocyst, or hatched blastocyst stages on day-8 postinsemination
Treatment
group

No. early
No.
blastocysts (%) blastocysts (%)

No. expanded
blastocysts (%)

No. hatched1
blastocysts (%)

P42

2/98 (2)

10/98 (10)

27/98 (26)

29/98 (28)a

Control

6/98 (6)

14/98 (15)

20/98 (21)

10/98 (11)b

1

Hatched blastocysts represents embryos developing to the hatching or hatched blastocyst
stages.
2
P4=progesterone.
a,b
Within a column, numbers with different superscripts are significantly different (P<0.05).

90

Table 5.4. Mean diameter of blastocyst stage bovine embryos in Experiment 5.1
cultured in respective treatments on day-7 post-insemination
Treatment
group
P41
Control
1
a,b

No.
blastocysts

Mean (±SE) embryo
diameter (µm)

23

183±2.1a

9

172±4.3b

P4=progesterone.
Within a column, means with different superscripts are significantly different (P<0.05).
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number of morula is based only on the number of embryos evaluated at this time which
was 98 embryos for per treatment group.
As noted in Experiment 5.1, the rate of embryo development in vitro was
advanced by P4 treatment. Among the treatment groups, significantly more (P<0.05) P4
treatment embryos (8 of 98; 8%) developed to the blastocyst stage by day-6 postinsemination compared with vehicle treatment embryos (3 of 98; 3%) and the control
group (0 of 98; 0%) (Table 5.5). There was a trend (P<0.10) for more 8-cell bovine
embryos developing to the morulae stage in the P4 treatment group (73 of 98; 75%) and
the control group (70 of 98; 71%) compared with the vehicle group (57 of 98; 58%)
(Table 5.6). Also, on day-7 post-insemination, there was a trend for more (P<0.10)
blastocysts in the P4-treated group (123 of 173; 69%) compared with the control group
(104 of 168; 62%). In addition, there were significantly more (P<0.05) blastocysts in the
P4 and control groups compared with the vehicle group (90 of 170; 53%) (Table 5.5). On
day 9 post-insemination, the P4 treatment group produced significantly more (P<0.05)
hatching and hatched blastocyst (57 of 173; 33%) compared with the vehicle group (37
of 170; 22%) and the control group (36 of 168; 21%) (Table 5.5).
On day 7 post-insemination, there were significantly more (P<0.05) Grade-1
blastocysts in the P4 treatment group (43 of 173; 25%) compared with the vehicle group
(26 of 170; 15%) and the control group (28 of 168; 17%) (Table 5.6). In contrast, there
were no statistical differences (P>0.05) in the number of Grade-2 blastocysts on day 7
post-insemination between any of the treatment groups.
From the blastocysts randomly selected from the P4 treatment (n=34), vehicle
treatment (n=28) and control treatment (n=30) groups on day 7 post-insemination, the
P4-treated embryos had a significantly larger mean(±SE) diameter (187±4.1 µm) than the
vehicle-treated embryos (174±3.3 µm) and the control embryos (176±3.4 µm) (Table
5.7). In addition, on day-8, post-insemination, there was a significantly greater proportion
(P<0.05) of all developed 8-cell embryos at the hatched blastocyst stage in the P4
treatment group (36 of 173; 21%) compared with the vehicle treatment group (21 of 170;
12%) and the control treatment group (14 of 168; 8%) (Table 5.8). Over the course of the
4-day evaluations there was a significant increase in the mean embryo red score for
embryos cultured in P4 compared with vehicle-treated embryos or control embryos for
day 6 and day 9 (Table 5.9). The mean embryo red score was significantly lower for
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Table 5.5. Number of P4-treated and control 8-cell bovine embryos in Experiment 5.2
that reached the morula, blastocyst and hatched blastocyst developmental
stages in respective treatments
Treatment
group

No. morulae1 (%)

No. blastocysts2 (%)

No. hatched
blastocysts3,4 (%)

P45

73/98 (75)a

123/173 (71)a

57/173 (33)d

Vehicle6

57/98 (58)b

90/170 (53)b

37/170 (22)e

Control

70/98 (71)a

104/168 (62)c

36/168 (21)e

1

Morulae were evaluated at 6 days post-insemination.
Blastocysts were evaluated at 7 days post-insemination.
3
Hatched blastocysts were evaluated at 9 days post-insemination.
4
Hatched blastocysts represents embryos developing to the hatching or hatched blastocyst
stage.
5
P4=progesterone.
6
Vehicle=ethanol.
a,b,c
Within a column, numbers with differing superscripts are significantly different (P<0.10).
d,e
Within a column, numbers with differing superscripts are significantly different (P<0.05).
2
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Table 5.6. Number of grade 1 or 2 bovine blastocyst staged embryos in Experiment 5.2
on day-7 post-insemination
Treatment
group

No. grade-1
blastocysts (%)

P41

43/173 (25)a

53/173 (31)a

Vehicle2

26/170 (15)b

43/170 (25)a

Control

28/168 (17)b

53/168 (32)a

1

No. grade-2
blastocysts (%)

P4=progesterone.
Vehicle=ethanol.
a,b
Within a column, numbers with different superscripts are significantly different (P<0.05).
2
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Table 5.7. Mean diameter of blastocyst staged bovine embryos in Experiment 5.2
cultured in respective treatments on day-7 post-insemination
Treatment
group

No.
blastocysts

Mean (±SE) embryo
diameter (µm)

P41

34

187±4.1a

Vehicle2

28

174±3.3b

Control

30

176±3.4b

1

P4=progesterone.
Vehicle=ethanol.
a,b
Within a column, numbers with different superscripts are significantly different (P<0.05).
2
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Table 5.8. Number of P4-treated and control 8-cell bovine embryos in Experiment 5.2
cultured in respective treatments that reached early blastocyst, blastocyst,
expanded blastocyst, or hatched blastocyst stage on day-8 postinsemination
Treatment
group

No. early
blastocysts

No.
blastocysts (%)

No. expanded
blastocysts (%)

No. hatched1
blastocysts (%)

P42

0/173 (0)

36/173 (21)

42/173 (24)

36/173 (21)a

Vehicle3

0/170 (0)

30/170 (18)

39/170 (23)

21/170 (12)b

Control

3/168 (2)

41/168 (24)

47/168 (28)

14/168 (8)b

1

Hatched blastocysts represents embryos developing to the hatching or hatched blastocyst
stages.
2
P4=progesterone.
3
Vehicle=ethanol.
a,b
Within a column, numbers with different superscripts are significantly different (P<0.05).
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Table 5.9. The mean red score per embryo per treatment over the four observatory
periods of embryo development
Mean±SE red score per embryo
Treatment
group

.
Day 6

P41

0.92±0.08

Vehicle2
Control
1
2
a,b

Day 7
a

Day 8
a

Day 9
a

1.88±0.14

2.56±0.23

3.26±0.27a

0.55±0.06b

1.43±0.14b

2.21±0.23ab

2.48±0.26b

0.68±0.06b

1.49±0.13ab

1.88±0.18b

2.52±0.26b

P4=progesterone.
Vehicle=ethanol.
Within a column, numbers with different superscripts are significantly different (P<0.05).
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vehicle-treated embryos on day 7 compared with P4-treated or control embryos (Table
5.9).
Discussion
In Experiments 5.1 and 5.2, the supplementation of P4 to the CR1aa culture
medium significantly increased the number of 8-cell bovine IVF-derived embryos that
developed to the blastocyst stage on day 7 and the hatched blastocyst stage on day 9,
post-insemination. These postive findings were not in agreement with those of Fukui et
al. (1982), Wiemer et al. (1987), Fukui (1989), Reggio (1997) and Goff and Smith (1998),
who added P4 to a co-culture embryo culture system for bovine embryos. Furthermore,
these studies supplemented P4 to the culture medium at 20 hours post-insemination
(Fukui et al., 1982; Wiemer et al., 1987; Fukui, 1989 and Goff and Smith, 1998). These
results may have occured because pre-cleavage stage embryos would not have been
exposed to moderate or elevated levels of P4 as they would have been if in vivo.
Moreover, elevated P4 levels following fertilization has been a characteristic of repeat
breeder cattle and/or infertile matings to fertile bulls (Erb et al., 1976; Gustafsson, 1986).
The results of Reggio (1997) may have been confounded by the use of water soluble P4
supplementation in the embryo culture medium. The levels of P4 used in these studies,
with the exception of Goff and Smith (1998), are much greater than the circulating levels
in the cow during the early stages of the estrous cycle. Also these experiments (Fukui et
al., 1982; Wiemer et al., 1987; Fukui, 1989; Goff and Smith, 1998) utilized co-culture
systems using bovine uterine cells, which could have confounded the results on the
direct effects of P4 on the developing embryo.
Using water soluble P4, Reggio (1997) reported that P4 supplementation in the
absence of a co-culture system did not significantly increase embryo developmental
rates. However, when water soluble P4 was used in the presence of a somatic cell coculture system P4 supplementation of the medium increased the number of embryos
developing to the blastocyst stage. An increase in the number of embryos developing to
the blastocyst stage has been previously reported with lipid soluble P4 supplementation
in the culture medium for mouse embryos (Kirkpatrick, 1971; Lavranos and Seamark,
1989) and rabbit embryos (EL-Banna and Daniel, 1972). In the present study, the
decrease in the number of embryos developing to the blastocyst stage in the P4 vehicle
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(ethanol) treatment group was unexpected. However, these findings indicate that P4, not
ethanol, must have a beneficial effect on the developing IVC embryos to increase the
number of embryos developing to the blastocyst stage in vitro.
Stachecki et al. (1994) reported that the exposure of murine embryos to ethanol
stimulated that rate of expansion of blastocyst stage embryos. In addition, Wiebold and
Becker (1987) reported that ethanol supplementation in the medium of murine embryos
increased the number of embryos that implanted when transferred but no significant
increase was observed in the number of pups born. In the present study, there was no
difference in the number of hatched blastocyst on day-9 post-insemination between the
vehicle treatment and control groups. The results of our experiment suggests the
opposite effect of ethanol on IVF-derived bovine IVC embryos compared with the effect
of ethanol reported for mouse embryos. It is possible that ethanol is subsequently
detrimental to pre-blastocyst staged bovine embryos but beneficial to blastocyst staged
bovine embryos. Additional experiments that utilize different carrier vehicles would be
beneficial.
Results from the current study indicate that the addition of a physiological level of
P4 (~15 ng/ml) to the culture medium of developing 8-cell bovine embryos increased the
rate of embryo development. In the P4-treatment group, on day-6 post-insemination,
there were significantly more early blastocysts and blastocysts compared with that of the
control culture medium in Experiment 5.1, and significantly more blastocysts compared
with that of the vehicle and control groups in Experiment 5.2. On day 8 postinsemination, there were significantly more hatched blastocysts in the P4 treatment
group compared with the control group in Experiment 5.1 and significantly more hatched
blastocysts compared with the vehicle and control groups in Experiment 5.2.
This increase in embryo developmental rates following P4 supplementation was
reported to occur in vivo (Garret et al., 1987; Garret et al., 1988). When ovine embryos
were transferred to an advanced stage uterus (asynchronous embryo transfer) the
embryos were found to hasten their developmental rate to match the stage of the uterus
(Wilmut and Sales, 1981). Furthermore, this accelerated rate of development was more
prevalent in early staged ovine embryos (prior to the blastocyst stage) than in later
staged ovine embryos (Lawson et al., 1983). Although, there are limits to the degree of
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asynchrony that ovine embryos can withstand and asynchrony greater than 4 days can
result in rapid development but without continued pregnancy (Lawson and Cahill, 1983).
This accelerated embryo developmental rate has also been reported in P4
supplemented cattle. Garret et al. (1988) demonstrated that rapid bovine embryo
development occurred when inseminated females were supplemented with P4 from day
1.4 to 4 (day 0 = estrus). An increased rate of uterine secretions was detected with P4
administration to cows during the first 4 to 5 days of the estrous cycle, and this treatment
was hypothesized to stimulate the rate of embryo development in vivo (Garrett et al.,
1988; Geisert et al., 1992). The increase in developmental rates have been reported to
have lasting effects on the ovine conceptus where fetuses from P4 supplemented ewes
on days 1 to 6 following mating had a significantly greater crown-rump length compared
with fetuses from control ewes (Kleemann et al., 1994; Kleemann et al., 2001). Geisert
et al. (1988) have reported that the increased bovine embryo developmental rates in vivo
were caused by P4, IGF-II and IGFBP-2 signaling in the uterine endometrium. However,
it remains to be determined if the increased embryo development in these studies is due
to the advanced uterine secretory state or due to a direct effect of P4 on the developing
embryo.
The accelerated embryo growth rate in our study was also evident in the
diameter differences of the developing IVC bovine embryos. Embryos cultured in the
presence of P4 had a significantly greater mean diameter than embryos in the vehicle
and control groups. This increased diameter is reflective of embryos undergoing
expansion earlier than embryos in the vehicle and control groups. This accelerated
development rate was also reported by Reggio (1997) when IVF-derived bovine
embryos were cultured in the presence of water soluble P4 and somatic cell co-culture.
In the present study, there were more grade-1 quality embryos on day-7 postinsemination produced in the P4 treatment group compared with the vehicle-treated and
control groups. In contrast, there was no difference in the number of grade-1 embryos
produced between the vehicle and the control group. This demonstrates that the
increased rate of development in the presence of P4 was not detrimental to embryo
quality. Furthermore, these results demonstrated that P4 may be a viable option for
supplementing IVC systems to increase the number of transferable bovine IVF-derived
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embryos. The next step would be to transfer embryos cultured in the presence of P4 to
verify that pregnancies can be established.
In conclusion, the addition of physiological levels of P4 to embryo culture medium
on day 3 post-insemination was beneficial to embryo development in several ways.
First, P4 supplementation increased the number of IVC embryos developing to the
blastocyst stage by day-7 post-insemination, as well as the number of hatched
blastocysts on day-9 post-insemination. Second, P4 supplementation hastened the rate
of embryo development and increased the number of grade-1 blastocysts on day 7 postinsemination. By supplementing the IVC culture medium with P4 at the same stage of
development that the embryo would normally be exposed to increasing levels of P4 it
was demonstrated that P4 can exert a positive direct effect on the developing IVC bovine
embryo.
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CHAPTER 6
AN ATTEMPT TO DETECT PROGESTERONE RECEPTORS IN EARLY STAGES OF
IN VITRO-PRODUCED BOVINE EMBYROS
Introduction
During metestrus in a pregnant cow, the 8-cell bovine embryo begins to undergo
genomic activation prior to its migration into the uterus (Barnes and First, 1991;
Crissman et al. 1980). Coincidently, the corpus luteum (CL) is beginning to synthesize
and secrete progesterone in measurable quantities into the circulatory system. It has
been established that P4 contributes to the control of the rate of embryo transport into
the uterus in the cow (EL-Banna and Hafez, 1970; Crisman et al., 1980). However, it is
unknown if endogenous P4 plays a direct role in regulating genomic activation in the
cow.
Benefits to increased P4 levels during early metestrus in cattle have been
demonstrated in vivo (see Chapter 4) and in vitro (see Chapter 5). When P4 is
administered to early pregnant bovine females there is an increase in embryo
developmental rates (Garrett et al., 1987; Garrett et al., 1988). In sheep, this increase in
development correlates to greater fetal growth later in gestation (Kleemann et al., 1994;
Kleemann et al., 2001). Geisert et al. (1988) have demonstrated that the
supplementation of P4 during metestrus stimulated the rate of maturation of the uterus
resulting in an increase in stromal glands within the uterus and uterine protein secretion
profiles that were similar to females at later days post-estrus. It has been hypothesized
that this increase in embryo development was likely the result of increased uterine
proteins and growth factors acting on the embryo (Garret et al., 1988). However, in vitro
co-culture systems that utilize uterine or oviductal cells and P4 for embryo culture have
produced variable results (Fukui et al., 1982; Fukushima and Fukui, 1985; Weimer et al.,
1987; Goff and Smith, 1998). Because the uterine peptide/protein secretion pattern
changes with stages of the bovine estrous cycle (Geisert et al., 1992) this may account
for the variation in reports on P4 supplementation of IVF-derived embryos such as the
use of uterine or oviductal cells harvested from cattle on different days of the estrous
cycle.
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Alternatively, the variation found with in vitro co-culure systems may be a result
of the use of cells from females of different ages, as age of the female has also been
demonstrated to affect fertility (Byerley et al., 1987, Quirke and Hanrahan, 1983).
Byerley et al. (1987) have reported that heifers experience low fertility during their first
two estrous cycles after puberty. Also in sheep, fertility following the mating of ewe
lambs is lower compared with mature ewes (Quirke and Hanrahan, 1983). Thus, if
uterine or oviductal tissue were harvested from mature fertile cows during metestrus it
would not be possible to determine whether P4 effects on the early embryo development
were directly on the embryo or via uterine peptide/protein secretions. In Chapter 5, it was
demonstrated that P4 could directly affect embryo development in vitro. However, the
mechanism by which P4 acted on the bovine embryo is still unknown. Therefore, the
objective of this study was to determine if early developing IVP bovine embryos had P4
receptors.
Materials and Methods
Media Prepartion
Oocytes were purchased from BOMED, Inc. (Madison, WI) or OvaGenix LP (San
Angelo, TX) and arrived in maturation medium between 38˚C and 39˚C. The oocytes
were allowed to remain in maturation medium for 24 hours. Oocyte and sperm washing
medium was prepared from Brackett-Oliphant (BO) stock medium (Appendix A and B).
The working stock solution of oocyte and sperm washing medium (BO-AB stock
solution) was prepared by the addition of 38 ml of BO-A stock solution to 12 ml of BO-B
stock solution and supplemented with 3.85 mg of pyruvic acid (P-4562, Sigma Chemical
Co., St. Louis, MO), 50 µl of gentamicin (15750-060, Gibco, Grand Island, NY) and 25 µl
of 10,000 IU/ml heparin sodium. The final sperm washing medium (BO-Caffeine) was
prepared by the addition of 24.3 mg of caffeine sodium (C-4144, Sigma Chemical Co.,
St. Louis, MO) to 25 ml of BO-AB stock solution.
The final oocyte washing solution (BO-BSA 0.3%) was prepared by the addition
of 30 mg of bovine serum albumin (BSA; A-7511, Sigma Chemical Co., St. Louis, MO) to
10 ml of BO-AB and the final sperm stock solution (BO-BSA 0.6%) was prepared by the
addition of 30 mg BSA (A-7511, Sigma Chemical Co., St. Louis, MO) to 5 ml of BO-AB.
All fertilization, culture and wash media was prepared at the Center for Reproductive
Biology at Louisiana State University, St. Gabriel, LA and equilibrated at 39˚C and 5%
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CO2. The embryo culture medium, CR1aa stock solution was prepared as described in
Appendix C (Rosenkrans and First, 1994).
In Vitro Fertilization
For the in vitro fertilization procedure, semen from a fertile Holstein bull (CSS
7H5918, Genex Cooperative Inc., Shawano, WI) was thawed in a water bath at 40°C for
15 to 45 seconds. The straw was wiped clean of residue water and expelled into a 15 ml
conical tube (Corning 15 ml conical tubes, Myriad Industries, San Diego, CA), extended
with 9 ml of BO-Caffeine and centrifuged at 200 x g for 6 minutes. Following the
completion of the first washing the supernatant was removed and 9 ml of fresh BOCaffeine medium was added to resuspend the sperm pellet and the wash procedure was
repeated. After completion of the second sperm washing the supernatant was removed
and the semen was resuspended in 4 ml of BO-Caffeine medium and 4 ml of BO-BSA
0.6%. Then 100 µl droplets of this solution were prepared in 35 mm Falcon™ plastic
petri dishes (Becton and Dickinson, Lincoln Park, NJ) under mineral oil and then placed
in an humidified incubator at 39°C and 5% CO2.
Following a 24-hour oocyte maturation period, oocytes were removed from the
maturation medium and washed through two 35 mm Falcon™ each containing 3.5 ml of
BO-BSA 0.3% medium. Following completion of the two oocyte washings 15 to 20
oocytes were placed in 100 µl fertilization droplets and all dishes were returned to the
incubator for 5 to 6 hours.
In Vitro Culture
When the 5- to 6-hour insemination period was completed the inseminated
oocytes were removed from the insemination droplets and washed through two 35 mm
Falcon™ plastic Petri dishes that contained 3.5 ml of 10 ml TCM-199 (Gibco
Laboratories, Grand Island, NY) and 30 mg of fatty acid-free bovine serum albumin
(FAF-BSA) (Fatty Acid Free-BSA, A-4503, Sigma Chemical Co., St. Louis, MO) solution.
Following the oocyte washing the cumulus cells were removed from inseminated
oocytes by vortexing (Vortex-genie mixer, Scientific Products, McGraw Park, IL) for 3
minutes in 1 ml of TCM-199 and 0.1 mg of hyaluronidase (H-3506, Sigma Chemical Co.,
St. Louis, MO) solution. After the vortexing was complete the oocytes were removed
from vortexing solution and washed through two dishes of 3.5 ml of TCM-199 and 30 mg
of fatty-acid-free bovine serum albumin (FAF-BSA). Following the final oocyte washing,
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the inseminated oocytes were then placed in 50 µl droplets of modified CR1aa [9.5 ml of
CR1aa (Appendix C), 200 µl of basal medium eagle (BME) (B-6766, Sigma Chemical
Co., St. Louis, MO), 100 µl of modified eagle medium (11140-050, Gibco Laboratories,
Grand Island, NY), 10 µl of gentamicin (Gibco Laboratories, Grand Island, NY), 1.46 mg
of L-glutamine (G-5763, Sigma Chemical Co., St. Louis, MO) and 30 mg of FAF-BSA].
Once oocytes were placed in CR1aa droplets the dishes were then placed in an airtight
modular incubator (Billups-Rothenberg®, Del Mar, CA) that was filled with 5% CO2, 5%
O2 and 90% N2 gas for 4 minutes at 2 psi and then placed in a humidified 5% CO2
incubator at 39°C.
At 3 days post-insemination, embryos were removed from embryo culture
medium and placed in fresh CR1aa embryo culture medium that was modified by the
supplementation of 500 µl of 10% heat-inactivated fetal bovine serum (FBS,
SH30070.02, Hi Clone Laboratories, Logan, UT).
Tissues Samples
Morphologically good quality embryos (n=47) were randomly removed from in
vitro culture at the 4-cell (n=3), 8-cell (n=5), 16-cell (n=3), morula (n=4), early blastocyst
(n=5), blastocyst (n=7), expanding blastocyst (n=8), hatching blastocyst (n=4) and
hatched blastocyst stage (n=8). In addition, adult bovine uteri (n=2) were collected from
an abattoir and histologically sectioned. Uterine samples collected were from the distal
portion of the uterine horn ipsilateral to the ovary bearing a mature CL.
Uterine Tissue Processing
Uteri were collected from a local abattoir (Hyde’s Slaughter Plant, Hammond,
LA). These uteri were collected from mature dairy cows and only reproductive tracts that
possessed a mature CL were collected. The reproductive tracts were transported (at
25˚C) to the Embryo Biotechnology Laboratory in physiological saline and once at the
laboratory ~1.5 cm sections were excised from the distal portion of the uterine horn (near
the utero-tubal junction) ipsilateral to the ovary bearing the CL. These sections were
then placed in 2% paraformaldehyde (Sigma Chemical Co., St. Louis, MO) solution and
transported to the Louisiana State University School of Veterinary Medicine (LSU SVM)
Pathology Laboratory.
The uterine sections were trimmed and then dehydrated by passing samples
through as series of alcohol concentrations and then alcohol was removed from the
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sections by placing the sample in a xylene solvent. Following this process, the sample
was infiltrated and impregnated with paraffin wax prior to embedding. The sample was
embedded with a Leica TP1050 (Leica Microsystems, Deerfield, IL). Samples are
sectioned (1 mm thickness) and mounted on a microscope slide for further staining.
Experimental Design
Uterine sections from the ipsilateral uterine horn to the CL collected from adult
cows served as positive controls to verify that the staining procedure was correctly
performed. For a negative control, embryos were used that underwent the fixation
process but did not undergo the staining process. All embryos except those at the
hatching or hatched blastocyst stages had the zona pellucida opened with a flexible
glass needle using a Nikon inverted microscope (Nikon Instech Co. Ltd., Kanagawa,
Japan).
Experimental Procedures
When embryos were randomly removed from in vitro culture on day 3 through
day 9, they were placed in a fixing solution of 1 ml of 2% paraformaldehyde (Sigma
Chemical Co., St. Louis, MO) and 7 ml of TCM-199 (Sigma Chemical Co., St. Louis,
MO). To ensure fixation of these selected embryos they remained in this 2%
paraformaldehyde solution, at room temperature, for 2 to 24 hours and afterwards they
were placed back into TCM-199 and refrigerated for later use. At time of P4 receptor
staining, embryos and uterine sections were washed with a washing solution of 50 ml of
PBS and 0.025 g of BSA (A-7511, Sigma Chemical Co., St Louis, MO). Embryos and
uterine sections were washed three times for 5 to 10 minutes per washing in a Falcon™
4-well dish (BD Biosciences, San Jose, CA). Embryos were then placed in a blocking
solution of 10 ml of TCM-199, 200 µl of goat serum (Equitech-BIO, Kerrville, TX), 2 mg
of BSA (A-7511) and 1µl of Triton-X (X-102, Sigma Chemical Co., St. Louis, MO) for 1
hour at room temperature.
Following removal from blocking solution, embryos and uterine sections were
then placed in 100-µl droplets of the primary antibody (AB) solution (Zymed Laboratories
Inc. (San Francisco, CA). Embryos and uterine sections were allowed to stay in the
primary AB droplet for 1 to 2 hours. Following this step, embryos were then washed in
washing solution 3 times for 10 to 15 minutes each in a Falcon™ 4-well dish. After the
embryos were washed they were then placed in a 1:1000 dilution of secondary AB (goat-
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anti-mouse Fc-conjucated to FITC, Sigma Chemical Co., St. Louis, MO). This step was
performed in the dark. The dish was covered with a piece of foil and embryos and
uterine sections were allowed to sit in the secondary AB for 1 to 2 hours (at room
temperature). Following removal from the secondary AB, the embryos and uterine
sections were washed in the washing solution two times for 10 to 15 minutes per
washing then once for 30 minutes.
Embryos and uterine sections were removed from the washing medium and
placed in an anti-avidin anti-fade solution (Vector Laboratories Inc., Burliname, CA). The
embryos and uterine sections were then evaluated for fluorescence using a Leica sp1
laser scanning confocal microscope equipped with a 20X objective. Stained embryonic
and uterine cells were excited with a 488 nm line from an argon laser and scanned
images were captured with an adjusted barrier wavelength of 520 to 560 nm. These
images were contrast enhanced in Adobe Photoshop 4.0 (Adobe System, Mountain
View, CA) for evaluation of fluorescence.
Results
Stained uterine tissue (positive controls) fluoresced with the appropriate green
pattern as expected, indicating the presence of P4 receptors in the endometrium (Figure
6.1). However, IVF-derived embryos from the 8-cell to the hatched blastocyst stages, as
well as, the unstained embryos (negative controls) only exhibited autofluoresence
(Figure 6.2, 6.3). The appropriate apple green fluorescence pattern was not detected in
embryos of any stage of development in this experiment.
Discussion
The presence of the correct fluoresce in the uterine tissue indicated that this
staining method was able to detect the presence of P4 receptors. However, IVP bovine
embryos unexpectedly exhibited only an autoflurencence. Due to this autoflurencence,
the procedure used to determine P4 receptors in IVP bovine embryos may not be the
most appropriate method. In unpublished attempts to detect P4 receptors in embryos
using this method, it was determined that the zona pellucida had to be perforated for the
stain to enter and exit the perivitelline space (Ferguson, unpublished data).
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Figure 6.1. Fluorence of sectioned bovine uterine tissue.
Note the specific staining of P4-receptors along
the luminal lining of uterine tissue.
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Figure. 6.2. Autofluorence of unstained IVF-derived bovine hatched
blastocysts. This indicates the staining procedure is not
applicable in bovine embryos.
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Figure. 6.3. Autofluorence of stained IVF-derived bovine hatched
blastocysts. Note the nonspecific staining pattern that
precludes the determination of the presence of P4
receptors.
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Due to the difficulty in the histological sectioning of bovine embryos, alternative
approaches, such as detection of mRNA for the P4 receptor may be an alternative
approach. Using this approach in mice, it was determined that mRNA for the P4 receptor
was not detected until the blastocyst stage (Hou and Gorski, 1993). In porcine embryos,
however, mRNA for the P4 receptor was detected at the 2-cell stage but levels had
declined by the 4-cell stage and were not detectable at any other stage of development
(Ying et al., 2000). Although P4 receptor mRNA was detected in the mouse and pig
embryo, there have been no reports of the expression of the P4 receptor in early
developmental stage bovine embryos.
Recent reports have shown that interferon-tau (INF-t) can improve IVF-derived
bovine embryo development (Takahashi et al., 2003). It was previously believed that the
bovine embryo did not express the INF-t receptor until day 15 of development (Han et
al., 1997) but Takahashi et al. (2003) reported the presence of a INF-t type I receptor in
IVF-derived bovine embryos from day 5 (morula) through day 8 (expanded blastocysts).
Interestingly, an increase in embryo development was noted when interferon alpha (INFα) was supplemented in place of INF-t, however, the receptor for INF-α was not
detected (Takahashi et al., 2003). It was hypothesized that the INF-α utilizes the INF-t
receptor, although with a lower binding affinity due the findings that a larger
concentration of INF-α was required to equal the proliferative effects on embryonic
development noted with INF-t supplementation. Therefore, is possible that the P4
receptor is present but an effective method of detection was not been developed in our
study.
There maybe an alternative approach to explain the improved development of
IVF-derived bovine embryos cultured in the presence of P4. There has been limited
evidence that some cells do not express classical genomic progesterone receptors
(Bramley, 2003). Indirect evidence from P4 supplementation in cell cultures of treated
cells that lacked a cell nucleus, the effect of P4 on the nucleated and enucleated cells
was the same indicating an ability to affect a cell without having a nuclear receptor
present. There is limited evidence for the nonnuclear P4 receptors, however, this
remains as a possibility to describe a mechanism by which P4 can affect an IVF-derived
bovine embryo without nuclear P4 receptors present.
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In conclusion, using this antibody conjugated-FITC P4 receptor staining
procedure indicated that P4 receptors were not present in IVC-produced bovine
embryos. However, the autoflurencence occurring in the IVC-produced bovine embryos
may prevent this method from being a viable method of P4 receptor staining. It seems
logical that the receptor staining method would generate more valuable data than
detection of mRNA for P4 receptors because the mRNA detection method does not
demonstrate the expression of the receptor that would be required to bind P4.
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CHAPTER 7
RESCUE OF PREGNANCIES IN BEEF CATTLE AFTER A
LUTEOLYTIC DOSE OF PROSTAGLANDIN F2α
Introduction
It is well known that PGF2α can induce luteolysis in cycling cattle and at various
times during pregnancy in cattle. When PGF2α is administered to cycling females,
luteolysis is usually accompanied by the emergence of a dominant follicle, estrus and
ovulation ~72 hours following PGF2α administration. Although PGF2α administration is not
always followed by 100% of pregnant females aborting (Lauderdale, 1972; Sloan, 1977;
Wright and Kiracofe, 1988), it has been reported to be very effective when administered
between 50 to 150 days of gestation (Jackson and Cooper, 1977).
It is also accepted that once PGF2α induced luteolysis is initiated in cattle the
corpus luteum (CL) can not be ‘rescued’. In early studies to determine effect of CL
ablation on the bovine pregnancy, researchers administered progesterone (P4) prior to
(Raeside and Turner, 1950a, 1950b; Zimbelman and Smith, 1966c) or simultaneously
(Raeside and Turner, 1951; McDonald et al., 1952; Tanabe, 1966; Kesler, 1997; Bridges
et al., 2000) to CL ablation. In these cases, pregnancy was maintained when P4 was
supplemented until near the end of gestation. However, it remains unknown if pregnancy
can be maintained when PGF2α is administered prior to the administration of
maintenance P4 and if this is possible, what are the time limitations from the time of
administration of PGF2α to the administration of maintenance P4. This is a pertinent
question due to the common use of PGF2α on farms and cattle ranches that utilize
estrous synchronization regimes and embryo transfer. In these situations, opportunities
exist for erroneous administration of PGF2α to pregnant females.
Although the prospect of saving a pregnancy of a prostaglandin-treated gestating
female may exist theoretically, there are other problems to overcome involving saving an
ongoing pregnancy. It has been demonstrated that cattle experience a higher incidence
of dystocia and premature calving when parturition is initiated in the absence of a CL
(Raeside and Turner, 1951; McDonald et al., 1952; Estergreen et al., 1967; Chew et al.,
1979; Kesler, 1997). This dystocia is usually accompanied by increased incidence of
retained placental tissues, increased cow and calf mortality and insufficient milk
production (during lactation) post-calving. In addition, Kesler (1997) reported reduced or
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absent maternal instinct behavior in beef females calving in the absence of a CL. An
increase in dystocia occurring in the absence of a CL has also been described in swine
(First and Staigmiller, 1973; Nara et al., 1981), however, it was later demonstrated that
the CL were the primary source of relaxin and suggested this to be the primary cause of
this dystocia problem in swine (Nara et al., 1981).
There have been reports of induction of luteal tissue during early pregnancy in
beef cattle (Lulai et al., 1994; Wright et al., 1994; Bridges et al., 2000). However, it was
demonstrated that if the induced CL was not present ipsilateral to the gravid uterine
horn, the induced luteal tissue was only transient (Lulai et al., 1994). Although, Wright et
al. (1994) and Bridges et al. (2000) demonstrated that induced luteal tissue, on the ovary
ipsilateral to the gravid uterine horn, could support pregnancy in the absence of P4
therapy, neither of these studies reported if these females calved or whether parturition
was normal.
These reports have provided insight into a possible mechanism to prevent
problems that commonly occur in cattle with the absence of a CL. Therefore, the
objectives of these experiments were to: (1) determine if pregnancy could be maintained
in the absence of a CL with administration of P4 or altrenogest (ALT) after PGF2α
treatment and (2) determine if induced luteal tissue could successfully support the
maintained pregnancy to term and result in normal parturition producing a viable
offspring.
Materials and Methods
Experiment 7.1
Experimental Animals
During the fall breeding season, 12 mature crossbred beef cows (Angus,
Charolais, Red Angus and Simmental) ranging in age from 4 to 8 years of age and with
body condition scores (BCS) of 5 to 7 (range 1=emaciated to 9=obese) were maintained
on Costal bermudagrass pastures at the Center for Reproductive Biology at Louisiana
State University, St. Gabriel, LA. All animals were treated in accordance with guidelines
set forth by the Animal Care and Use Committee of the Louisiana State University
Agricultural Center.
These females were pasture mated with two crossbred beef bulls and diagnosed
pregnant at 30 days of gestation (range = 32 to 42 days) via ultrasonography using an
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Aloka 500-V ultrasound unit (Corometrics, Wallingford, CT) equipped with a 5 MHz rectal
probe. A pregnancy was defined as the presence of a fetus with a viable heart beat.
Experimental Design
Once females were diagnosed as pregnant (n=12) at 32 to 42 days of gestation
they were randomly assigned to receive one of five treatments (Part I of this study). All
females received a luteolytic dose (25 mg) of PGF2α (Lutalyse®, Pharmacia & UpJohn,
Kalamazoo, MI) (i.m.) at time 0 hour. Following PGF2α treatment, females received 100
mg of P4 (Progesterone, Sigma Chemical Co., St. Louis, MO) (i.m.) dissolved in 3 ml of
100% ethanol (Aaper Alcohol, Shelbyville, KY) at 2 hours post-PGF2α (Treatment A)
(n=2), 6 hours post-PGF2α (Treatment B) (n=3), 10 hours post-PGF2α (Treatment C)
(n=3), 14 hours-post PGF2α (Treatment D) (n=2) or 18 hours post-PGF2α (Treatment E)
(n=2) in this experiment.
Experimental Procedure
During P4 treatments, blood samples were collected via jugular venapuncture
immediately prior to PGF2α administration and then at 2-hour intervals thereafter until the
time of the respective P4 treatment. Blood samples were not collected from an animal
shortly after P4 administration due to the cross reactivity of the P4 administered with that
of endogenous P4. Blood samples were stored at -20°C until the P4 radioimmunoassay
was performed. Blood serum samples were analyzed following extraction with acetone
for P4 levels using a commercial progesterone radioimmunoassay kit (Diagnostic
Systems Laboratory, Webster, TX). The intra- and inter-assay coefficients of variation
and assay sensitivities were 5%, 9%, and 0.05 ng/ml, respectively.
Following PGF2α treatment, females received daily administration of 100 mg of P4
for 7 days in an effort to maintain pregnancies. A successfully saved pregnancy was
defined as a viable (fetal heartbeats detected) pregnancy that was maintained for 7 days
in females that underwent successful luteolysis, as determined by ultrasonography.
Three females from those that remained pregnant were selected for induction of
luteal tissue (Part II of this study). These females were monitored three times weekly (via
ultrasonography) for the development of a ≥10 mm diameter follicle on the ovary
ipsilateral to the gravid uterine horn. Once a ≥10 mm follicle was detected, 2,500 IU of
hCG (Chorulon®, Intervet Inc., Millsboro, DE, USA) was administered (i.m.) to the
pregnant females. Females were monitored three times weekly until luteal tissue was
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detected, via ultrasonography. After luteal tissue was detected, the maintenance dose of
P4 was decreased to 50 mg of P4 per day for 7 days then 25 mg of P4 for 3 days and
then the daily treatment was terminated.
Experiment 7.2
Experimental Animals
During the spring breeding season, 7 crossbred beef cows (Angus, Red Angus and
Simmental) ranging in age from 4 to 8 years of age and with BCS of 5 to 6 (range
1=emaciated to 9=obese) were pastured on Costal bermudagrass at the Center of the
Reproductive Biology at Louisiana State University, St. Gabriel, LA. All animals were
treated in accordance with guidelines set forth by the Animal Care and Use Committee
for Louisiana State University Agricultural Center. These females were pasture mated
with two crossbred beef bulls and diagnosed pregnant at 80 days of gestation (range =
74 to 90 days) via ultrasonography using an Aloka 500-V ultrasound unit equipped with a
5 MHz rectal probe. A pregnancy was defined as the presence of a fetus with viable
heartbeats.
Experimental Design
Females at 70 to 90 days of gestation were randomly assigned to receive one of
three treatments. All pregnant females received a luteolytic dose (25 mg) of PGF2α (i.m.)
at time 0 hour. Following PGF2α treatment, females received 100 mg of altrenogest
(ALT) (Regu-mate, Intervet, Millsboro, DE) (orally) at 2 hours post-PGF2α (Treatment A)
(n=3), 6 hours post-PGF2α (Treatment B) (n=2) or 12 hours post-PGF2α (Treatment C)
(n=2). At 24 hours-post ALT treatment; all females received two 15 mg norgestomet
implants (s.c.).
Experimental Procedure
Blood samples were collected via jugular venipuncture at 0 hours, 2 hours, 6
hours, 12 hours and 24 hours post-PGF2α. These samples were stored at -20°C until
assayed for P4. The serum samples collected from blood were analyzed using an
extraction process with acetone. The concentration of P4 was determined by using a
commercial progesterone radioimmunoassay kit (Diagnostic Systems Laboratory,
Webster, TX). The intra- and inter-assay coefficients of variation and assay sensitivities
were 5%, 9%, and 0.05 ng/ml, respectively.
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Females were monitored (via ultrasonography) 3 and 7 days post-PGF2α treatment
to determine fetal viability. A successfully maintained pregnancy was defined as a viable
fetus present at day 7 in females that underwent luteolysis, as determined by
ultrasonography. These females (n=3) were then monitored once or twice weekly for the
development of a 10 mm follicle or greater on the ovary ipsilateral to the gravid horn.
Once a follicle of this criterion was detected 2,500 IU of hCG was administered until new
luteal tissue could be detected via ultrasonography. After luteal tissue was detected via
ultrasonography for 2 consecutive weeks then the norgestomet implants were removed.
Experiment 7.3
Experimental Animals
During the fall breeding season, 10 mature crossbred beef heifers (Red Angus and
Simmental) of 3 years of age that ranged in BCS of 5 to 6 (BCS 1=emaciated to
9=obese) were maintained on a Costal bermudagrass pasture at the Center for
Reproductive Biology at Louisiana State University, St. Gabriel, LA. All animals were
treated in accordance with guidelines set forth by the Animal Care and Use Committee
of the Louisiana State University Agricultural Center. These females were treated with
altrenogest for estrous synchronization (as described in Chapter 2) and PGF2α after 7
days of altrenogest treatment. Following PGF2α administration, females were introduced
to two fertile crossbred beef bulls (one was common to all breeding seasons) and mating
was detected by visual observation and Estrus Alert (Estrus Alert, Apple Valley, MN)
estrus detection aids. Then 30 to 40 days after PGF2α administration, females (n=7)
were diagnosed as pregnant (range = 30 to 40 days) via ultrasonography using an Aloka
500-V ultrasound unit equipped with a 5 MHz rectal probe were used. A pregnancy was
defined as the presence of a fetus with viable heartbeats.
Experimental Design
Pregnant females (30 to 40 days of gestation) were randomly assigned to receive
one of three treatments. All pregnant females received a luteolytic dose (25 mg) of
PGF2α (Lutalyse, Pharmacia & UpJohn, Kalamazoo, MI) (i.m.) at time 0 hour. Following
PGF2α treatment, females received 100 mg of altrenogest (Regu-mate, Intervet,
Millsboro, DE) orally at 6 hours post-PGF2α (Treatment A) (n=2), 12 hours post-PGF2α
(Treatment B) (n=2) or 18 hours post-PGF2α (Treatment C) (n=3). At 24 hours post-ALT
treatment two 15 mg norgestomet implants were inserted (s.c.) into each female.
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Experimental Approach
Blood samples were collected via jugular venipuncture at 0 hours, 6 hours, 12
hours, 18 hours, 30 hours and 72 hours post-PGF2α. These samples were stored at
-20°C until P4 radioimmunoassay was performed. The blood serum samples were
analyzed for P4 concentration using a commercial progesterone radioimmunoassay kit
(Coat-A-Count Progesterone, DPC, Los Angeles, CA).The intra- and inter-assay
coefficients of variation and assay sensitivities were 5%, 9% and 0.05 ng/ml,
respectively.
Females were monitored (via ultrasonography) 3 and 7 days post-PGF2α to track
fetal viability. A successfully maintained pregnancy was defined as a viable fetus present
at day 7 in females that underwent successful luteolysis, determine by ultrasonography.
These females were then monitored once weekly for the development of a follicle 10 mm
or greater in size on the ovary ipsilateral to the gravid horn. Once a follicle of this criteria
was detected, 2,500 IU hCG or 150 mcg GnRH (Fractrel®, Fort Dodge Animal Health,
Fort Dodge, IA) was administered until luteal tissue could be detected via
ultrasonography and serum P4 radioimmunoassayed. After luteal tissue was detected,
via ultrasonography and by circulating serum P4 levels for two consecutive weeks then
the norgestomet implants were removed.
Results
Experiment 7.1
In Part I of this experiment, 11 of 12 females (92%) responded to PGF2α
administration as determined by ultrasonography and verified by serum P4 levels.
However, since the P4 that was administered to save the pregnancy was highly cross
reactive with the P4 assay, only blood samples recovered from females prior to the
administration of P4 was used to determine luteal regression. The mean(±SE) serum P4
levels (number of animals) at 0, 2, 6, 10, 14 and 18 hours were: 5.5±0.7 ng/ml (n=11),
4.8±0.3 ng/ml (n=7), 4.0±0.5, ng/ml (n=4), 1.6±0.7 ng/ml (n=6), 0.9±0.2 ng/ml (n=3) and
1.4±0.26 ng/ml (n=2), respectively (Figure 7.1). The mean P4 levels did not decline
below 2 ng/ml until 10 hours (4 of 5 females) and 14 hours (3 of 3 females).
Pregnancy was maintained in 2 of 2 (100%), 3 of 3 (100%), 2 of 3 (67%), 1 of 2 (50%)
and 0 of 1 (0%) females in Treatments A (2 hour), B (6 hour), C (10 hour), D (14 hour)
and E (18 hour), respectively. It was determined that one female in the 18-hour
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Figure. 7.1. The circulatory progesterone (P4) pattern constructed from mature
crossbred beef cows (n=12) 30 to 40 days of gestation following
prostaglandin (PGF2α) treatment (Experiment 7.1).
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treatment group did not undergo complete luteolysis following PGF2α and was excluded
from the data set.
Of the nine females in which pregnancy was maintained, three pregnant females
were used to induce luteal tissue (Part II of this study) in an effort to support pregnancy
in the absence of exogenous P4 treatment. In female No. 1 (from Treatment A), a follicle
greater than 10 mm in diameter appeared on day 10 after PGF2α and two follicles greater
than 10 mm appeared on day 15 after PGF2α. By days 19 and 24 post-PGF2α. luteal
tissue was detected via ultrasonography (Figure 7.2). This female (given PGF2α at ~30
days of gestation) gave birth to a healthy bull calf at 284 days of gestation (Figure 7.3)
with no incidence of dystocia. The cow exhibited normal maternal behavior and lactation.
With female No. 2 (from Treatment B), a 10 mm follicle appeared on day 10 after PGF2α.
This follicle luteinezed in response to hCG by day 23 after PGF2α, however, this female
lost the pregnancy at ~60 days after PGF2α. With female No. 3 (from Treatment B), a
follicle greater than 10 mm appeared on day 10, however, by 3 days later (following
PGF2α administration) the fetus was lost.
Experiment 7.2
In Experiment 7.2, 5 of 6 females responded to PGF2α treatment as determined
by ultrasonography and P4 blood samples. The mean serum P4 levels at 0, 2, 6, 12 and
24 hours were: 8.5±1.6 ng/ml, 9.5±2.1 ng/ml, 4.6±1.0 ng/ml, 2.7±0.3, 1.5±0.4 ng/ml,
respectively (Figure 7.4). Mean serum P4 levels did not decline below 2 ng/ml until 12
hours (2 of 7, 29% of females) and 24 hours (6 of 7, 86% of females). Pregnancy was
maintained in 2 of 3 (67%), 1 of 1 (100%) and 0 of 2 (0%) of females in 2-hour treatment,
6-hour treatment and 12-hour treatment group, respectively. These results are excluding
the one female that did not respond to PGF2α.
In the three females that pregnancy was maintained, induction of luteal tissue
was attempted in two of these females. The remaining female was selected to serve as
a control to assure that if a pregnancy was lost it was from the delayed P4 treatment and
not from a failure of the norgestomet implant to maintain pregnancy. Of the two females
in which induction of luteal tissue was attempted, both had a follicle >10 mm on day 7
following PGF2α on the ipsilateral ovary to the gravid uterine horn. Both of these females
received hCG at this time. One female received a second dose of hCG 15 days later
because luteal tissue could not be verified via ultrasonography and a follicle 10 mm or
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Days Post-PGF2α
Day 1
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Day 24

Luteal Tissue
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Figure. 7.2. Development of follicles ≥10 mm in pregnant crossbred beef cows and their subsequent
luteinization after the administration of 2,500 IU of hCG following the initial prostaglandin
(PGF2α) treatment, as recorded via ultrasonography.
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Figure 7.3.

First calf (bull calf weighing 35 kg) produced from a crossbred beef cow
(No. 1) that was administered a luteolytic dose of prostaglandin and
supplemented progesterone (P4) starting 2 hours following prostaglandin
administration for 24 days. The pregnancy was continued on hCG-induced
luteal tissue at ~45 days of pregnancy.
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Figure. 7.4. The circulatory progesterone (P4) patterns constructed from mature
crossbred beef cows (n=12) at 80 to 90 days of gestation following
prostaglandin (PGF2α) treatment (Experiment 7.2).
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greater was present on the ipsilateral ovary to the gravid uterine horn.
Following hCG treatment(s) both females formed luteal tissue as determined by
ultrasound and a serum P4 radioimmunoassay. These two females continued to maintain
their pregnancies in the absence of supplemental P4. One hCG-treated female (No. 1)
calved at 271 days of gestation and gave birth to a live heifer calf, however; this calf died
from heat stress 3 days following birth (Figure 7.5). The second hCG-treated cow (No. 2)
gave birth to a healthy bull calf at 286 days of gestation. This calf was healthy and viable
at birth and subsequently exhibited a normal growth pattern (Figure 7.5). The
norgestomet implant control female (No. 3), became ill requiring veterinary intervention
and subsequently lost the pregnancy (~25 days after receiving norgestomet implant). For
the two hCG-treated females that calved exhibited normal maternal behavior and
subsequent lactation. The surviving calf was raised by the dam without any intervention
needed.
Experiment 7.3
In Experiment 7.3, all pregnant females (30 to 40 days of gestation) responded to
PGF2α treatment based on ultrasound and circulating serum P4 levels. The mean serum
P4 levels at 0, 2, 12, 18, 30 and 72 hours were: 12.4±1.5 ng/ml, 4.2±0.5 ng/ml, 2.6±0.6
ng/ml, 1.3±0.0 ng/ml, 1.3±0.1 ng/ml and 0.7±0.2 ng/ml, respectively (Figure 7.6).
Mean(±SE) serum P4 levels did not decline below 2 ng/ml in 3 of 7 (43%) females until
12 hours and finally in 7 of 7 (100%) females until 18 hours after PGF2α.
Pregnancy was maintained in 100% of females for all treatments and thus all of
these females were used to attempt to induce luteal tissue. Cumulatively, on day 7 (4 of
7, 57%), day 14 (5 of 7, 71%) and by day 21 (7 of 7, 100 %), following PGF2α
administration, pregnant-females had a follicle 10 mm or greater on the ovary ipsilateral
to the gravid uterine horn.
Luteinization had occurred in (3 of 5 hCG/GnRH-treated females) by day 21, (3
of 4 hCG/GnRH-treated females) by day 28 and (1 of 1 hCG/GnRh-treated females) by
day 49 following PGF2α administration. When compared by treatment groups there were
no differences in the time from PGF2α administration to luteal tissue formation. The 3
females forming luteal tissue by day 21 were represented by 2 females from the
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Figure 7.5.

The second calf (heifer calf weighing 23 kg) and third calf (bull calf
weighing 34 kg) produced from cows (No. 1 and 2) that were administered
altrenogest 2 hours after a luteolytic dose of prostaglandin (PGF2α) was
administered. The pregnancies were maintained on exogenous
progesterone (P4) until luteal tissue was induced by hCG administration. At
19 days, post-PGF2α administration, exogenous P4 was discontinued and
the pregnancies were continued to term from hCG-induced luteal tissue.
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Figure. 7.6. The circulatory progesterone (P4) pattern constructed from mature
crossbred beef heifers 30 to 40 days of gestation following
prostaglandin (PGF2α) treatment (Experiment 7.3).
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18-hour treatment group and 1 female from the 6-hour and 12-hour treatment groups.
For the 2 females forming luteal tissue by 28 days following PGF2α one was from the 6hour and 12-hour treatment groups. The final female forming luteal tissue by 49 days
following PGF2α administration was from the 12-hour treatment group. The mean number
of hCG or GnRH administrations required to induce luteal tissue was 2.2 per female and
the mean time required to induce luteal tissue was 40.2 days per female. Excluding the
last females that required 49 days to respond to hCG/GnRH administration the mean
time required from luteotrophin administration to luteal tissue formation was 21 days.
One female (No. 1, from the 12-hour treatment group) lost her pregnancy by 44
days following PGF2α and one female (No. 2, from the 18-hour treatment group) lost her
pregnancy by 79 days following PGF2α. One of these females (No. 2, 18-hour treatment
group heifer) had induced luteal tissue without a norgestomet implant while the other
(No. 1, 12-hour treatment group heifer) had induced luteal tissue and the norgestomet
implants at time of pregnancy loss. The remaining five females (2 from 6-hour, 1 from
12-hour and 2 from 18-hour treatment groups), with induced luteal tissue, remained
pregnant with norgestomet implants removed following the confirmation of induced luteal
tissue.
Of the five remaining pregnant females, four gave birth to live healthy calves at ~ 285
days of gestation (Figure 7.7). However, one female (No. 3) died during parturition and
the carcass was disposed without a necropsy being performed, and this prevented
determining the cause of death of the cow and the calf. Of the four heifers that calved
normally; one heifer (No. 4) from the 6-hour treatment group produced a healthy bull calf
that weighed 35 kg, one heifer (No. 5) from the 12-hour treatment group produced a
healthy heifer calf that weighed 36 kg, and two heifers (No. 6 and No. 7) from the 18hour treatment group produced a healthy heifer calf that weighed 33 kg, and a healthy
bull calf that weighted 38 kg. Parturition was normal in the four surviving heifers as well
as maternal instinct and lactation. All calves experienced normal growth rates and were
raised by the dam without intervention.
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Figure 7.7. The fourth calf (heifer calf weighing 36 kg at birth) and fifth calf (bull calf
weighing 38 kg at birth) (A) sixth calf (heifer calf weighing 33 kg at birth) (B)
and seventh calf (bull calf weighing 35 kg at birth) (C) produced from cows
that were administered altrenogest 6 hours (1 calf) 12 hours (1 calf) and 18
hours (2 calves) after a luteolytic dose of prostaglandin (PGF2α) was
administered. The pregnancies were maintained on exogenous
progesterone (P4) until luteal tissue was induced by hCG administration. At
21 to 49 days post-PGF2α administration, exogenous P4 was discontinued
and the pregnancies were continued to term on induced luteal tissue.
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Discussion
In these experiments, a total of 25 of 27 (93%) cows (between 30 and 90 days of
gestation) responded to the PGF2α administration with a decline in circulating P4 (levels
less than 2 ng/ml). This is consistent with other reports for administration of PGF2α to
pregnant cows (50 to 150 days of gestation) (Jackson and Cooper, 1977; Wright and
Kiracofe, 1988). In Experiments 7.2 and 7.3, cows responding to the PGF2α
administration had serum P4 levels below 2 ng/ml by 12 to 18 hours after PGF2α. Other
reports have shown that P4 levels decline below 2 ng/ml by 24 hours after PGF2α in
pregnant beef cattle (Jackson and Cooper, 1977; Guilbault et al., 1988; Wright and
Kiracofe, 1988) but unfortunately, these studies did not report P4 values during the postadministration intervals (12 to 24 hours).
In the present study, pregnancy was maintained in 86% of females that received
P4 prior to 10 hours after PGF2α treatment compared with 60% of females maintaining
pregnancy when P4 was administered ≥12 hours post-PGF2α treatment. These
observations suggests that when progestin treatment occurred prior to the time of
prostaglandin-induced P4 levels declining below 2 ng/ml, there is an increased chance of
maintaining the pregnancy. However, in cows at 80 to 90 days of gestation, in which
there were no pregnancies maintained when progestin administration occurred at 12
hours (12-hour treatment group) the two females had 2.5 and 2.9 ng/ml serum P4 levels
at 12 hours post-PGF2α treatment. This indicates that the stage of gestation at which
PGF2α is administered may affect the efficiency of rescuing pregnancy by utilizing this
protocol.
For heifers at 30 to 40 days of gestation, 3 of 3 females maintained pregnancy
with progestin treatment starting at 18 hours following prostaglandin administration.
These females had a serum P4 level of 1.3, 1.5 and 1.4 at 18 hours post-PGF2α. Overall,
these results suggest that serum P4 levels at time of progestin treatment may not directly
affect the chances of fetal survival during the early implantation period (30 to 40 days of
gestation) compared with those treated with PGF2α at a post-implantation period (e.g.,80
to 90 days of gestation).
Part II of these experiments was designed to prevent loss of calves and hopefully
decrease dystocia at parturition. This problem has been previously well documented in
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cattle (beef and dairy) calving without a CL (Raeside and Turner, 1951; McDonald et al.,
1952; Estergreen et al., 1967; Chew et al., 1979; Kesler, 1997). It has been
demonstrated that induced luteal tissue was capable of supporting pregnancy in
luteoctomized cattle (CL removed before day 10 of gestation) in the absence of
maintenance progestin (Lulai et al., 1994; Wright et al., 1994; Bridges et al., 2000).
However, there was a low success rate in these cases if the induced luteal tissue was on
the contralateral ovary to the gravid uterine horn (Wright et al., 1994; Bridges et al.,
2000).
Also, there have been no reports of females calving as a result of continued
pregnancy on induced luteal tissue. The successful maintenance of pregnancy in this
fashion was not reported to result in calving (Bridges et al., 2000) however, this
procedure provided a mechanism by which a ‘saved pregnancy’ could be maintained
without the use of long-term progestin treatment and possibly result in normal parturition.
In Experiment 7.1, of two females with induced luteal tissue, one female required
two separate hCG administrations 5 days apart, while the remaining female only
required one hCG administration. In these two females, one female (receiving a single
injection of hCG) aborted by 90 days of gestation, while the other produced a healthy
bull calf at 286 days of gestation. This female did not exhibit dystocia or have retained
placental membranes. The cause of the lost of pregnancy at 90 days is unknown. The
pregnancy was not lost until 23 days following P4 removal and this was confirmed by
pregnancy checks weekly until ~ 21 days following P4 removal. Unlike the third female
in Experiment 7.1 that aborted during the attempt to induce luteal tissue it is possible
that the increased frequency of rectal palpation could have resulted in the loss of this
pregnancy. Also, this lost pregnancy may be one that is normally observed in nonmanipulated cattle (Vaillancourt et al., 1979; Thurmond and Picanso, 1993). However, in
the female which lost the pregnancy at 60 days following the induction of luteal tissue, it
is possible that the newly formed CL was not capable of supporting the pregnancy to
term, although it was successful in the female that calved. Although, there were no
differences in the size of follicles that luteinized in these two females, the female that
calved may have formed more luteal tissue in response to two administrations of hCG. It
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should be noted that one of the live calves produced from Experiment 7.2 was from a
female that received only a single administration of hCG.
The reason for the loss of one heifer during parturition in Experiment 7.3 is
unknown, since a necropsy was not performed. However, this heifer required 49 days
following prostaglandin administration to induce luteal tissue and it is possible that the
luteal tissue was short-lived however, the pregnancy continued to ~270 days of
gestation. For this physiological model to be valid, the adrenal-placental axis would had
to support the pregnancy from ~90 days of gestation until 210 days of gestation. This is
unlikely based on reports that pregnancy in the cow can not be maintained without a CL
or maintenance P4 until ~210 days of gestation and generally resulting in parturition
beginning ~265 days of gestation (Raeside and Turner, 1951; McDonald et al., 1952;
Tanabe, 1966). The other females (No. 4, 5, 6, 7) calved normally and readily accepted
and raised their respective calves without outside intervention. This further supports the
results from Experiment 7.1 and 7.2.
In these experiments, females that calved following hCG-induced luteal tissue
displayed normal maternal recognition and subsequent lactation following parturition.
Previous descriptions of beef and dairy cows that pregnancy was maintained to term
with exogenous P4, in the absence of a CL, displayed a lack or absence of maternal
behavior and insufficient lactation to raise calf (Kelser, 1997). However, the females in
this study had normal births, raised their own calves without assistance and only with
two calves lost shortly after birth. The reason(s) for this loss of these two calves is
believed to be unrelated to pregnancy rescue treatments.
Woody et al. (1967) have reported administration of exogenous P4 administered
during the first 6 days of CL development (1 to 7 days of estrous cycle) results in
premature luteal regression (8 to 10 days of the estrous cycle). Thus it would be difficult
to speculate on the mechanism responsible for bovine luteal tissue development under
elevated exogenous P4 for maintenance of pregnancy. However, it has been reported
that the bovine embryo produces luteotrophins (PGE2 and PGI2) during early
development (Hwang et al., 1988) and others have reported luteotrophic proteins in the
allanotic fluid prior to day 37 of gestation (Hickey et al., 1989; Hansel and Blair, 1996). In
addition, Ryan et al. (1992) demonstrated that the placenta produced luteotrophic
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substances during the first trimester in beef cattle. These findings provide a potential
model for how the induce luteal tissue continues to persist under elevated exogenous P4
and is capable of supporting pregnancy to term in the absence of maintenance P4. It is
possible that these factors could stimulate the induced luteal tissue to continue to
function throughout gestation. Ryan et al. (1992) reported that pregnant females which
received PGF2α in conjunction with induced fetal death returned to estrus in a mean of
6.2 days while females that underwent induced fetal death without PGF2α did not return
to estrus until a mean of 13.5 days. This finding suggests that placental tissue could
prolong luteal function in the absence of a viable fetus.
In conclusion, these data illustrate that a valuable pregnancy can be salvaged
following an erroneous administration of PGF2α without having to administered
progesterone for an extended interval during gestation. In addition to saving the
pregnancy, the pregnancy can be supported to term and result in normal parturition,
normal maternal behavior and normal lactation. This procedure could provide a valuable
means to prevent financial losses that can occur on farms/ranches by utilizing this
approach of preventing abortions from occurring in valuable embryo transfer recipient
females that may have erroneously receive PGF2α. Also, this procedure can exclude
unnecessary veterinary expenses and increased chances of cow or calf mortality due to
parturition occurring in the absence of a CL.
To our knowledge this is the first report of successful births of calves from
prostaglandin-treated pregnant beef cows that were administered P4 or altrenogest
following the prostaglandin administration. Also, to our knowledge this is the first report
of calves produced from cows allowed to continue to term with induced luteal tissue
maintaining the pregnancy. Finally, to our knowledge this is also the first report of a
bovine pregnancy being maintained with altrenogest in the absence of a luteal tissue.
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CHAPTER 8
SUMMARY AND CONCLUSIONS
In these experiments the primary objective was to determine if altrenogest (ALT)
used for monogastric animals would act as a biological progestin in cattle (a ruminant). A
secondary objective was to evaluate the effect of progestins on early embryo
development in vivo and in vitro. The effects of ALT in cattle were unknown due to the
fact it had not been assessed as a progestin for use in cattle.
In Chapter 3, it was demonstrated that ALT could serve as a progestin in beef
cattle. It was proposed that ALT would synchronize the estrous cycle in beef heifers
similar to that of MGA, which has been long known to synchronize beef cattle. ALT
successfully synchronized beef females in this study and there were no detectable
detrimental effects of ALT on subsequent fertility or on the health parameters of the
calves produced from ALT-treated beef females.
In Chapter 4, ALT effectively improved pregnancy rates in repeat breeder
females (RPB) when administered on days 3 to 5 following the onset of estrus. In the
course of this experiment it was found that mated cattle that have a greater increase in
circulating progesterone from day-3 to day-4 of the estrous cycle were more likely to
become pregnant as a result of the mating. By administering a low dose of P4 or ALT
during this interval the P4 levels in RPB females mimicked that of control fertile females
increasing the pregnancy rate to greater than expected in RPB females.
In Chapter 5, the ability of P4 to exert a positive direct effect on the developing in
vitro produced (IVP) bovine embryo was evaluated. When P4 was administered to the 8cell stage IVP bovine embryos, significantly more developed to the blastocyst and
hatched blastocyst stages on both day-7 and day-9 post-insemination, respectively.
Also, more P4-treated IVP bovine embryos developed to grade-1 quality blastocysts on
day 7 post-insemination. In addition, P4-treatement hastened the developmental rate of
IVP bovine embryos while in in vitro culture and this could ultimately increase transfer
pregnancy rates. These findings demonstrated that P4 exerts a direct effect on
developing IVP bovine embryos.
In Chapter 6, it was determined that using an antibody staining method that P4
receptors were not present in developing IVP bovine embryos. Because IVP bovine
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embryos exhibited an autofluorence, however, this finding needs further verification.
Additional PCR based experiments to determine the presence of mRNA for the P4
receptor will also be needed to support these findings.
In Chapter 7, the ability to ‘rescue’ a pregnancy in beef females between 30 and
90 days of gestation following the administration of a luteolytic agent (PGF2α) was
attempted. In these experiments, a maintenance dose of P4 was administered at set time
intervals of 2 to 18 hours following prostaglandin administration. It was determine that
pregnancy could be salvaged in females with administration of P4 initiated as late as 18
hours following PGF2α administration. In addition to salvaging pregnancy, these females
were induced to ovulate to prevent the continued need to administer a maintenance
dose of P4. From these experiments, seven calves were produced from prostaglandintreated pregnant beef cows and heifers. To our knowledge this is the first report where
calves were produced from prostaglandin-treated (30 to 90 days of gestation) pregnant
cattle. Also, this is the first report to our knowledge by anyone of beef cattle calving as a
result of induced luteal tissue maintaining the pregnancy to term. Parturition, maternal
instinct and subsequent lactation were normal in all but one of these cows.
In conclusion, it was demonstrated that ALT could serve as a progestin in cattle.
In addition, it was determined that ALT administration during early pregnancy could
enhance pregnancy rates in RPB females. Also, P4 may also have a direct effect on the
developing embryo in vitro. The next step would be to evaluate if this response can be
generated by ALT.
Furthermore, ALT can maintain pregnancy in a pregnant beef cow given a
luteolytic dose of prostaglandin while the beef cow is in the process of having induced
luteal tissue form. Calves produced from pregnant beef cow treated with ALT appear to
be normal and reproductively sound following puberty. These findings provide beef
producers with a new progestin that can be used for estrous cycle synchronization,
improving pregnancy rates in problem breeder females and maintaining pregnancy in
pregnant beef cows that experience luteal regression.
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APPENDIX A

BO-A STOCK SOLUTION1

Component

Product number

Company

Amount

NaCl

S-5886

Sigma

4.3092 g

KCl

P-5405

Sigma

0.1974 g

CaCl2•2H2O

C-7902

Sigma

0.2171 g

NaH2PO4•H2O

S-9638

Sigma

0.0743 g

MgCl2•6H2O

M-2393

Sigma

0.0697 g

Milli Q

500 ml

Sigma

0.1 ml

Milli Q Water
Phenol Red 0.5%
1

P-0290

Solution was prepared in a 500-ml bottle and stored in refrigerator for up to
3 months.
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APPENDIX B

BO-B STOCK SOLUTION1

Component
NaHCO3

Product number
S-8875

Milli Q Water
Phenol Red 0.5%
1

P-0290

Company

Amount

Sigma

2.5873 g

Milli Q

200 ml

Sigma

0.04 ml

Solution was prepared in a 250-ml bottle and CO2 was introduced into
bottle for 1 to 2 mintues (until coloration becomes peach-colored). This
solution was stored in refrigerator for up to 3 months.
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APPENDIX C

CR1aa STOCK SOLUTION1

Component

Product number

Company

Amount

NaCl

S-5886

Sigma

0.6703 g

KCl

P-5405

Sigma

0.0231 g

NaHCO3

S-8875

Sigma

0.2201 g

Pyruvic Acid

P-4562

Sigma

0.0044 g

L (+) Lactic Acid

L-4388

Sigma

0.0546 g

Glycine

G-8790

Sigma

0.0039 g

Sigma

0.0045 g

Milli Q

500 ml

Sigma

0.2 ml

L-Alanine

A-7469

Milli Q Water
Phenol Red 0.5%
1

P-0290

Solution was prepared in a 100-ml bottle filtered with a 0.04 µm filter and
stored in refrigerator for up to 3 months.
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